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ABST RACT 
Intracellular Traits of Chimeric tRNALYs3-Ribozymes 
and Their Inhibition of HIV-1. 
by 
Zongli Chang 
Host tRNALYs3 is the primer recruited by HIV-1 for initiating reverse transcription. 
When ribozymes targeted upstream of the primer binding site of the HIV-1 genome are 
tethered to the 3' end of the tRNALYs3, it is expected that the tRNA will carry the 
ribozymes into the virions. We made constructs that express chimeric tRNALYs3-
ribozymes from internal tRNA promoters. These chimeras were also adjoined 
downstream of a U6 promoter, resulting in a hybrid U6/tRNA expression cassette with 
extragenic U6 and intragenic tRNA promoters. Juxtaposition of the tRNA and U6 
promoters significantly enhanced expression levels compared to the tRNA promoter 
alone. A U6/tRNA expression cassette with two mutations in B box of the tRNA moiety 
gave rise to the highest expression level, suggesting that the mutations reduce the steric 
interference of the tRNA gene with the U6 promoter. Qualitative changes in the initiation 
site of one minor species of transcripts were observed. These may have resulted from 
steric interference between the U6 and tRNA promoter elements. In an anti-HIV assay, it 
was found that tRNA-ribozyme chimeras could be encapsulated into HIV virions leading 
to reduced infectivity. 
The intracellular stability and processing of the chimeric tRNALYs3-ribozymes were 
also studied. Point mutations in B box were found to reduce the intracellular processing 
of the tRNA-ribozymes in a Wit analysis of the transcripts by Northern hybridization 
analysis. A deletion of one guanidine residue immediately upstream of the B box led to 
increased stability in a processing assay using cell extract with tRNA processing 
activities. Nevertheless, the transcripts from these constructs can still be exported to the 
cytoplasm as demonstrated by fluorescence in situ hybridization and can be packaged 
into the virions. Constructs with these changes were also found to inhibit HIV infectivity 
more efficiently. Changes in the tRNA sequence that enhance transcript stability could be 
useful in the design of other tRNA expression cassettes for RNA-based therapeutics. The 
tc/t analysis proposed could be useful for screening other changes in tRNA expression 
cassettes for increased transcript stability. 
INT ODUCTION 
A. tRNALYs3 as the primer for reverse transcription in HIV 
Human immunodeficiency virus (Hrv) is the causative agent of acquired immune 
deficiency syndrome (AIDS). During its replication cycle (Figure 1), the HIV single-
stranded RNA genome is reverse transcribed into double stranded DNA (proviral DNA). 
The process is catalyzed by reverse transcriptase, a viral-encoded enzyme that is 
encapsidated into the virion (Figure 2). Proviral DNA is then transported into the nucleus 
and integrated into the host chromosome. The primer for HIV DNA synthesis is tRNALYs3 
(Figure 3), which is derived from the host cells and packaged into virions (Figure 1). The 
nucleotide sequence at the 3' end of the primer tRNA hybridizes to a complementary 18 
nucleotide viral sequence, termed the primer binding site (PBS), near the 5' end of the 
RNA genome (Figure 4). The following introduction provides more details about this 
process; review articles are also available (Litvak et al., 1994; Marquet et al., 1995; Gotte 
et al., 1999). 
1. HIV reverse transcriptase 
Reverse transcriptase (RT) is the key enzyme for the replication of the retroviral RNA 
genome in the process of reverse transcription (Figure 2, see Goff, 1990; DeVico et al., 
1992; Kupiec et al., 1996, for reviews). It is an RNA-dependent DNA polymerase with 
three enzymatic activities: 1) an RNA-dependent DNA polymerase activity involved in 
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Figure I eplication cycle of HIV4 and the mechanism of packaging of tN Lys3 
and chimeric tRNALYs3-ribozymes. 
tRNALYs3-ribozymes: chimeric tRNALYs3.-ribozymes. Adapted and modified from Mak 
and Kleiman (1997). 
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Figure 2. Reverse transcription of retroviral genomic RNA into double-stranded 
proviral DNA. 
Step 1: Annealing of primer tRNA to the PBS, and synthesis of minus-strand strong-stop 
cDNA, with the resulting degradation of R and U5 RNA by the RNase H activity of the 
reverse transcriptase. Step 2: The first strand transfer, in which minus-strand strong-stop 
cDNA is annealed to the 5' terminus of the genomic RNA via R-R' hybridization. Steps 3  
and 4: Further synthesis of minus-strand cDNA, during which the genomic RNA is 
further degraded by RNase H. A small piece of RNA, the polyuridine tract (PPT), 
remains undegraded and serves as the primer for plus-strand strong-stop cDNA (step 5). 
Step 5: Termination of plus-strand strong-stop cDNA synthesis 18 nucleotides into the 
primer tRNA, thereby generating a new PBS sequence; the tRNA is released from the 
minus-strand cDNA. Step 6: The second strand transfer, in which plus-strand strong-stop 
cDNA is annealed to the 3' terminus of minus-strand cDNA via PBS-PBS' hybridization. 
Step 7: Completion of synthesis of double-stranded proviral DNA. Figure adapted from 
Mak and Kleiman (1997). 
3 
,OH 
G • C 
• G 
G • G 
G • G 
G • C 
A • 
TT Ticcc 
C U C rn m5CAGGG 




C • G 
A • U 




Figure 3. Nucleotide sequence of tRNALYs3 presented in cloverleaf form. 
Modified nucleotides are: D, dihydrouridine; pseudouridine; S, 5-(methoxycarbonyl-
methy)-2-thiouridine; R, N-[N-(9-P-D-ribofuranosy1-2 methylthiopurine-6-y0carbamoyl] 
threonine; Tm, 2'-0-methyl ribosylthymine; at other position, m indicates a methylated G 
or A, with the position of methylation indicated. The solid line indicates 18 nucleotides at 
the 3' end of the tRNA complementary to the 14W-1 primer binding site. (Adapted from 
Wilson and Abbotts, 1992). 
Figure 4. Schematic representation of nucleic acid interactions leading to the 
formation of a complex between primer tRNA and the complementary region on the 
retroviral genome. 
PBS, primer-binding site. 
(Adapted from Litvak et al., 1994). 
the synthesis of the minus strand of the proviral DNA; 2) a DNA dependent DNA 
polymerase activity that catalyzes the synthesis of the plus DNA strand; and 3) an RNase 
H activity, a nuclease activity that degrades the RNA portion of the RNA-DNA hybrid, 
generating the RNA primer used for the synthesis of the plus DNA strand. 
RT is encoded downstream from the gag gene in a large coding region. This coding 
region is translated to yield a 160 kD Gag-Pol fusion protein Pr160Gag-poi  (Figure 1). This 
polyprotein is subsequently cleaved by a viral protease to generate the mature RT present 
in the infectious virion. The initial product is a 66-1d) polypeptide that has both a 
polymerase domain and an RNase H domain. Limited proteolysis of p66 by a retrovirus-
encoded protease generates a p51 polypeptide. The reverse transcriptase isolated from 
HIV particles is a heterodimer of p66 and p51. The p66 subunit has the DNA polymerase 
and RNase H activities, and is considered to be the catalytic core for the enzyme. The 
precise role of p51 in the virion active polymerase remains to be determined. 
2. tRNALYs3 as the initiator of DNA synthesis: complementarily of tRNALYs3 and 
PBS 
Reverse transcriptase requires a primer with a free 3'-hydroxyl to initiate DNA 
synthesis. All retrovinises are known to use host cellular tRNAs as primers to initiate 
reverse transcription during their replication cycles. Different retroviruses use different 
tRNAs as primers (Table 1). 
Table 1: Primer tRNAs used by different retroviruses 
Retroviruses Primer tRNA 
Human immunodeficiency virus (HIV) 
Mouse mammary tumor virus (MMTV) 
Equine infectious anemia virus (EIAV) 
Feline immunodeficiency virus (FIV) 
Mason-Pfizer monkey virus (MPMV) 
Visna 
Human spuma retrovirus (HSRV) 
Moloney murine leukemia virus 
Spleen necrosis virus (SNV) 
Human T-cell leukemia virus I and II (HTLV) 
Bovine leukemia virus (BLV) 
Avian sarcoma and leukosis virus (ASLV) 
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tRNALYs3 (Figure 1) is the primer used by H1V-1 and 2 for replication (Wain-Hobson 
et al., 1985; Ratner et al., 1985 and Raba et al., 1979). The 18 nucleotides at the 3' end of 
tRNALYs3 are complementary to a sequence near the 5' end of the HIV genome (Figure 3 
and Figure 4). The sequence is the primer binding site (PBS). When isolated from the 
virion, the 3'end of primer tRNALYs3 is found annealed to the PBS. The PBS consists of 
nucleotides 183-200 of the HIV RNA genome. Furthermore, tRNALYs3 can act as a 
functional primer for synthesis of the minus strand in vitro starting at the PBS on HIV 
genome (Figure 2). This in vitro DNA synthesis reaction requires the HIV nucleocapsid 
protein, as well as the RT and tRNALYs3. Furthermore, although several different tRNA 
species can be isolated from Hrv virions, tRNALYs3 is one of the main species. 
3. Selection of primer tRNA from host cells: selective incorporation of tRNALYs3 
into virions 
The primer tRNA found in retrovirus particles originates from the host cell tRNA 
population, from which it is selectively packaged during virus assembly (Figure 1). RT 
binds cellular tRNAL"3 and both are packaged along with genomic RNA and other 
proteins into the virions formed in the cytoplasm of infected cells. There are more than 
100 different species of tRNAs in the cells, but only a limited population is found in the 
virions. In HIV virions, tRNA Lysl, 2,3 and tRNAlle are the major species incorporated in 
the viral particles (Jiang, et al., 1993). It is reported that HIV virions contain a subset of 
five to ten species of cellular tRNA, depending upon the cell type analyzed (Kleiman et 
al., 1991). Only tRNALYs3 is tightly associated to the viral genome in wild type virus and 
8 
it is believed that tRNALYs3 is the primer tRNA for HIV RT. The tRNALYsl' 2 isoacceptors 
found in the virions probably do not serve as primers. Their incorporation reflects the fact 
that they contain a recognition signal shared by all three tRNALYs species (Jiang, et aL, 
1993). tRNA'' and tRNALYs2 differ by only one base in the anticodon stem, while the 
difference between these and tRNALys3  is much larger. In COS-7 cells transfected with 
HIV-1 proviral DNA, the isoacceptors of t NALYs represent only 6% of the low 
molecular-weight RNA isolated from the cytoplasm, but they represent 60 percent of the 
low-molecular-weight RNA isolated from virus particles. This observation suggests that 
tRNALYs is selectively incorporated into HIV-1 particles. 
Genomic RNA packaging is not required for the incorporation of primer tRNA into 
the virion (Jiang M. et al., 1993, Mak et al., 1994). However, selective packaging of the 
primer tRNA does not occur in RT-negative HIV-1 isolates (Mak et al., 1994). This 
demonstrates the importance of RT sequences in selective primer packaging. Gag-Poi 
polyprotein, the precursor of RT, is involved in viral assembly and is not cleaved until 
budding, Gag-Pol precursor can be inferred to be involved in the primer tRNA selection 
(Figure 1). This hypothesis is supported by the following findings of Mak and colleagues 
(Mak et al., 1994). First, selective tRNALYs incorporation and wild-type amounts of 
tRNALYs3 were maintained in a protease-negative virus unable to process Pr55gag and 
Pr160Gag-m precursors. This finding indicated that precursor processing was not required 
for primer tRNA incorporation. Second, viral particles containing only unprocessed 
Pr55gag protein did not selectively incorporate tRNALYs, while vi ions containing both 
unprocessed Pr55gag and Pr160Gag-m proteins demonstrated selective tRNALYs3 
9 
packaging. Third, studies with a proviral mutant containing a deletion of most reverse 
transcriptase sequence and approximately one-third of the integrase sequence in the 
Pr160Gag-Poi  precursor resulted in the loss of selective tRNA incorporation and an eight 
fold decrease in the amount of tRNALYs per two copies of genomic RNA (Mak et al., 
1994). In mutant avian sarcoma and murine leukemia viruses that lack RT, the selection 
of incorporated tRNAs becomes nonspecific. 
4. Interaction between the primer tRNA and genomic RNA for initiation of reverse 
transcription 
The 3' 18 nucleotides of tRNALYs3 are complementary to the primer binding site 
(PBS) of HIV. Studies have shown that a minimum degree of complementarity needs to 
be maintained for efficient reverse transcription (Kohistaedt et al., 1992). There are more 
copies of tRNALys3 than copies of genomic RNA in each virion. Consequently, some of 
the primer tRNA is bound to the genome and some is free. 
Besides the tRNA-PBS interaction, several other interactions were also found and 
these are illustrated in Figure 5. The PBS sequences of HIV and ALV (Avian Leukosis 
Virus) are not sufficient determinants for the primer tRNA identity. Virions produced 
from cells transfected with proviral DNAs that have mutational changes in the PBS 
sequence making it complementary to other tRNAs show slow initial replication kinetics 
in HIV (Das et al., 1995; Li et al., 1994; Wakefield et al., 1995) or ALV (Whitcomb et 
al., 1995). However, after extended in vitro culture, the mutant genomes eventually revert 
10 
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Figure 5. Proposed regions of base pairing between IRNALYs3 and the HIV-1 
genome. 
In addition to the PBS interaction, other regions in the viral genomic RNA may interact 
with the tRNA. These regions include the A-rich regions upstream (Isel et al., 1996, Jiang 
et al., 1993) and downstream (Lanchy et al., 1996) of the PBS, which interact with the 
anticodon loop (shown by the two arrows), as well as an interaction of the IVC loop with 
a 115 region upstream of the PBS (Aiyar et al., 1992, Aiyar et al., 1994). Adapted from 




to the wild-type PBS sequences complementary to the natural primers and the virions 
grow at wild-type rates again. The A-rich loop was found to play a role in determining 
the identity of the primer tRNA used by HIV-1. When the PBS of the HIV-1 genome was 
substituted with a sequence complementary to tRNAllis rather than tRNALYs3, the initial 
rate of viral replication was low, but after extended in vitro culture the production rates 
approached those of wild-type virus. This increased replication efficiency was 
accompanied by the reversion of the tRNA'" s PBS to the wild-type tRNALYs3, indicating 
that tRNALYs3 is eventually selected as the primer (Wakefield et al., 1995). 
5. Role of nucleocapsid protein 
Since tRNAs are highly structured molecules, cofactors are required for the 3' end to 
base pair with the PBS of the viral genome. HIV-1 nucleocapsid (NC) protein was found 
to facilitate the annealing of tRNALYs3 to in vitro-transcribed genomic RNA sequences 
(de Rocquigny et al., 1992; Huang et aL, 1997; Cen et aL, 1999) probably by unwinding 
the secondary structure of tRNALYs3 (Khan and Giedroc, 1992). In addition to primer 
tRNA annealing, the NC protein is also involved in genomic RNA packaging and 
dimerization, and minus-strand strong-stop cDNA strand transfer (Darlix et al., 1995; 
Guo et aL, 1997). 
12 
B. Hammerhead ribozymes 
1. Definition of ribozymes 
Ribozymes are RNAs that possess enzymatic properties: They catalyze the 
endoribonucleolytic cleavage of RNA molecules. Upon formation of a complex with their 
complementary target RNA molecule, they catalyze the degradation of the target via a 
cleavage reaction. In this way, the substrate RNA can be inactivated at a catalytic rate 
and with a high degree of substrate specificity. 
2. Classification of ribozymes 
Ribozymes were initially discovered in a group I self-splicing intron of the 
Tetrahymena pre-rRNA (Kruger et al., 1982) and in the RNase P enzyme purified from 
E. coli (Guerrier-Takada, 1983). There are several classes of naturally occurring 
ribozyme structures. The Tetrahymena ribozymes were described as molecules capable of 
autocatalytic cleavage during the RNA splicing process in Tetrahymena (Cech, 1987) and 
belong to the Tetrahymena group I intron family. Guerrier-Takeda et al. (1983) 
elaborated a second class of ribozyme structure, ribonuclease (RNase) P. RNase P is an 
endoribonuclease involved in the 5' processing of pre-tRNA molecules resulting in the 
formation of the mature 5' end of tRNA moleculs (see next section for more details about 
RNase P). The third class of ribozyme structure is the hairpin ribozymes. They were 
identified in the minus-strand of the satellite RNA of the tobacco ringspot viroid (Hampel 
and Tritz, 1989). Upon hybridization of the ribozyme catalytic domain consisting of 50 
nucleotides with the substrate strand, a characteristic hairpin-like structure forms. Hence, 
the name hairpin ribozymes. The fourth group of ribozymes shares a two-dimensional 
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structural motif known as the "hammerhead." The hammerhead ribozymes have a 
common secondary structure consisting of three stems connected by three single-stranded 
regions. They have been identified in plant viroids, virusoids and satellite viruses. 
Another class of catalytically active ribozyme motif was found in hepatitis delta virus 
(HDV). The HDV contains a circular single-stranded RNA genome. The genome has 
extensive intramolecular basepairing potential and a self-cleaving domain has been 
identified within the HDV genome (Wu et al., 1989; Perrota et al., 1990). An RNA 
molecule encoded by an 881-nt mtDNA plasmid isolated from Neurospora was also 
found to have self-cleaving activity (Saville and Collins, 1990). 
3. Hammerhead ribozymes 
The hammerhead ribozyme is a very small RNA motif that may cleave at a specific 
phosphodiester bond to produce 2',3' cyclic phosphate and 5' hydroxyl termini (Hutchins 
et al., 1986; Forster & Symons, 1987). Cleavage by hammerhead ribozymes is 
magnesium-dependent and is site-specific. The hammerhead consists of three helices 
connected by three single-stranded regions. 
In nature, hammerhead ribozymes are utilized by a number of small pathogenic plant-
viroid and satellite RNAs for processing during roiling-circle replication (Symons, 1992) 
and they act "in cis" (on the same strand of RNA). Later, the hammerhead ribozyme was 
designed to work "in trans" [work against other RNA molecules (Uhlenbeck, 1987)]. The 
trans-acting hammerhead ribozyme has two antisense arms (stems I and III) and a 
catalytic domain with a flanking stem II as well as a loop section. In the hammerhead 
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motif, a specific set of three nucleotides is required at the cleavage site. The triplet is 
defined by NUH (where N is U, G, A, or C, and H is U, C, or A), with cleavage 
occurring 3' to H. The GUC triplet is the most commonly used site in nature (Forster & 
Symons, 1987) and is cleaved most efficiently (Ruffner et al., 1990). This is the target 
site of choice in designing a new ribozyme. However, the optimal triplet depends also on 
the composition and nucleotide lengths of stem I and III. Because —UH- occur very 
frequently in RNA (once in every six nucleotides on average), the hammerhead ribozyme 
can be designed to target any RNA. The ribozyme hybridizes to the complementary 
sequences flanking the —UH- cleavage site within the target RNA. The complementary 
sequences form stems I and III. If these two stems are short enough, the cleavage 
products can dissociate from the ribozyme easily, allowing the ribozyme to bind and 
cleave another molecule. By repeating the cycles, one ribozyme molecule can be recycled 
to cleave many substrate molecules. The length and sequence of stems I and III affect the 
dissociation of the hammerhead ribozyme from the substrate and affect the catalytic 
properties of the ribozyme. The optimal lengths of each section of stems I and III are 9-
12 nucleotides (Herschlag, 1991). Other factors that should be considered in optimizing 
the efficiency of hammerhead ribozymes include substrate secondary structure, creation 
of A-rich sequences in the hammerhead ribozyme that minimize U-G wobble pairs, and 
increased discrimination against non-targeted mRNAs (Herschlag, 1991; Bertrand et al. 
1994). 
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4. Factors affecting hammerhead ribozyme cleavage in vitro 
Forster and Symons (1987) defined a consensus sequence as the catalytic core of 
hammerhead ribozymes. Single base changes in each of the 14 conserved sites show 
some effect on catalytic efficiency (Ruffner et al., 1990). Mild to significant loss of 
catalytic activity can result from any change in the consensus sequence of the ribozyme 
catalytic core (Ruffner et al., 1990). 
Magnesium is needed to stabilize the 5'-oxygen leaving group (Taira et al., 1990) 
probably due to its ability to stabilize the tertiary structure of the hammerhead complex. 
Spermidine has been found to lower the concentration of magnesium required for 
hammerhead ribozyme cleavage, suggesting that spermidine can replace magnesium in 
stabilizing the active ribozyme structure (Dahm et al., 1991). 
5. Potential therapeutic applications of hammerhead ribozymes 
Ribozymes can target specific RNA molecules and each molecule has the potential to 
cleave multiple copies of a given RNA. The hammerhead ribozyme is one of the smallest 
ribozymes known and can have great potential in gene therapy. The effects of 
hammerhead ribozymes have been shown to be due to catalytic activity rather than to a 
simple antisense effect. 
Traditional pharmaceuticals inhibit protein function. However, ribozymes either 
disrupt the flow of genetic information from DNA to protein or may even directly disrupt 
RNA genomes, as in the case of RNA viruses. Diseases that result from undesirable 
16 
expression of RNA, such as neoplastic disorders and viral illnesses, are amenable to such 
a therapeutic approach. Hammerhead ribozymes have been studied as a therapeutic agent 
for many viral infections as well as malignancies and genetic diseases. 
Rossi and colleagues described the first use of a hammerhead ribozyme to inhibit 
HIV-1 replication in tissue culture cells (Sarver et al., 1990). In this study, a ribozyme 
targeting the gag sequence was stably expressed in HeLa-CD4+ cells and the p24 levels 
were reduced compared with the non-ribozyme expressing cells upon infection with HIV. 
Hammerhead ribozymes developed against the HIV-1 tat and tat/rev genes (Zhou et al., 
1994) have been in clinical trials for several years. There have been reports of 
hammerhead ribozymes targeting other HIV genes including vif(Lorentzen et al., 1991), 
int (integrase) (Sioud et al., 1991) and the 5' UTR leader sequences (Weerasinghe et al., 
1991). Each of these ribozymes resulted in delays or reduction in virus expression. 
Hammerhead ribozymes can be used for other viral infections such as the chronic 
management of chronic hepatitis B (HBV) infections en et aL, 1999; Kim et al., 1999; 
Hsieh and Taylor, 1992; Netter et al., 1993). 
Since ribozymes can distinguish RNA transcripts that differ from the wild-type 
transcripts by only one nucleotide, they can be designed to eliminate mutated transcripts 
while leaving wild-type transcripts intact. One example is the mutant H-ras gene 
implicated in bladder carcinoma targeted by a hammerhead ribozyme (Tone et al., 1993; 
Kashani et al., 1992). Another example is the bcr-abl transcript caused by the 49;22) 
translocation in chronic myelogenous leukemia (CML) (Wright etal., 1993; Shore et al., 
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1993). Other potential targets for ribozyme-based cancer therapeutics include the MDR-1 
(multidrug resistance gene) transcripts, topoisomerase a, methylguanine 
methyltransferase, dihydrofolate reductase, bc1-2, bc1-x and certain cytokines such as 
interleukin 6 and 9. 
6. Problems that underlie successful ribozyme applications 
Development in the following areas are prerequisites for successful ribozyme-based 
strategies: 1) persistent high-level expression in transduced cells; 2) targeting of the 
ribozyme into the correct subcellular compartment and colocalization of the ribozyme 
with its substrate; and 3) appropriate folding of the ribozyme for catalytic activity; and, 4) 
stable intracellular maintenance of the ribozyme. 
C. Promoters for expressing ribozymes 
1. RNA polymerase II promoters 
Hammerhead ribozymes can be expressed by insertion under transcriptional control 
of RNA polymerase II promoters (Pol. II promoters), that may be of viral origin, a 
retroviral long terminal repeat, or a strong endogenous promoter. Ribozymes can be 
inserted into the untranslated regions of genes transcribed by RNA polymerase II which 
have strong promoters, such as the SV 40 early promoter (Cameron et al., 1989), the 
CMV 1E-1 promoter (Mahieu et al., 1994), a retroviral long terminal repeat (Koizumi et 
al., 1992) and the 13-actin gene promoters (Sarver et al., 1990). A polyadenylation signal 
needs to be added to the 3' end of the gene to enable transcription termination and the 
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addition of the poly(A) tail. The poly(A) tail, together with the m7G cap, can increase the 
stability of the transcripts and facilitate the transport of the transcripts to the cytoplasm. 
However, the RNA polymerase II promoter is generally not suitable for production of 
short RNAs (Sanfacon et al., 1990). Extra sequences need to be added to both ends of the 
hammerhead ribozymes and several hundred nucleotides between the promoter and the 
terminator are needed to ensure effective transcription and termination at the correct sites. 
However, the extra sequences may have undesirable effects on cleavage activity 
(Chowrira et al., 1994; Cameron and Jennings, 1989). Expression of the ribozymes under 
the RNA polymerase II promoter does have the advantage of the availability of tissue-
specific as well as regulatable promoters. When ribozyme expression is desired only in 
certain tissues or when expression needs to be turned on or off within a given tissue, 
RNA polymerase II promoters are the promoters of choice. 
2. RNA polymerase HI promoters 
RNA polymerase III promoters (Poi III promoters) direct transcription of a variety of 
small nuclear and cytoplasmic RNAs that are abundant in all cell types. RNA polymerase 
III promoters have been widely used to express short RNA molecules, including 
antisense sequences, ribozymes and RNA decoys. The promoters used include the human 
snRNA U6 gene promoter, adenovirus-associated RNA 1 (Ad VA1) gene promoter, as 
well as tRNA (mainly tRNAmet and tRNAval) promoters. Advantages of Poi III promoters 
over Poll! promoters include: 1) RNA Poi III transcribed transcripts are more abundant 
than poly(A r RNAs transcribed from Poll! promoters (Palmer et al., 1990); 2) RNA Poi 
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III-transcribed genes can be ubiquitously expressed; and 3) Pol III transcripts are short, 
thereby minimizing the possibility that the ribozyme activity may be masked in a long 
transcript. 
D. The processing of tRNAs 
Transfer RNAs are small (about 76 nucleotides) molecules that possess a cloverleaf 
secondary structure and maintain a compact tertiary L-shaped structure. They are 
transcribed as larger precursors with redundant 5' end leaders and 3' end trailers and 
must be processed through a series of steps by different enzymes to yield the mature 
tRNAs. These processing pathways, which differ in different systems, include 5' and 3' 
removal of extra sequences, the addition of CCA to the 3' end, nucleotide modifications 
at specific residues, and in some tRNA gene transcripts, splicing of intervening 
sequences (Deutscher, 1984; Westaway and Abelson, 1995). 
1. 5' processing of tRNAs 
Ribonuclease P (RNase P) is the endonuclease required for generating the mature 
tRNA 5'-end. Because of its role in the biosynthesis of tRNA, it is an essential enzyme 
for cell growth. This enzyme is present in representatives of all three domains of life 
(Archaea, Bacteria and Eucarya) as well as in mitochondria and chloroplasts. RNase P 
cleaves precursor tRNAs (pre-tRNAs) specifically by phosphodiester hydrolysis. The 
cleavage is endonucleolytic and the products of pre-tRNA cleavage retain 3' OH and 5' 
phosphate groups (Guerrier-Takada, 1983). Divalent metal ions (preferably Mg2+) are 
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absolutely required for activity. Cellular RNase Ps are complex enzymes composed of 
essential RNA and protein submits (Darr et cd., 1990). The structural and functional 
organization of RNase P differs significantly across phylogenetic domains. The RNA 
component of bacterial RNase P is catalytically active in the absence of the protein 
subunit and is considered to be a ribozyme. in the case of nonbacterial RNase P, 
ribozyme activity has not been demonstrated although the RNA component is essential 
for catalytic activity (Frank and Pace, 1998). 
There are about 60 precursor tRNA substrates for RNase P. Nevertheless, there is no 
sequence homology around the cleavage site in any of these. In the case of one precursor 
tRNA isolated, RNase P was found to cut at the 5' side of the first nucleotide of the 
tRNA domain and the upstream sequences were released. in other natural RNase P 
substrates in E. coli, such as 4.5 S RNA or 10S RNA, RNase P cuts at completely 
different sequences, but at similar sites in the proposed secondary structures (Altman, 
1995). 
2. 3' processing of tRNAs 
The 3' trailer of mammalian pre-tRNA is removed by the 3' processing 
endoribonuclease (3' tRNase) which cleaves the RNA immediately downstream of the 
discriminator nucleotide (which is the unpaired nucleotide 3' of the last base pair of the 
aminoacyl acceptor stem) onto which CCA residues are added to produce mature tRNAs. 
The CCA sequence is required for aminoacylation. 
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In prokaryotes, the 3' trailers of tRNAs are removed by a redundant family of 3'-
exonucleases (reviewed by Deutscher, 1995). The CCA sequence is transcriptionally 
encoded. The 3"-exonucleases which remove the 3'-trailer can produce a mature tRNA 
that is ready for aminoacylation. The CCA-adding enzyme, tRNA nucleotidyl transferase 
(tNtase), is also present in prokaryotes. However, it is not required for viability but rather 
principally performs a repair function in prokaryotes (Deutscher, 1995). 
In eukaryotes, precursor tRNAs are subject to 5' and 3' processing in the nucleus (Figure 
6). The 3' processing endoribonuclease (3'-tRNase) is responsible for trimming the 3' 
trailer. 3'-tRNase can endonucleotically rempve the 3' trailer by cleaving at the 3' side of 
the discriminator base (Solari & Deuscher, 1983; Castel° et al., 1985; Frendewey et al., 
1985). 3'-exonuclease may sometimes be involved (Furter et aL, 1992; Yoo & Wollin, 
1997). In addition, the CCA-adding enzyme, tRNA nucleotidyl transferase (tNtase), is 
essential for eukaryotic viability because the CCA sequence is not transcriptionally 
encoded in eukaryotic tRNA genes (Sprinzi et al., 1998). CCA must he added by the 
tNtase. 
It was established that mature tRNA (tRNA-Y+ CCA) is not a YARNase substrate 
(Nashimoto, 1997; Nashimoto et al., 1999). The 3"-tRNase is also extremely poorly 
inhibited by tRNA+CCA, ensuring that the 3'-tRNase can remain free to process 
precursor tRNAs with Yend trailers and tRNAs can progress to aminoacylation. The 
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Figure 6. Substrate and products in the eukaryotic tRNA end-processing pathway. 
A: Precursor Drosophila tRNAHis has a 16-nt 5' end leader and a 36-nt 3'end 
trailer. B: The 5' end leader has been catalytically removed by RNAse P, producing 
the 3'-tRNase substrate. C. The 3' end trailer has been endonucleotically removed 
by 3'-tRNase, producing the tNtase substrate. D: tNtase has added CCA to the 3' 
end of substrate tRNA, using CTP an ATP as additional substrates (adapted from 
Mohan et al., 1999). 
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active site of 3'-tRNase was postulated to have evolved to make an especially poor fit 
with tRNA+CCA (Mohan et cd., 1999; Nashimoto, 1995). 
E. The transport of tRNAs 
Despite the short sequence of tRNAs, the biogenesis of functional and mature tRNAs 
is amazingly complicated. In addition to removal of the 5' leader and 3' trailer sequences 
and CCA addition, the tRNA molecules also undergo a complex set of base modifications 
by a series of enzymes that recognize specific features of tRNA structure. A subset of 
pre-tRNAs also contain intervening sequences (introns) and these have to be removed by 
a dedicated set of tRNA splicing enzymes. The processed tRNAs then must be exported 
from the nucleus to the cytoplasm and must be aminoacylated before they can participate 
in protein synthesis (see chapters in Soll et al., 1995 for reviews) 
Transport of protein and RNA molecules through the nuclear pore has recently shown 
to be mediated by energy dependent receptors that are saturable and recognize 
specific signals on the various cargo molecules (reviewed in Izaurralde and Adam, 1998; 
Mattaj and Englmeier, 1998; Weis, 1998). The receptors are recycled to initiate 
additional rounds of transport after the cargoes are delivered. All nuclear import and 
export receptors thus far identified fall into the importin f3 superfamily and bind to the 
GTPase Ran (Fomerod et al., 1997; Gorlich et al., 1997), regardless of the differences in 
the transported substrates. The substrate associates with the receptor on one side of the 
nuclear pore envelope and dissociates on the other. The GTPase Ran imparts 
directionality of either the import or the export process by acting as a molecular switch 
for receptor-cargo interaction (see below for more details of exportin-t receptor). 
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Export of tRNAs to the cytoplasm is no exception. Mature tRNAs were recently 
found to be recognized by a specialized receptor called exportin-t. This receptor has been 
identified as the receptor responsible for mediating the export of tRNAs from nucleus to 
the cytoplasm (Arts et al., 1998a, Kutay et al., 1998). Exportin-t was found to shuttle 
rapidly between the nucleus and cytoplasm and binds tRNA in a RanGTP-dependent 
manner. Ran binds GTP but the GTP-bound form can change to a GDP form by GTP 
hydrolysis and nucleotide exchange. This is catalyzed by the GTPase activating protein 
RanGAP1 that is only present in the cytoplasm. Thus, RanGTP is depleted from the 
cytoplasm. In the nucleus, RanGTP is generated by the nucleotide exchange factor 
RCC1. Therefore, RanGTP is thought to exist in higher concentration in the nucleus than 
in the cytoplasm. This gradient leads to loading of tRNA in the nucleus and, after passing 
through the nuclear pore complex, unloading in the cytoplasm. The correct tRNA shape 
and the TivC loop were recently reported to be critical for exportin-t binding (Lipowsky 
et al., 1999; Arts et al., 199814 For reviews on tRNA export, see Simos and Hurt, 1999 
and Wolin and Matera, 1999. 
F. Goals, hypothesis, and objectives 
Various tRNAs are used by different retroviruses as primers for initiating reverse 
transcription (Table 1). The primer employed by HIV is host tRNALYs3. The primer 
tRNALYs3 can be recruited from the host cell cytoplasm and become encapsidated during 
packaging of HIV virions. This recruitment process has been shown to be mediated by 
interaction of tRNALYs3 with the reverse transcriptase (RT) sequence in the precursor 
polyprotein Pr160Gag-P°1 (Mak et al., 1994). 
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Work in this laboratory (Sarver et al., 1990; Taylor et aL, 1991 and 1992; Bertrand et 
al., 1994; Zhou et al., 1994 and 1996; Westaway 1995 and 1998; see Rossi, 1999 for 
review) and other laboratories (Lorentzen et aL, 1991; Sioud et al., 1991; Weerasinghe et 
al., 1991) showed that ribozymes targeting different sequences of HIV can inhibit the 
infection of tissue cultured cells by HIV (see more details in section B Hammerhead 
ribozymes) of this chapter). 
Since tRNA can be used to express ribozymes and is packaged into HIV virions 
during encapsidation, we hypothesized that a ribozyme sequence could be inserted 
downstream of the tRNALYs3 gene and used for inhibition of HIV replication. We 
therefore designed the ribozyme to target immediately upstream of the primer binding 
site (PBS) of HIV-1. The expression of such a construct inside cells would give rise to 
chimeric tRNALYs3-ribozyme transcripts. Computer RNA folding predicted that the 
chimeric transcripts could maintain their native tRNA structure. Thus we hypothesized 
that chimeric transcripts would be capable of interacting with the precursor of RT, the 
Pr160Gag- mpolyprotein, and become packaged into virions. The tRNA moiety in such a 
construct is expected to function both as an expression cassette as well as a carrier for 
bringing the ribozyme into virions. If the chimeric tRNALYs3-ribozymes are expressed at 
sufficient levels, they would also function as decoys of the natural primer tRNALYs3 and 
competitively bind to the RT sequence of Pr160Gag- Pol during packaging, thereby reducing 
the copy number of tRNALYs3 packaged. 
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To test the above strategy, several problems had to be addressed, some of which were 
experimentally examined before I came into the laboratory. These problems were: 
1. Are transcripts from the chimeric tRNALYs3-ribozyme construct capable of binding 
reverse transcriptase, the presumed prerequisite for the chimera to be packaged into 
HIV virions? Computer RNA folding modeling suggested a positive answer. 
Chimeric tRNALYs3-ribozyme with a G deletion in the TwC stem can bind to the RT 
with an affinity similar to that of wild type tRNALYs3 (Westaway et al., 1995). 
2. Is the construct effective in inhibiting HIV? Chimeric tRNALYs3-ribozyme with a 
deletion of one G in the TwC stem was demonstrated to be effective in reducing the 
infectivity of a viral stock that was produced from transiently transfected cells bearing 
the chimeric gene (Westaway et al., 1995). Ribozyme with one G deleted was also 
able to be exported into the cytoplasm, a prerequisite also for the ribozyme to get 
packaged into the virions and inhibit HIV. 
To help achieve the laboratory's goal of an effective chimeric tRNALYs3-ribozyme 
approach for therapeutic treatment of HIV infection, I identified the following objectives 
for my research. 
1. To establish the encapsidation and packaging of the chimeric tRNALYs3-ribozymes. 
2. To enhance the expression of the chimeric transcripts by using dual RNA polymerase 
III promoters: human U6 small nuclear RNA gene promoter (extragenic) and tRNA 
intragenic promoter (intragenic) and test the feasibility of using hybrid promoters by 
quantitatively analyzing the expression. The level of expression from such a system is 
• hard to predict because there may be steric hindrance between transcription factors 
bound to the different promoter elements. The expression level may be higher, the 
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same or even lower than expression from tRNA promoter alone. The initiation of 
transcripts may change due to the steric hindrance. 
3. To establish enhanced HIV inhibition by the hybrid U6/tRNA promoter expression 
cassette if the level of expression is increased. 
4. To determine the intracellular localization of transcripts made from the chimeric 
tRNALYs3-ribozymes under the tRNA promoter alone and under the dual promoters. 
5. To determine the stability of the transcripts in transient and stable expression systems. 
6. To express the chimeric tRNALYs3-ribozymes in stable cell lines either by transfection 
or transduction of ribozymes cloned into AAV vectors. 
7. To compare active with inactive ribozymes to establish the benefit of ribozyme versus 
antisense effects in HIV inhibition. 
8. To compare transcription from constructs with a wild type versus a mutant B box in 
the tRNA gene. 
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II. MATERIALS AND METHODS 
A. Materials 
1. Cells 
Human embryonic kidney 293 cells were obtained from the American Type Culture 
Collection (Rockville, MD). 
2. Reagents 
Fetal calf serum was purchased from Irvine Scientific, Inc., (Irvine, CA). G418 was 
obtained from GIBCO/BRL-Life Technologies, Inc. (Gaithersburg, MD). MEGAscriptTM 
Kit and T7-MEGA ShortScript Kit were purchased from Anibion Inc. (Austin, TX). 
Oligonucleotides were synthesized by the DNA Core Facility of the Center for Molecular 
Biology and Gene Therapy of Loma Linda University (Loma Linda, CA) or 
DNA/Peptide Core Facility of the City of Hope Medical Center (Duarte, CA). 
3. Solutions 
Deionized formamide:  Formamide was melted at room temperature and 50m1 was 
deionized with 5 g AG 501 X 8 resin (BioRad) by stirring for 30 min at room 
temperature. The solution was filtered twice with Whatman #1 paper, aliquoted and 
stored at —20°C. 
Denhardt's 50 X stock: 1% Ficoll, 1% polyvinylpyrrolidone, 1% bovine serum albumin. 
The solution was then filtered through a disposable 0.22 micro Nalgene filter. 
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10 X MOPS: 0.2 M 3-(N-morpholino) propanesulfonic acid, 5mM sodium acetate, 5 m1VI 
EDTA, pH 7.0. 
DEPC water: 0.1% diethyl-pyrocarbonate was added to double-distilled water overnight. 
The treated water was then autoclaved. 
RNA loading buffer: 80% (vol/vol) formamide, 1 mM EDTA, pH 8.0, 0.1% 
bromophenol blue, 0.1% xylene cyanol. 
20 X SSPE: 3.6 M NaC1, 0.03 M NaH2PO4, 0.02 M EDTA, pH 7.4. 
20 X SSC: 3.0 M NaC1 and 3.0 M sodium citrate, pH 7.0. 
10 X TBE:  0.4 M Tris-HCI, pH 8.0, 0.4 M boric acid and 0.012 M EDTA, pH 8.3 
TE buffer: 0.01 M NaOH, 0.01 M Tris-HC1, pH 8.0, 1 mAil EDTA and 0.1% SDS  
TBE loading buffer:  20% glycerol, 80% 10XTBE, 0.4% bromophenol blue and 0.4% 
xylene cyanol. 
4. Miscellaneous Materials 
The dNTF's and NTPs were purchased from Phamiacia (Piscataway, NJ). QIAprep 
Miniprep Kit, QIAprep Maxiprep Kit, QIAquick Gel Extraction Kit, QTAquick PCR 
Purification Kit and QIAquick Nucleotide Removal Kit were purchased from Qiagen Inc. 
(Chatsworth, CA). The pBluesciptIISIC(+) plasmid was purchased from Stratagene (San 
Diego, CA). Plasmids pTZU6+1 and pAAVU6+1 were constructed by Edourad Bertrand 
(Bertrand et al., 1997). 
30 
B. Methods 
1. Restriction enzyme digestion 
Plasmid DNA or PCR products were digested with restriction enzymes from New 
England Biolabs (Beverly, MA) or Boehringer Mannheim Corporation (Indianapolis, 
IN). Appropriate amount of DNA in 20 to 50 ti volumes was incubated with 1 to 5 U 
enzyme/11g DNA at 37°C or at the manufacturer's suggested temperature for I to 4 h. 
After digestion, the reaction mixture was analyzed by agarose gel electrophoresis. 
2. Ligation of DNA 
T4 DNA ligase (New England Biolabs) was used for ligation. Approximately 400 ng 
of total DNA was used in 10 to 20 pi reaction volumes with vector-to-insert ratios 
between 1:2 to 1:5. Ligation reactions were incubated at 16°C for at least 15 h. 
3. Preparation of competent cells and transformation (DMSO/PEG method of Cung 
and Miller, 1988) 
Preparation of competent cells: Bacteria were grown to the early log phase (0D600 of 
0.3-0.6) in LB broth or terrific broth and then collected by centrifugation at 1000 X g for 
10 min at 4°C. Bacteria were resuspend in 1/10 volume of transformation and storage 
buffer (TBS) in LB broth pH 6.1 [10% PEG (MW 3350), 5% DMSO, lOmM MgCl2 and 
10mM MgSO4, filter sterilized (0.22 micron), stored at 4°C]. Bacteria were then 
incubated on ice for 10 min and frozen in prechilled tubes at —70°C for later use. 
To clone the chimeric tRNALYs3-ribozymes into the AAVU6+1 vectors. I used 
commercially available Max Efficiency Stb12 Competent Cells from Life Technologies. 
31 
Plasmids with repeat sequences may not be stable in regular bacterial strains. This 
bacterial strain has the potential to stabilize certain plasmids. AAV vectors have two 
inverted terminal repeats (ITRs) and could remain more stable in this strain. 
Bacterial transformation: One hundred microliters of competent cells were incubated 
with 100 pg of DNA for 5-30 min at 4°C. Then 0.5-0.9 ml of SOC medium was added 
and the cells were incubated at 37°C in a shaker for 60 min. Cells were plated on 
antibiotic plates and incubated at 37°C. (Expected transformation efficiency: 2X108 
transformants/microgram of DNA.) 
4. Frozen bacterial of stocks 
In screw cap tubes, 930 gl rich-grown culture (16-18 h of culture) were mixed with 
70 IA of DMSO. After mixing, the tubes were transferred to dry ice for 10 to 20 min, then 
stored at —70°C. 
5. Plasmid preparation 
When plasmid preparations were used for identifying clones with the correct inserts, 
minipreps of plasmids were prepared with the QIAprep Miniprep Kit (Qiagen). When 
plasmid preparations were used for transfections, maxipreps were prepared with the 
Qiagen Plasmid Maxi Kit. Minipreps and Maxipreps were done according to the 
manufacturer's instructions. 
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6. Agarose gel electrophoresis of DNA 
DNA samples of appropriate quantity were mixed with 1/6 volume of 6X sample 
loading buffer. 0.8-2% (wt/vol.) agarose was dissolved in TE buffer. For visualizing 
smaller fragments (100-200 bp, such as the chimeric tRNALYs3-ribozymes), 2% agarose 
gels were usually used. For bigger fragments, 1% agarose gels were usually used. The 
DNA samples were loaded in wells and current was applied (approximately 90-100 V for 
30-45 min). Thereafter, gels were removed from the electrophoresis apparatus (BioRad) 
and incubated in TE buffer containing ethidium bromide (0.5 rig,/m1 final concentration) 
for 15 min. DNA bands were observed and analyzed using an ultraviolet transilluminator 
or an AlphalmagerTM 2000 system (Alpha Innotech Corporation). 
7. Denaturing acrylamide gel 
For most applications related with the chimeric tRNALYs3-ribozymes, a 6% denaturing 
acrylamide gel was used. For a total volume of 60 ml gel, add together 25.2 g urea, 9 ml 
of 38% acrylamide/2% bisacrylamide, 6 ml of 10 X TBE and 24 ml of water. 
For a minigel, 5-7 ml of gel solution was normally used. The gel was polymerized 
with 8 ill of TEMED and 40111 of 10% ammonium persulfate. The samples were 
electrophoresed at about 200 volts for about 20 min. 
For a medium-sized gel, 30 ml of gel solution was used. The gel was polymerized 
with 30 il of TEMED and 144 ill of ammonium persulfate. After a prerun, the gel was 
loaded with samples and run at 25 mA for 1 to 2 In. 
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8. Native (non-denaturing) acrylamide gel 
Thirty milliliters of 4% 60:1 acrylamide native (non-denaturing) gel was prepared as 
follows.: 4 ml 30% 60:1 acrylamideibisacrylamide, 0.75 ml 10 X TBE, 3 ml 50 % 
glycerol were mixed together with water to a total volume of 30 ml. Then 30 pi TEMED 
and 144 Ill 10 ammonium persulfate were added to catalyze gel formation. The gel was 
electrophoresed at 4°C at 250 V for about 3 hr for this medium sized gel. 
9. Radioactive oligonucleotide probe labeling 
Oligonucleotides were diluted to 5 pmo141,1. A 10 ill reaction was setup as follows: 2 
tl (10 pmol) of oligonucleotide, 1 ill 10X T4 PNK buffer, 6 jil of water, 0.5 ill of [7-32P 
ATP] and 0.5 pa of T4 PNK kinase were mixed. The reaction were then incubated at 
37°C for 30 min. Then the kinase were heat inactivated at 90°C for 2 min. The tube was 
placed on ice and 10 ill water was added to a final concentration of 0.5 prnoWl. 
10. Primer extension 
1) Oligonucleotide primer was labeled as described in method 9 (above). 
2) Annealing (hybridization): 1111 (0.5 pmol) of 32P-labeled primer was mixed with• 
5-50 lag of total RNA as follows: 1 gl labeled oligo, 111,1 RNA, 6 ttl water and 3 
p.! 5X AMV RT buffer. After the mixture was heated to 80°C for 3 min, it was 
cooled to 37°C over a 90 min period. 
3) Primer extension: To the ii p.1 annealing mixture, 3 Ill 5X dNTP mix (5x dNTP 
solution: 2mM each dNTP in water) was added. Then1 pa of AMV RT was added 
and the reaction was incubated at 37°C for 30 min. At the end, an equal volume of 
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sample loading buffer was added and the reaction was then heated to 90°C for 2 
min and chilled on ice. The reaction was then analyzed in a denaturing acrylamide 
gel (load about 4-5 pa sample per lane). 
11. In vitro transcription 
In vitro transcription was carried out with MEGAscript, MEGAshortscript or 
MAXIscript kits (Ambion) according to the manufacturer's instructions. Alternatively, in 
vitro transcription was carried out as follows. An appropriate amount of DNA template 
was used (about 1 jig for a 3-4 kb plasmid). A 20 pa reaction was prepared from an 
appropriate volume of DNA template, 2 jii lox NEB RNA polymerase buffer, 1 jil of 
NTP mix (10 mM each of ATP, CTP and GTP, 0.5 mM final concentration), 1 jfl of 1 
mM UTP (0.05 mM final concentration), 1 pi of 32P-UTP and I pi of T7 or T3 RNA 
polymerase (NEB, 50 u4t1) and water to make the total volume 20 jil. The reaction was 
incubated at 37°C for 2 hr. 
12. In vitro transcription for preparing radioactive RNA transcripts 
1) Preparation: Linearize DNA with a restriction enzyme downstream of the desired 
transcripts. MEGAscript kit (Ambion) may be used for this purpose. Make a 
'transcription mix' with enough volume for number of reactions desired. Mix 2 jil each of 
ATP, CTP, GTP, and 10X transcription buffer for each reaction planned. Add 1/8 vol. 
(0.25 1.1,1) of UTP (1/8 of 2 ill times number of reactions planed). Dispense 8.25 ill into 
each reaction tube. 
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2) In vitro transcription: Into 8.25 pi of the 'transcription mix', add 1 pg of linearized 
plasmid, 2 pi of [a 32N-UTP (3000 Ci/mmol), 2 gl of the Enzyme mix of T7 or T3 
MEGAscript kit (Arnbion) or appropriate amount of T7 or T3 polymerase and add water 
to a final volume of 20 p.1. incubate at 37°C for 2- 2.5 hr. Add 1 g1 of DNase I; incubate 
at 37°C for 15 min. 
3). Purification: Separate the in vitro transcribed RNA with free nucleotides in a 6% 
denaturing acrylamide gel. Expose the gel for 5 min on an X ray film to determine the 
position of the desired transcripts. Cut out the corresponding gel piece and crush into 
very fine pieces on a clean Petri dish. Elute the gel pieces overnight in 350 pl of elution 
buffer (0.5M NE140Ac, 1m114 EDTA, 0.1% SDS) at 25-37°C. Pour the eluted contents 
into Costar Spin-X centrifuge filter unit. Centrifuge for 3 min at maximum speed using a 
microcentrifuge. Add 1 pi of glycogen (Boehringer), 1/10 volume 3M NaAc and 2.5 
volume ethanol to the supernatant. Centrifuge and wash the pellet with 70% ethanol. 
Resuspend in 20 p.1 RNase free water or TE buffer. Measure an aliquot for cpm and OD 
to estimate the specific activity and concentration of the transcripts. 
13. Chimeric tRNALYs3-ribozyme-RT binding assay 
In vitro transcribed chimeric tRNALYs3-ribozyme transcripts from WW and MW were 
transcribed and labeled with 32P-UTP as described above. Radioactive labeled transcripts 
from tRNALYs3 and tRNAval were obtained in the same way and used as controls. The 
molar concentrations of the transcripts were calculated for HIV RT (NIH Research 
Reagents Repository) and for these transcripts. The activity of the HIV RT was tested in 
a primer extension assay. The binding was carried out at the following condition: 20mNI 
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Tris-HC1, pH 7.5, 50 rnM NaCi, 0.1 rn EDTA, 5% glycerol. A 5X binding buffer was 
prepared. The binding reactions were carried out as follows: 5X binding buffer 2 Ill, 
RNAse inhibitor (Boehringer Mannheim) 0.5111, RNA transcripts 0.4 pmol - 2pmol 
(about 7000 cpm) and HIV RT 2 pmol were added together. The binding reactions were 
left at room temperature for 1 hour. The binding reactions were separated in a 4%, 60:1 
acrylamide native (non-denaturing) gel, as previously described. The gel was then dried, 
subjected to autoradiography at -80°C and then analyzed. 
14. Preparation of radioactive labeled size markers 
(according to Shawn Westaway, personal communication) 
Plasmid DNAs with known sizes were digested with restriction enzymes (an example 
is pBSSK± digested with Hpa II). To 1 jig of precut markers or commercially available 
DNA ladders, 2 ill of 10X Klenow buffer (minus DTT), 2 jil of 0.1 M DTT, I jil Klenow 
(Boehringer Mannheim, 2 U/m1) and 1 ill [a-32P] dCTP at 10 	were added. Then 
water was added to a total volume of 20 jil. The reaction was incubated at 37°C for 45 
min. The markers were purified by phenol extraction and ethanol precipitation, then 
dissolved in 40 jil water. The radioactivity of a I ill sample was determined (cpm should 
be 500,000 to 1,000,000 cpm per ill). The samples were diluted 10-fold to 50,000 to 
100,000 cpmilal and 1 —5 jii per lane were loaded onto the appropriate gel system. 
15. PCR (polymerase chain reaction) 
In a 50 ill reaction, add appropriate amount of template DNA, 5 jil of 10 X PCR 
buffer, 5 Ill of 2.5 mM dNTPs, 50 pmol each of 5' and 3' primer and then add water to a 
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final volume of 49 Add 50 ill mineral oil on top and preheat the samples to 94°C and 
add 1 1.11 Taq polymerase. The PCR reactions were carried out at 94°C, 40°C and 72°C for 
30 cycles and an additional extension was usually performed for 10 min at 72°C. 
16. RT-PCR 
When total RNA from transiently transfected cells were used, the following 
procedure was followed. Total RNA was diluted and 0.1 pg total RNA was used as 
template. In a 50 IA reaction, 15 or 30 pmol of 5' and 3' primers, 5 p110 X PCR buffer, 8 
IA of dNTP mix (1.25 mM each of dATP, dGTP, dCTP and dTTP; 0.25 mM final 
concentration) were added. Then an add appropriate amount of water was added to make 
the total volume to 49 p1. Heat sample to 90°C and let cool to room temperature over a 10 
to 15 min period (some primers may give better result with a slower cooling). Also a 
quick (1 to 3 min) cooling may be sufficient. Put all samples on ice and add 1 p1(1 U/R1 
or 2 U/pd) AMV RT (For each sample, one control reaction without adding RT is 
necessary to rule out amplification from contaminating DNA templates). Transfer all 
tubes to a 37°C (37°C to 55°C) water bath and incubate 3 to 5 min. Then transfer to 95°C, 
incubate 5 min. Put back on ice and add 1 ill Tag. The PCR reactions were carried out at 
94°C, 51°C and 72°C for 30 cycles and analyzed the products on an agarose gel. 
17. Design and construction of chimeric tRNALYs3-ribozymes 
The original DNA fragments used for cloning into pffluescript were synthesized from 
annealing of several oligonucleotides and amplification by a PCR. The sequence of the 
DNA fragments for making the original clones is shown in Figure 1, with mutations 
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5' -AC GCG TCG ACG CCC GGA TAG CTC AGT CGG 
3' -TG CGC AGC TGC GGG CCT ATC GAG TCA GCC 
Sail 
TAG AGC ATC AGA CTT TTA ATC TGA GGG TCC 
ATC TCG TAG TCT GAA AAT TAG ACT CCC AGG 
(Mutant B box) 
C A 
	
boundary of tRNALYs3 and ribozyme 
AGG GTT CAA GTC CCT GTT CGG GCG CCA CTG 






CTA GAC TGA TGA GTC CGT GAG GAC GAA ATT 
GAT CTG ACT ACT CAG GCA CTC CTG CTT TAA 
+ 
TGC CAT TTT TCC GCG GAA TTC CG- 3' 
ACG GTA AAA AGG CGC CTT AAG GC- 5 
EcoRI 
Figure 1. Sequence of the DNA fragments obtained by the PCR reactions used for 
cloning of the chimeric tRNALYs3-ribozyme constructs into the pBluescript. 
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indicated by arrows. The construction of the chimeric tRNALYs3-ribozymes was 
performed as follows. Gene fragments of the chimeric tRNA-ribozymes were synthesized 
by polymerase chain reactions (PCR) from oligonucleotides with Sal I and EcoRl 
restriction sites at the 5' and 3' ends, respectively. The following oligonucleotides were 
used (mutations introduced were shown in boldface letters): 
(A) 5'-GTCTGATGCTCTACCGACTGAGCTATCCGGGCGTCGAC- 3' 
(B) 5'-GTAGAGCATCAGACTTTTAATCTGAGGGTCCAGGGTTC- 3' 
(C) 5'-GTAGAGCATCAGACTTTTAATCTGAGGGTCCAGGCTAC- 3' 
(D) 5'-GCGCCCGAACAGGGACTTGAACCCTGGACCCT- 3' 
(E) 5'-GCGCCCGAACAGGGACTTGTAGCCTGGACCCT- 3' 
(F) 5'-CCCTGTTCGGGCGCCACTGCTAGACTGATGAGTCCGTGAGG- 3' 
(G) 5'-CGGAATTCCGCGGAAAAATGGCAAATTTCGTCCTCACGGACTCAT- 3' 
(H) 5'-CGGAATICCGCGGAAAAATGGCAAATTTTGIVCIVACGGACTCAT- 3' 
(I) 5'-ACGCGTCGACGCCCGGATAGCTCAGTCGG- 3' 
Four annealing and extension reactions were performed with 5 pmol each of the 
following oligonucleotides: A, B, D, F, G for wild type tRNALYs3-wild type ribozyme 
(WW), A, C, E, F, G for mutant tRNALYs3-wild type ribozyme (MW), A, B, D, F, H for 
wild type tRNALYs3-mutant ribozyme (WM) and A, C, E, F, H for mutant tRNALYs3-
mutant ribozyme (MM). The mixture was denatured at 94°C for 2 min, annealed at 40°C 
for 2 min and extended at 72°C for 10 min in the presence of 250 rnM dNTPs and 2 U 
Taq polymerase in lx Tag polymerase buffer (Boehringer). 
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Aliquots (50 from each of the extension reactions were used as templates for 
subsequent PCRs. Fifty picomoles of oligonucleotides I and G were used as the 5' and 3' 
primer for WW and MW, and oligonucleotides I and H for WM and MM. The PCRs 
were carried out for 30 cycles (94°C for 1 minute, 40°C for 1 minute and 72°C for 2 min) 
in the presence of 250 mM dNTP and 2 U Tag polymerase. The PCR products were 
purified with phenol/chloroform extraction, precipitated with ethanol in the presence of 
0.3 M sodium acetate, dissolved in TE buffer and analyzed on 2% agarose gel. PCR 
products were digested with Sail and Ecolti, and cloned into the same sites in 
pBluesciptSK (+) (Stratagene, La Jolla, CA) to create the plasmid pWW, pMW, pWM 
and pMM. pAGTRz is also a chimeric tRNA-ribozyme with a deletion of one G at the 
'PIT stem loop junction of tRNALYs3 (Figure 1), which was introduced fortuitously and 
was described previously (Westaway et aL, 1998; the plasmid was named pAGtRNALYs3-
ribozyme in this thesis). 
Plasmids pWW, pMW, pWM and pMM were digested with Sail and Pstl and 
tRNALYs3-ribozyme fragments were gel purified and ligated into the prEZU6+1 vector 
(Bertrand et al., 1997) between the Sail and Psti sites downstream of the U6+1 promoter, 
which contains the entire U6 promoter sequence plus one nucleotide of the U6 snRNA 
structural gene. These constructs represent the dual U6ARNA promoters series of 
plasmids pU6WW, pU6MMT, pU6WM and pU6MM. 
Plasmids pWW, pMW and pWM were digested with Sail and Spel and the tRNALYs3-
ribozyme fragments were gel-purified and ligated into the pAAV U6+1 vector (Bertrand 
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et al., 1997) between the Sail- and Spei sites downstream of the U6+1 promoter. These 
ligations created the plasmids pAAVU6WW, pAAVU6MW and pAAVU6WM. 
pU6AGTRz was constructed from pAAVU6AGTRz (Westaway et al., 1997; renamed 
pAAVU6+1AGtRNALYs3-rbz). pAAVU6AGTRz was digested with Sail and Xbal and the 
AGtRNALYs3-ribozyme fragment was gel-purified and ligated into the pTZU6+1 vector 
(Bertrand et al., 1997) between the Sall and Xbai sites downstream of the U6+1 
promoter. 
pU6Rz was constructed from the following two oligonucleotides: 
5' -ACGCGTCGACCTGCTAGACTGATGAGICCGTGAGGACGAA-3' 
5 ' -TGCGTCTAGACGCGGAAAAATGGCAAATTTCGTCCTCACG-3' 
These two oligonucleotides have 12 bases of complementarity at their 3' ends. These 
were annealed and amplified by the polymerease chain reaction (PCR) as described 
previously. The final PCR product was analyzed and purified with a Nucleotide Removal 
Kit (Qiagen), digested with Sall and Xbal and ligated into the Sall and Xbal sites of 
pTZU6+1 vector. 
18. Cell culture and transfections 
Human 293 cells were grown in DMEM medium supplemented with 10% fetal 
bovine serum, penicillin (100 units/m1), streptomycin (100 jig/ml), 2 mM L-glutamine, 
and .' mM sodium pyruvate. Cells were plated at 70% confluency in a 100 mm tissue 
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culture dish the day prior to transfection. The medium was changed 3 hr before 
transfection. Cells were transfected with the CellPhect Transfection Kit (Pharmacia) 
according to the manufacturer's instructions. 10 jig of chimeric ribozyme plasmids were 
cotransfected with 1 jig of pTKGH (human growth hormone hGH gene under the control 
of the HSV TK promoter). 48 hr later, the concentration of growth hormone in the 
supernatant was measured using the HGH-TGES 100T Kit (Nichols Institute 
Diagnostics) according to manufacturer's instructions in order to normalize transfection 
efficiencies (see below). Alternatively, 5 ILig of a plasmid expressing GFP (green 
fluorescent protein) was cotransfected for normalizing transfection efficiency. 
19. Use of hGH fusion genes as internal controls for normalizing transfection 
efficiency 
pTKGH plasmid was cotransfected with chimeric tRNA1 Ys3-ribozyme constructs in 
transfection experiments for normalizing transfection efficiency. 100 pi samples of 
culture media were taken before isolation of total RNA. The samples were assayed for 
growth hormone level using a HGH-TGES 100T Kit (Nichols institute Diagnostics). A 
standard curve was obtained from assay of standard reagents. The GH levels of unknown 
samples were obtained by comparison with the standard curve and the transfection 
efficiencies were normalized accordingly. The assay procedure and standard curve 
derivation were done according to manufacturer's instructions. 
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20. Total RNA extraction 
Total RNA from cultured cells was isolated and purified using RNA STAT-60 (TEL-
TEST "B", Inc.) according to manufacturer's instructions. The isolated RNA was 
subjected to DNase I treatment to remove the template DNA. 
21. Stable cell lines expressing chimeric tRNAL1s3-ribozymes 
Human embryonic kidney 293 cells were transfected with pAAVU6WW, 
pAAVU6MW or pAAVAGTRz. These constructs contain a neo gene expressing 
aminoglycoside phosphotrasferase and allowing selection with G418. After transfection, 
cells were allowed to grow under nonselective conditions and to double twice. The cells 
were diluted 1:15 into selective medium containing 800 jig/ml G418 (Mediatech, Inc., 
Herndon, VA). The cells were fed with fresh medium twice a week. Single colonies were 
picked and maintained in selective medium after 2 weeks. 
22. Frozen stocks of stable transformants 
Prepare freezing medium; complete medium supplemented with 10% to 20% (v/v) 
fetal bovine serum (FBS) and 5% to 10% (v/v) DMSO, 4°C. Harvest cells and wash with 
complete medium. Resuspend cells in 4 ml of 4°C freezing medium and place on ice. 
Count cells and dilute as necessary to get a final cell concentration of 	to 107 cells/mi. 
Pipet 1 ml aliquots of cell suspension into cryovials and place vials 1 hour to overnight at 
—70°C. Then transfer to liquid nitrogen. 
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23. Northern hybridization 
The following protocol was followed for Part C of Chapter III. 48 hr after 293 cells 
were transfected with chimeric tRNALYs3-ribozymes, total RNAs were isolated and 
purified using RNA STAT-60 (TEL-TEST "B", Inc.) according to manufacturer's 
instructions. The isolated RNAs were subjected to DNase I treatment, then 10 jig of total 
RNA and in vitro transcribed RNAs (as a size marker) were fractionated on a 6% 
acrylamide denaturing gel and transferred to a Flybondm-N+ nylon membrane 
(Amersham) by electroblotting. The RNA was then crosslinked to the membrane with a • 
Stratagene UV Stratalinker. The membrane was prehybridized in 6X SSPE, 7% SDS, 5X 
Denhardt's at 48°C for 3 hr. 10 pmol of oligonucleotide was labeled with ['y-3211ATP 
using T4 polynucleotide kinase(New England Biolabs). The probe was added to the 
prehybridization solution and hybridization was carried out overnight at 48°C. 
Membranes were washed and exposed to both Fuji X-ray film and a Phosphoimager 
screen and subsequently analyzed with ImageQuant Tools software (Molecular 
Dynamics). The first probe used was specific for tRNA and had the following sequence: 
TGGCGCCCGAACAGGGAC. After hybridizing with this probe, the same membrane 
was stripped in 200 ml 0.1X SSC, 0.5% SDS at 95°C and rehybridized under the same 
conditions with a ribozyme-specific probe: TGGCAAATTTCGTCCTCACGG. The 
membrane was stripped again and then probed with another probe specific for 
endogenous U6 snRNA which is used as an internal control. The quantitation of the 
signals obtained by the Phosphoimager was normalized with U6 snRNA to account for 
loading variation and with growth hormone concentration to account for transfection 
efficiency variation. 
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Alternatively (Part B of Chapter III), 10 jig of total RNA and in vitro transcribed 
RNA (as a size marker) were fractionated on a 1% formaldehyde-agarose gel and 
transferred to a HybondTm-N+  nylon membrane (Amersham) by the method of Sambrook 
(Sambrook et aL, 1989). The RNA was then crosslinked to the membrane with a 
Stratagene UV Stratalinker. The membrane was prehybridized in 6XSSPE, 7% SDS, 5X 
Denhardt's at 48°C for 3 hr. 10 pmol of oligonucleotides were labeled with 32P using T4 
polynucleotide kinase (New England Biolabs). The probes were added to the 
prehybridization solution and hybridization was carried out overnight at 48°C. 
Membranes were washed and exposed with both Fuji X ray film and a Phosphoimager 
screen and subsequently analyzed with ImageQuant Tools software (Molecular 
Dynamics). One probe used was a specific antisense sequence of the ribozyme 
TGGCAAATTTCGTCCTCACGG. After hybridizing with this probe, the same 
membrane was stripped in 200 ml 0.1X SSC, 0.5% SDS at 95°C and rehybridized under 
the same condition with another probe specific for the endogenous U6 snRNA which 
served as an internal control. The quantitation of the signals obtained by phosphoimager 
was normalized with U6 snRNA for loading variation and growth hormone concentration 
for transfection efficiency variation. 
24. Labeling of riboprobes for fluorescent in situ hybridization 
Templates for making DIG-labeled riboprobes were synthesized by polymerase chain 
reaction from two oligonucleotides. T7 and T3 promoter sequences are included at the 5' 
and 3' ends, respectively. The sequences of the templates for making the probes were as 
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follows: 1) ribozyme specific probe: 
TAATACGACTCACTATAGGGctgetagactgatgagtccgtgaggacgaaatttgccaCCCTTTAGT 
GAGGGTTAATT; 2) tRNALYs3 specific probe: 
TAATACGACTCACTATAGGGgcccggatag ctcagtcggt agagcatcag acttttaatc tgagggtcca 
gggttcaagt ccctgttcgg gcgccaCCCTTTAGTGAGGGTTAATT and 3) U6 snRNA specific 
probe: 
gtgctcgcttcggcageacatatactaaaattggaacgatacagagaagattagcatggccectgegcaaggatgacacgcaaa 
ttcgtgaag cgttccatatttttCCCTTMTGAGGGTTAATT. Promoter sequences are in 
uppercase and sequences of structural genes are in lowercase. Antisense and sense probes 
were prepared and labeled with digoxigenin-11-UTP by in vitro transcription using T3 
polymerase and T7 RNA polymerase, respectively. Transcription reactions were 
performed using the Genius 4 Kit (Boehringer). The DIG-labeled riboprobes from these 
transcriptions were purified and yields of probes were estimated according to 
manufacturer's instructions [The Genius 4 Kit was used in combination with DIG Wash 
and Block Buffer Set (Boehringer) as described in GeniusTM  System User's Guide For 
Membrane Hybridization (Boehringer)]. 
25. Fluorescent in situ hybridization (FISH) 
Cells were plated at 70% confluency on coverslips treated with 0.5% gelatin and after 
24 hr, transiently transfected with the constructs as described above. 48 hr later, the cover 
slips were treated with PBS containing 4% paraformaldehyde and 10% acetic acid for 10 
min at room temperature, washed with PBS twice and then permeabilized with 70% 
ethanol overnight at 4°C. Prior to hybridization, cells were rehydrated with 2 X SSC, 
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50% formamide for 5 min at room temperature. 25 ng of digoxigenin-labeled probes were 
mixed with 40 jig carrier tRNA in 20 [1,1 formamide and heated at 85°C for 1 min. The 
mixture was then added to 20 jii 2X hybidization solution (4X SSC, 20% dextran sulfate, 
0.02% RNase-free BSA and 2 mM vanadyl ribonucleoside complex). Hybridization was 
carried out at 37°C overnight and the coverslips were washed twice in 0.1X SSC, 50% 
formamide for 30 min at 42°C. The coverslips were treated with a sheep anti-digoxigenin 
antibody (Boehringer) at 1:200 dilution in AB buffer (3X SSC, 10% formamide) in the 
presence of 0.1% RNAse free BSA, 2 mM vanadyl ribonucleoside complex for 30 min at 
37°C. They were then washed twice in AB buffer and treated with a donkey anti-sheep 
IgG antibody conjugated to FITC (Sigma) at 1:150 dilution in the same solution as the 
first antibody, for 30 min at 37°C, and subsequently washed once with 2X SSC. The 
coverslips were then counterstained with Propidium iodide/Antifade (Oncor) reagent, 
which would stain the cell nucleus red, and mounted onto micro slides. Fluorescence 
microscopy was performed using an Olympus BX50 microscope. Slides were examined 
by successive exposure of the sample with a FITC filter to visualize the probe, Cy3 filter 
to visualize the propidium iodide stained nuclei, and dual (FITC and Cy3) filter to 
visualize the probe in the context of red-stained nuclei to determine the subcellular 
localization of the probed RNA transcripts. Micrographs were taken with a 3 CCD video 
camera system DET-750 (Optronics Engineering) using the Image-Pro PLUS software 
(Media Cybernetics). 
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26. HIV-1 antiviral assays 
Human 293 cells were cotransfected with ribozyme plasmids and HIV-1 DNA pNI4-
3 as described above. The DNA mixture contained 4 jig control or test plasmid, 1 jig 
human growth hormone (HGH) gene pTKGH (as a transfection efficiency control) and 
0.1 jig pNI4-3. After 2 days, supernatants were collected and the RI activity was 
assayed. CEM cells were infected with the supernatants from the transfection with 
equalized RT counts. The p24 level in culture media from these infections was assayed 
and compared after six and seven days. 
27. Total RNA isolation 
Total RNA was isolated and purified using RNA STA1-60 (TEL-TEST "B", Inc.) 
according to the manufacturer's instructions. When isolated from transiently transfected 
cells, RNA was subjected to DNase I treatment to remove contaminating plasmid DNA. 
28. Establishment of stable cell lines expressing chimeric tRNAL"3-ribozymes: 
Human embryonic kidney 293 cells were transfected with pAAVU6WW, 
pAAVU6MW and pAAVAGTRz. These constructs contain a NeoR gene expressing 
aminoglycoside phosphotrasferase which allows selection with G418. After transfection, 
cells were allowed to grow under nonselective conditions for two doublings. The cells 
were then split 1:15 into selective medium containing 800 Kg/m1 G418 (Mediatech, Inc., 
Herndon, VA). Cells were replaced with fresh media containing G418 twice a week. 
Single colonies were picked and maintained in selective medium after 2 weeks. 
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29. Half-life determination of in vivo expressed ribozymes 
Intracellular stability of the transcripts from different constructs was compared by 
measuring the half-life of the RNAs after halting the transcription with actinomycin D. 
Half lives wre determined in transiently transfected 293 cells and in stable cell lines (see 
above). In transient transfections, 293 cells were transfected with 10 jig pU6WW, 
pU6MW, pU6AGTRz or pU6Rz and I jig of pTKGH (normalizing transfection 
efficiency). Stable cell lines AAVU6WW, AAVU6MW and AAVAGTRz were also used. 
48 hr after transient transfection or 24 hr after splitting the stable cell lines, 10 jig/m1 of 
actinomycin D (Sigma, St Louis, MO) was added to the culture medium. Cells were 
harvested and total cellular RNA was isolated at 0, 0.5, 1, 2,4 hr (8 hr also for transient 
transfections) after actinomycin D treatment. The RNA samples were analyzed by 
Northern hybridization with a ribozyme-specific probe and a U6 snRNA-specific probe. 
Quantitation was normalized to the transfection efficiency and the U6 snRNA internal 
control, taking into account the published half-life of endogenous U6 snRNA. 
30. Preparation of cell extracts with tRNA processing activity 
Human embryonic kidney 293 cells were grown to 80% confluency, collected and 
rinsed three times in phosphate-buffered saline (PBS), and two times the cell pellet 
volume of Hypotonic Buffer (10 inN4 Tris, pH 7.5, 10 mM KCl, 1.5mM MgCl2, 1.4 mM 
13-mercaptoethanol) was added. Cells were incubated on ice for 10 min and then 
homogenized with a Dounce (20 strokes). One-tenth volume of S20 Spin Buffer (230 
miVI Tris, pH 7.5, 1.275 M KC1, 40 mM MgCl2, 6.4 mM p-mercaptoethanol) was added. 
The extracts were centrifuged at 20, 000 x g for 10 min at 4°C, and supernatants were 
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transferred to fresh tubes, stored on ice, and subsequently used fresh in the processing 
assays (see below). 
31. Chimeric tRNALYs3  ribozyme transcript processing assays in cell extracts 
Chimeric tRNALYs3-ribozymes were transcribed and labeled with [a-3211-UTP by in 
vitro T7 RNA polymerase transcription using linearized plasmids as templates. The 
transcripts were precipitated to remove unincorporated radioactive UTP. One-sixth (5 
approximately 50, 000 cpm ) of each transcription reaction was incubated in a 50 gl 
reaction in tRNA 3'-end processing buffer (Nashimoto, 1995; 10 mM Tris, pH 7.5, 1 mM 
DTT, 3.2 mM spermidine, 40 U RNasin) with or without spermidine, and with or without 
10 pi 293 cell extract, for 30 min at 37°C. Incubations were phenol extracted, ethanol 
precipitated and resuspended in 15 Ill water. One third (5 p,1) of each reaction was then 
combined with an equal volume of formamide loading dye, heated to 65°C for 5 min and 
analyzed in a denaturing 10% acrylamide gel (8M urea). The gel was dried and 
autoradiographed with a BioMax (Kodak) screen at —70°C overnight. 
32. Commonly used calculations 
1) Total pmol of an oligonucleotide = (OD 260 X 90 X 103)/length. 
2) Molar concentration of in vitro transcribed chimeric tRNALYs3-ribozyme and 
tRNALYs3 transcripts: 
Measure OD and calculate the concentration (W gg/g1) of the RNA samples. The 
molar concentration (mo1/111) of the samples equals (W X 10-6 g/111)/ [length (mt.) 
of the transcripts X 330 g/moi]. The length of the chimeric tRNALYs3-ribozyme 
transcripts is 114 nucleotides and the length of the tRNALYS3  is 76 nt. 
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III. EXPERIMENTAL RESULTS 
A. Virion Encapsidation of tRNA3I-Ys R bozyme 
Chimeric RNM Inhibit  HIV infection 
Shawn K. Westawayl, Laurence Cagnon2, Zongli Chang3, Shirley Li4, Haitang Li5, 
Garry P. Larson6, John A. Zaia7, And John J. Rossi8 
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expressing AGtRNA31 Ys-rbz, and participated in the RT-PCR assay of viral RNA. 
2' 4Postdoctoral fellow and researcher who did anti-HIV assays involving the 
manupulation of infectious HIV-1 agent. 
3Graduate student who constructed four constructs: ptRNA314s-rbz/mrbz and 
pU6tRNA31 Ys-rbz/mrbz, established the much higher expression efficiency of the 
U6/tRNA expression cassette than the tRNA expression cassette alone in expressing 
chimeric tRNA-ribozymes. The latter two constructs using the U6/tRNA expression 
cassette were then effectively utilized in anti-HIV and virion encapsidation assays. 
5
Laboratory technician who performed the RT-PCR assay with the postdoctoral fellow 
Shawn Westawayl . 
6Former member of the laboratory who constructed the construct p AGtRNA314s-rbz and 
pPBS-rbz and carried out the in vitro assays of the chimeric ribozymes. 
7Graduate committee member of the graduate student3 and principal investigator of the 
researcher Shirley LA4 who supervised and guided part of the work. 
8Student's mentor and graduate committee chairperson who supervised the work and 
preparation of the manuscript. 
This is a paper published by Antisense Nucleic Acid Drug 
Development (Antiense Nucleic Acid Drug Dev 8:185-197, 1998). 
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ABSTRACT 
Retrovinises require a specific host cellular tRNA primer for initiation of first strand 
DNA synthesis. This primer is bound by viral proteins and copackaged into virions. We 
have exploited this property in the design and testing of an antiviral ribozyme fused to 
tRNAPYs, the primer utilized for lentiviral replication, including human 
immunodeficiency virus (H1V-1 and HIV-2). The chimera consists of tRNAPYs 
covalently attached to a hammerhead ribozyme which is targeted to the region 
immediately upstream of the Primer Binding Site of the HIV-1 genome. The tRNA-
ribozyme chimeric transcript is catalytically active in vitro and is efficiently bound by 
HIV reverse transcriptase with an affinity similar to that of tRNA31-Ys. We have expressed 
the chimeric RNAs from either the tRNAPYs intragenic RNA Polymerase III promoter or 
from a human U6 snRNA promoter. The U6 promoter results in up to 10-fold enhanced 
expression of the tRNA-ribozyme. Most importantly, the tRNAPYs-ribozymes are 
encapsidated in HIV-1 virions such that they are effective in substantially reducing the 
level of infectious virus produced from cells cotransfected with HIV-1 proviral DNA. 
These results demonstrate the feasibility of using this novel strategy to reduce HIV 
infectivity and more generally indicate the potential power of utilizing the retroviral 
primer tRNAs as tools for expressing and delivering ribozymes and other anti-retroviral 
RNAs to the virion capsid. 
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INTRODUCTION 
Reverse transcriptase (RT) is the viral enzyme responsible for copying single-stranded 
RNA to double-stranded DNA in all retroviruses, including Human Immunodeficiency 
Virus-I (HIV-1), the causative agent of Acquired Immunodeficiency Syndrome (AIDS). 
The currently used inhibitors of HIV act by blocking various replication functions. These 
inhibitors become ineffective over time due to the rapid mutation of the virus (Richman, 
1993; Schinazi et al., 1992). HIV RT is extremely error-prone, misincorporating a 
nucleotide at the rate of 1. in 6900 for RNA-dependent DNA polymerization or I in 5900 
for DNA-dependent DNA polymerization (ii and Loeb, 1992). These mistakes occur 
throughout the HIV genome, although there is evidence to indicate that the excessive 
mutation rate is not totally random but may be linked to regions of unusual or highly 
unordered RNA structure (Schinazi et al., 1994). Some of these mutations allow the RT 
itself to overcome the effects of anti-ADS drugs, such as the block of polymerization 
caused by AZT (3'-azido-3'-deoxythymidine). In order for anti-HIV therapeutic agents to 
be effective, they must target a well-conserved and essential function of the virus. 
We have exploited the replication cycle of HIV-1 in a strategy which fuses a 
therapeutic ribozyme to the cellular tRNAPYs required for viral replication. HIV RT uses 
this tRNAPYs as the primer to initiate synthesis (for reviews, see Varmus and Brown., 
1989; Temin, 1992). HIV RT binds the host primer tRNA and both are packaged along 
with the viral genomic RNA and other proteins into HIV virions in the cytoplasm of 
infected cells. Though tRNA1 ,2LYs are also packaged into HIV virions (Jiang et al., 1992; 
Jiang et al., 1993), tRNA31-Ys is the primer utilized for HIV replication (Roy et al., 1982; 
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Craig et al., 1989). Eighteen nucleotides of the 3-end of human tRNA31-Ys are 
complementary to the Primer Binding Site (PBS) of HIV-1 and HIV-2 RNA (Wain-
Hobson et al., 1985; Ratner et al., 1985), and are used for priming of first-strand DNA 
synthesis. The specificity of this primer-target interaction is exemplified by the fact that 
tRNA1 ,21-Ys, which differ from tRNA31-0 in 5 of the 18 positions complementary to the 
PBS, cannot serve as primers for reverse transcription, and are not found tightly 
associated with the genome (Jiang et al., 1992; Jiang et al., 1993; Mak et aL, 1994; 
Kohlstaedt and Steitz, 1992; Das et al., 1995). 
Current approaches employed to colocalize a ribozyme to its target RNA take 
advantage of viral genome characteristics, and include tethering ribozyrnes to viral 
packaging signals (Sullenger and Cech, 1993). We developed a unique approach for 
directing a hammerhead ribozyme to its target by attaching it to the 3'-end of human 
tRNA314s. The hammerhead ribozyme, which occurs naturally in the genome of several 
plant satellite RNAs (Symons, 1992), can be functionally separated into substrate binding 
arms, and the active site, thus effectively allowing site-specific cleavage to occur in trans 
(Uhlenbeck, 1987). A potential target for the ribozyme is the Primer Binding Site (PBS) 
of HIV RNA, located just 3' to the 5'-long terminal repeat (5'-LTR). If this region is 
cleaved, it will prevent copying of viral RNA into DNA and subsequently block infection. 
In addition, the PBS is highly conserved among HIV and SW variants, since priming is 
accomplished solely from the tRNA31-0 bound to this site. 
tRNAPYs is complementary to the 18 nucleotides of PBS RNA, bound by HIV RT 
(Kohistaedt and Steitz, 1992), co-packaged in the infectious virion, and required to 
initiate viral replication. We reasoned that fusing a ribozyme to the host cellular 
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tRNA3LYs primer could result in incorporation of the ribozyme into the virion. Packaging 
of tRNAPYs-ribozymes'woulci occur via interactions with HIV RT, nucleocapsid proteins, 
and the viral RNA, resulting in colocalization to its target, consequent cleavage of the 
target, and inhibition of HIV replication. Most importantly, using the tRNA primer to 
deliver a ribozrne to the viral RNA target circumvents HW's genetic variability problem 
because the tRNA, the PBS target, and HIV RT would each have to mutate at the same 
time in the host and the virus to accomplish escape tRNAPYs-primed first strand DNA 
synthesis. 
MATERIALS AND METHODS 
Construction of ribozymes and substrate 
The AGtRNAPYs-ribozyme (6,GtRNA314s—rbz) was constructed by the polymerase 
chain reaction (PCR) as described (Dillon and Rosen, 1990), with the following synthetic 
oligonucleofides in the PCR reactions: 
(1 ) 5 '-GACTCGAGCCCGGATAGCTCAGICGGTAGAGCATCAGACITTTAATCTGAGGGTCCAGG-
3 ' (2) 5 '-GCGCCCGAACAGGGACTTGAACCCTGGACCCTCAG-3 ' 
(3) 5 '-CCCTGTTCGGGCGCCACTGCTAGACTGATGAGTCCGTGAGGACG-3 ' 
(4) 5 '-GTCCGCGGAAAAATGGCAAATITCGTCCICACGG-3 ' 
50 pmol each of #1 and #2 were combined, denatured at 94°C for 3 min, cooled to 25°C, 
and extended at 72° for 10 min in the presence of 125 piM dNTP's, 2.5 mM MgC12, and 2 
Units Taq polymerase in 1X Tag polymerase buffer. The same reaction was carried out 
for oligonucleotides #3 and #4. Reactions were diluted to 100 111. 50 pmol each of the 
outside PCR primers (#1 and #4) were combined with 1 ti of the #1/#2 reaction (0.5 
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pmol), I pA of the #3/#4 reaction, 125 ii,N4 dNTP's, 2.5 mM MgC12, and 1 Unit Tag 
polymerase in 1X Taq polymerase buffer. The PCR was carried out for 25 cycles at 94°C, 
2 min; 55°C, 2 min; 72°C, 3 min The PCR products were separated on a 6% 
nondenaturing acrylamide gel (0.5X TBE) and the 134-bp expected product was excised, 
crushed, and eluted overnight in 10 mM EDTA at 37°C. Supernatants were extracted 
once with phenol, once with chloroform, ethanol precipitated with 0.5 M NaC1, and the 
pellet was resuspended in 20 11.1 TE. The PCR product was digested with Sad' and Xhoi, 
phenol extracted, ethanol precipitated, ligated into Xhol/Sacii cleaved and 
dephosphorylated prnuescriptSK(±) vector (Stratagene) and transformed into MC1061 E. 
coli cells to create the plasmid pAGtRNAPYs-rbz. This construct has a deletion of one G 
at the TwC stem-loop junction, just at the beginning of the tRNA B box internal 
promoter, caused inadvertently during the PCR used for gene synthesis (see Fig. 1). The 
PBS-rbz was constructed by PCR using the following synthetic oligonucleotides: 
(5) 5'-GACICGAGTCCCIEGTTCGGGCGCCACTGCTAGACTGATGAGTCCGTGAGGACG-3' 
and #4 above. 20 pmol of each oligonucleotide were incubated under the PCR conditions • 
as described above and cloned into pRluescriptSK(+) vector to create the plasmid pPBS-
rbz. Plasmid ptRNA-SUB was constructed by cloning the 148 bp Hindill/Saci fragment 
(IIIVHXB2 coordinates 532 to 680) into the Hindi11/Saci sites of p1719U (Pharmacia 
Biotech). 
Human tRNAPYs-rbz or a mutant ribozyme version, containing a single point 
mutation in the catalytic core which eliminates ribozyme cleavage in vitro (Ruffner et cd., 
1990) (tRNAPYs-mrbz), and containing the correct wild-type sequence for tRNA LYs was 
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and either (6) or (7) for wild- e or mutant ribozyrne, respectively (single mutation is 
shown in bold): 
(6,7) 5'-CGGAATTCCGCGGAAAAATGGCAAATTI(C to 
T)GTCCTCACGGACTCAT-3' 
The two tRNA31-Ys-ribozymes (tRNAPYs-rbz and tRNAPYs-mrbz) were cloned into the 
Sal I and EcoRI sites of pBluescriptSK+ (Stratagene) to yield ptRNA314s-rbz and 
ptRNA314s-mrbz. These two constructs were also cloned downstream of a U6+1 snRNA 
promoter cassette in the plasmid pIZU6+1 (Bertrand et al., 1997) to yield pU6tRNA314s-
rbz and pU6tRNA3LYs-mrbz. 
tRNAVal-ribozymes (ptRNAValPBS-rbz and ptRNAVaIPBS-mrbz) were cloned by 
the PCR of plasmid pPBS-rbz with a 5'-primer containing a Xhoi restriction site and a 3% 
primer containing a Mu/restriction site and either wild-type or mutant ribozyme 
sequences to yield PBS-rbz or PBS-narbz PCR duplexes. These were digested and cloned 
into the compatible sites of ptV5 (kindly provided by A. Hampel) downstream of the 
tRNAval sequence. Intracellular expression of these chimeric RNAs is driven by the 
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tRNAval intragenic RNA Polymerase III promoter, and transcription terminates at the 
four thymidine residues at the 3'-end of the ribozyme. 
The AGtRNAPYs-rbz sequence was PCR amplified from pdGtRNAPYs-rbz with 5'-
and 3'- primers containing flanking Sail sites, cloned into the Sail site of AAVU6+1 
vector (Bertrand et al., 1997), to create pAAVU6+1AGtRNA31-31s-rbz. Fig. la is a diagram 
of the different constructs bound to the HIV PBS target. Fig. lb is a schematic of the 
constructs and their names as used in the text and figures. 
In vitro transcriptions 
1.6 gg plasmid ptRNA-SUB was linearized with 10 Units EcoRl in 1X BRL React 
Buffer 3 for 2 hrs. at 37°C, phenol/chloroform and chloroform extracted, ethanol 
precipitated, and used for transcription. EcoRI-linearized ptRNA-SUB yielded in vitro T7 
RNA Polymerase transcripts (performed as below) of 162 bp. All in vitro cleavage and 
gel shift assays were done with tRNA314s, PBS-rbz, or AGtRNA31-Ys-rbz transcripts 
derived from the PCR amplification of the pAGtRNA LYs-rbz plasmid with the 
appropriate 5'-primer containing an 18-nucleotide sequence encoding the bacteriophage 








For the PCR duplex product T7:PBS-rbz (78 nt), the PCR primer pairs were: 
(9) 5'-ITAATACGACTCACTATAGGGICCCTGTTCGGGC-3' and #8 above. 
The PCR reactions contained 2 ng pAGtRNAPYs-rbz plasmid, 100 pmol of each primer, 
0.2 mM dNTP's, 2.5 Units Tag DNA,Polymerase, in 50 IA of 'IX Tag Polymerase buffer. 
Reactions were carried out for 35 cycles at 94°C, 2 min; 40°C, 2 min; and 72°C, 3 min 
Transcriptions of the PCR duplexes were carried out using the Ambion T7 Megascript 
Kit in a 20 p.1 volume for 4-6 hr at 37°C according to the manufacturer's protocol with the 
following modifications: 3 gl of the PCR duplex and an additional 50 Units T7 
polymerase were added, and I gl [a-32NUTP (3000 Ciimmol) was added for radioactive 
transcripts. RNase-free DNase incubations were performed according to the 
manufacturer. Transcripts were purified on 6% polyacrylamide (30:1 
acrylamide:bisacrylamide), 7 M urea, 1X TBE gels, eluted, and ethanol precipitated. In 
vitro transcriptions of plasmid templates were performed as above except 0.5 pg of 
plasmid linearized downstream of inserts was used as template. 
In vitro ribozyme cleavage reactions 
1 pmol of radiolabeled HIV substrate RNA transcript was incubated with 1 pmol 
PBS-rbz, AGtRNAPYs-rbz, or tRNAPYs transcripts in 50 mM Tris, pH 7.5 at 37°C for 1 
hour. If present, Mg+2  was at a final concentration of 20 mM. Products of the cleavage 
reaction were separated on 6% PAGE, 7 M urea, IX Tris-borate-EDTA gels and exposed 
to autoradiographic film for 18 his. at -70°C with an intensifying screen. 
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In vitro binding of RT to tRNA or tRNA-rbz 
To measure the specificity of binding of tRNA31-Ys or AGtRNA LYs-rbz to HP/-I RT, 
binding assays were performed at 25°C for 30 min in 10 ti reactions containing 100 nM 
radiolabeled tRNA36's or AGtRNAPYs-rbz transcripts, 40 mM Tris, pH 8.3, 60 mM 
NaC1, 6 mM MgC12, 5 mM dithiothreitol, and 100 nM AMV, MoMuLV, or HIV RT 
(p66/p51 heterodimer obtained from NTH AIDS repository). 1. jil loading buffer (30% 
Ficoll, 1X TBE, 0.05% bromphenol blue and xylene cyanol) was added and samples were 
electrophoresed under non-denaturing conditions at 4°C in a 4% polyacrylamide gel (60:1 
acrylamide:bisacrylamide) with 0.5X TBE buffer. To demonstrate competition between 
tRNA31-Ys and AGtRNA31-Ys-rbz for binding to HIV-1 RT, 4 to 20 tM nonradiolabeled 
tRNA31-Ys or LiGtRNAPYs-rbz was added after preincubation of HIV RI with 1 pmol 
radiolabeled AGtRNA31-Ys-rbz or tRNAPYs, respectively. 
Transcription of RNA in vivo 
Human embryonic kidney cells (293 cells) were transiently transfected with 10 lig of 
ptRNA3LYs-rbz, ptRNAPYs-mrbz, or pU6tRNA31-Ys-rbz using the CellPhect Transfection 
Kit (Pharmacia). 1 lig pTKGH was cotransfected with the samples for quantitation of 
transfection efficiency (HGH-TGES 100T Kit, Nichols Institute). Transfection efficiency 
- was measured at 20%. After 2 days, RNA was prepared from transfected cells by the 
RNA STAT-60Tm reagent according to the manufacturer's directions (Tel-Test "B", Inc., 
Friendswood, TX). Total RNA (25 p.g) was resolved on 1% formaldehyde-agarose gels, 
blotted, and hybridized first to a probe specific for the ribozyme moiety, then washed and 
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hybridized to a U6 snRNA probe as a loading control. The oligonucleotide probes were 
kinased in 10 pi of 70 mM Tris, pH 7.6, 10 mM MgC12, 5 mM DTT, 1501.1,Ci [y- 
32MTP, 10 Units T4 Polynucleotide Kinase (New England Biolabs), at 37°C for 30 min 
Blots were exposed to autoradiograph film overnight. 
HIV transfection and infection of cultures 
293 cells were transiently transfected with HIV-I proviral DNA (pNL4-3, Adachi et 
al., 1986) and ribozyme or control plasmids at a ratio of 1:10 HIV:ribozyme using the 
Cell-Phect Kit (Pharmacia). Transfection efficiencies were estimated at 20% using the 
pTKGH human growth hormone standard. Supernatants were collected three days post 
transfection and the RT activity of the supernatant was determined (Goldstein et al., 
1990). The different supernatants were standardized according to their RT activity, and 
used to infect the T cell line CEMX174. From 3 to 10 days after infection, supernatants 
were collected and assayed for HIV RT activity and HIV p24 antigen (Coulter) according 
to the manufacturer's instructions. Virion production peaked in a control culture at days 
6-7. Infections were done in triplicate and results were averaged. 
RT-PCR of viral RNA 
Virions were prepared from supernatants of 3-day post-transfected 293 cells. 500 pi 
of cell-free supernatant were loaded onto a 10-ml Sepharose A colt= (SIGMA), and 
eluted in 20 mM Tris-HC1, pH 7.5, 1 mM EDTA, 100 mM NaCl. RNA was isolated from 
virions in fractions containing the peak of RT activity and p24 antigen using I. ml of RNA 
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STAT-60Tm reagent for 200 jil eluted virus (Tel-Test "B", Inc.). RNA was DNase treated 
by incubation in 50 mM Tris, pH 7.7, 5 m1V1 MgC12, with 15 Units RNase-free DNase I 
(Boehringer Mannheim) in 30 IA volumes at 37°C for 1 hr, followed by two 
phenol/chloroform extractions, one chloroform extraction and ethanol precipitation. RNA 
from approximately 4 pti of cell supernatant was used for reverse transcription-PCR 
(RT-PCR). Samples were heated to 90°C in 50 ptl reactions with 30 pmol each 5' and 3' 
primers, lx PCR buffer (Boehringer Mannheim) and 0.2 mM dNTP's, and allowed to 
cool slowly to room temperature. 1 Unit AMV Reverse Transcriptase (Life Sciences) was 
added, samples were incubated at 37°C for 5 min, and the PCR was subsequently 
performed with 2.5 Units Tag DNA Polymerase (Boehringer Mannheim) for 30 cycles at 
94°C, 1 min; 42°C, 1 min; and 72°C, 2 min Products were first electrophoresed on 
acrylamide gels, gel purified and sequenced. Products were also electrophoresed on 
agarose gels, blotted, probed with a ribozyme-specific probe, and autoradiographed as 
described above. 
Establishment and Analysis of Stable Cell Lines Expressing tRNA31-Ys-rbz 
Plasmid pAAVU6+16,GtRNA3LYs-rbz or pAAVU6+1 vector alone was transfected 
into human 293 cells using the Cell-Phect Kit (Pharmacia). Clones were selected in G418 
(Mediatech, Inc.) by virtue of the NeoR gene encoded in the plasmid. Total RNA was 
prepared from subconfluent clonal cultures using the RNA STAT-60Tm reagent (Tel-Test 
"B", Inc.). Total RNA was resolved on 1.5% agarose-formaldehyde gels, and passively 
blotted to Zeta-Probe membranes (BioRad). In vitro T7 RNA polymerase transcribed 
tRNA314s-rbz was used as a size marker and positive control. Membranes were 
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hybridized with 32P-kinased probes specific to either tRNA31-0 or to the ribozyme 
moiety, washed and autoradiographed as described above. 
RESULTS 
Design of a chimeric tRNA-ribozyme targeted to HIV RNA 
The primer for HIV RT must have a 3'-hydroxyl at the end of the 18 nucleotide 
region of complementarity to the PBS to allow for initiation of reverse transcription 
(Shimada et al., 1994). We wished to eliminate the possibility that a chimeric tRNA3I-Ys-
rbz transcript could support the initiation of replication, therefore we constructed the 
tRNA-rbz with the ribozyme moiety at the 3'-side of the tRNA (Fig.1 a). Though there has 
to be a limited amount of complementarity between the 3'-flanking arm of the ribozyme 
and its target RNA in order to bind and cleave, it would not be expected that RT would 
recognize or bind to the ribozyme moiety. However, the tRNA314s-rbz should bind RT 
via its tRNA31-0 moiety and bind to the PBS of HIV RNA via complementary base 
pairing. This should result in packaging into the virion, where it can inhibit replication 
through ribozyme cleavage or by blocking HIV RT polymerization. Our strategy assumes 
that the tRNA moiety of the tRNA31-0-rbz will retain its natural conformation in vivo as 
well as in vitro, and that RT will bind the tRNA 1-0-rbz with the same affinity as 
tRNA3LYs. 
All the chimeric transcripts contain a polyuridine tract downstream of the 3'-guide 
sequence of the ribozyme to allow RNA Polymerase HI-mediated termination of the 
transcript. This RNA Polymerase III termination signal has been shown to consist of a 
stretch of 4 uridines at the end of the transcript (Cozzarelli et al., 1983; Campbell and 
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Setzer, 1992). An important in vitro observation is that the tRNA31-Ys-rbz complexed with 
the HIV primer binding site is incapable of supporting initiation of DNA synthesis from 
the 3'-end (data not shown). 
The various tRNA-rbzs were constructed using synthetic oligonucleotides, or by the 
PCR from existing plasmids (see Materials and Methods). The first tRNA314s-rbz has a 
deletion of one G at the TwC stem-loop junction, just at the beginning of the tRNA B box 
internal promoter (AGtRNA31-Ys-rbz), caused inadvertently during the PCR used for gene 
synthesis. Two other constructs have the wild-type tRNA31-Ys sequence fused upstream of 
either a standard hammerhead ribozyme sequence (tRNAPYs-rbz) or a mutant ribozyme 
(tRNAPYs-mrbz) which is catalytically inactive in vitro (Ruffner et aL , 1990) . These two 
constructs were also cloned downstream of a U6 snRNA promoter to increase levels of 
transcription in vivo (U6tRNA314s-rbz or U6tRNA314s-rnrbz). As a control for 
localization, the tRNA31-Ys moiety was replaced by a human tRNAval gene (plasmid ptV5) 
containing mutations which prevent 3'-end processing (Hampel, 1998, in press). These 
constructs still contain the 18 nucleotides complementary to the PBS, followed by the 
hammerhead ribozyme or mutant ribozyme and terminator sequences (tRNAValPBS-rbz 
or tRNAValPBS-mrbz). An important aspect of these constructs is that they lack the 
majority of the tRNAPYs elements required for recognition and binding by HIV RT. The 
tRNAval gene provides the RNA Polymerase III promoter for in vivo transcription. Fig. la 
is a diagram of all the tRNA-ribozyme constructs and their HIV target, and Fig. lb is a 
schematic of the different plasmid constructs along with their names as used in the text. 
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Synthetic tRNA31-Ys-rbz transcript cleaves its synthetic HIV target RNA in 
vitro 
Fig. 2 shows that both the AGtRNA31-Ys-rbz and PBS-rbz transcripts effectively cleave 
the 162 bp HIV RNA substrate in vitro in the presence of Mg+2, yielding the expected 
cleavage products of 100 and 62 bp. Since the region of nucleotide sequence 
complementarity between the flanking sequences of the ribozyme and the HIV RNA 
substrate is quite long (7 and 26 base pairs), dissociation of the cleavage products is rate 
limiting, and ribozyme turnover is not expected. There is virtually no difference in 
cleavage efficiency between the PBS-rbz and the AGtRNA31-Ys-rbz. 
HIV-1 RI binds tRNA3I-Ys-rbz with an affinity similar to tRNA31-Ys 
Specific domains of tRNA31-Ys which interact with HIV-1 reverse transcriptase have 
been identified (Barat et al., 1989; Barat et al., 1991; Sarih-Cottin et al., 1992; Wohrl et 
al., 1993). The AGtRNAPYs-rbz construct retains these sequences, but it was not known 
whether the single G deletion and the appended ribozyme would affect RT binding. To 
examine this interaction of RT with the AGtRNAPYs-rbz, we carried out in vitro binding 
assays with HIV RT. An electrophoretic gel mobility shift assay was employed to 
compare the HIV RT binding of in vitro synthesized tRNA3ILYs to the AGtRNAPYs-rbz. 
Although differences have been discovered between the affinity of in vivo-isolated 
tRNA31-Ys versus in vitro transcribed =modified tRNA314s for HIV-1 RT (Barat et al., 
1991), we reasoned that a comparison of the relative binding affinities of RT with in vitro 
synthesized tRNA LYs and AGtRNAPYs-rbz would reflect the relative in vivo affinities. 
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Specific recognition of tRNAPYs occurs via HIV-1 RT. In vivo, however, the GAG-POL 
precursor protein is involved in the primer selection process (Mak et al., 1994). In 
addition, alignment of the primer on the PBS may be facilitated by other viral proteins, 
such as the nucleocapsid protein, NCp7. The tRNA31-Ys-ribozymes would, at a minimum, 
need to be selectively bound by HIV RT. 
To examine whether or not the AGtRNA31-Ys and the appended ribozyme moiety 
would affect the interaction with HIV RT, binding assays were performed (Fig. 3). This 
figure depicts an autoradiograph of native polyacrylamide gel electrophoresis of HIV RT 
complexed with tRNAPYs or AGtRNAPYs-rbz, demonstrating a shift in electrophoretic 
mobility upon binding by HIV RT. Both tRNAPYs and AGtRNAPYs-rbz interact with 
HIV-1 RT (p66/p51) while they do not interact with Avian myeloblastosis virus (AMV) 
or Moloney murine leukemia virus (MoMIN) reverse transcriptases under identical 
conditions. These data demonstrate that both tRNAs share a similar secondary and 
tertiary structure which allows for the preferential recognition by 11W-1 RT. In addition, 
nonradiolabeled AGtRNA31-Ys-rbz competes effectively and specifically with radiolabeled 
tRNA31-Ys for binding to HIV RT (Fig. 4a), and vice versa (Fig. 4b). Nonspecific RNA 
does not compete with either tRNA LYs or AGtRNA31-Ys-rbz for binding (data not shown). 
Native polyacrylamide gel electrophoresis was used to compare the binding 
affinities of HIV RT to tRNAPYs and AGtRNA314s-rbz by titrating a fixed amount of 
each RNA with increasing amounts of HIV-1 RT. The AGtRNA31-Ys-rbz binds to HIV RT 
with a similar dissociation constant as that of tRNAPYs. Neither the one base deletion nor 
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the appended ribozyme alters the binding kinetics of the AGtRNA31-Ys-rbz by HIV RT 
(Westaway et al., 1995). 
U6 snRNA promoter significantly increases transcription in vivo 
Evidence that HIV virions contain an average of eight copies of the tRNA primer per 
two copies of the genome (Mak et al., 1994) suggests that more of the tRNA-rbz 
construct could be packaged if we increased its intracellular concentration. We chose the 
upstream promoter element of the human U6 snRNA gene to drive transcription of the 
tRNAPYs-ribozymes and increase the levels of expression. The rationale for this approach 
is: 1) The preservation of the characteristics of an RNA Polymerase III transcript, for 
example, a discrete transcript start and endpoint; 2) The high level of transcription of the 
U6 snRNA gene compared to tRNA31-Ys; and 3) The 5'-coding sequence of the U6 gene is 
not included, thus preventing the tRNA-rbz transcript from being capped as a U6 snRNA 
transcript (Good et al., 1997). 
To compare levels of expression of genes driven by tRNAPYs promoter elements with 
genes driven by the U6 snRNA promoter, human 293 cells were transiently transfected 
with these constructs. 48 hr post-transfection, total RNA was prepared and analyzed. 
Northern blot analysis of total RNA was hybridized to a probe specific for the ribozyme. 
' Cells transfected with the chimeric gene driven by the tRNAPYs promoter showed poor 
expression levels in vivo, whereas transcription of the tRNA314s-rbz by the U6+1 
promoter resulted in an approximately 10- to 20-fold increase in transcription (Fig. 5, 
lanes 3 and 4). The difference in relative abundance of the U6+1 versus tRNAPY's 
promoter-driven chimeric RNAs could be the result of transcript levels and/or differential 
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3'-end processing of the ribozyme from the tRNA moiety. This difference also indicates 
that the presence of a fully functional internal tRNA promoter does not interfere with 
transcription by U6 promoter elements. The blot was also hybridized to a probe specific 
for U6 snRNA, as a loading control (Fig. 5, lanes I and 2). Given the high levels of 
tRNA31-Ys-rbz expression obtained from the U6+1 promoter-driven constructs, we chose 
to use these constructs for subsequent HIV challenge experiments. 
The tRNA31-Ys-rbz inhibits HIV replication by altering virion infectivity 
Based on the recognition of the AGtRNAPYs-rbz by HIV RT in vitro and its efficient 
expression in transfected cells, we predicted that tRNA31-Ys-rbz transcripts would be 
incorporated into viral particles. These particles should be defective, since the ribozyme 
moiety might be expected to cleave the genome and prevent the initiation of reverse 
transcription prior to, or soon after entry into a cell. To test the ability of the tRNAPYs-
rbz to reduce viral infectivity, we asayed the infectivity of viral particles produced from 
cells expressing the chimeric constructs according to the procedure diagrammed in Fig. 6. 
First, human 293 cells were cotransfected with proviral HIV-1 DNA and the various 
tRNA-rbz plasmids. Since human 293 cells have no CD4+ receptor, reinfection cannot 
occur, and HIV undergoes only a single round of replication. Three days after 
transfection, when virion production peaked, supernatants were collected and assayed for 
HIV reverse transcriptase activity. No significant differences in RT levels were detected 
in supernatants from cells transfected with the tRNA-rbz genes versus the U6 or tRNA"al 
vector alone control (data not shown). These results suggest little if any ribozyme activity 
in these cells. 
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In order to evaluate whether or not the tRNA-rbz affected viral infectivity by 
rendering virions defective for subsequent infection, an infectious assay using 
supernatants from the transfected 293 cells was carried out. Viral stocks were prepared 
from the cotransfected 293 cells and used to infect CD4+ human T-cells (CEMX174). 
Supernatants from this infection were analyzed for RT activity and p24 antigen 
production from 3 to 10 days post infection. HIV RT levels correlated well with p24 
antigen results. When p24 antigen production from cells infected with virions produced 
from the U6-tRNA31-Ys-rbz transfected cells was compared to the p24 antigen production 
from cells infected with virions produced from cells transfected with U6 vector alone, a 5 
to 6-fold reduction could be measured, indicating that the ability of the virus to infect had 
been significantly reduced. Fig. 7 is a graph of the p24 antigen in supernatants from day 6 
post-infected CEMX174 T-cells. These results demonstrate that the presence of the 
tRNAPYs-rbz in 293 cells reduces the titer of infectious virions produced from these 
cells. A tRNA-rbz construct with a point mutation in the catalytic core of the ribozyme 
which abolishes cleavage in vitro is also effective at reducing the titer of infectious 
virions produced from cells transfected with it. However, the wild-type tRNA-rbz is 
reproducibly more efficient at reducing titer than the tRNA-mutant-rbz construct. 
Fig. 8 is a graph of p24 antigen production from CEMX174 T-cells, 7 days after the 
infection with virions from 293 cells transfected with the AGtRNA3I-Ys-rbz, U6tRNA31-Ys-
rbz or tRNAValPBS-rbzs. These results demonstrate that ribozymes of the same 
hybridization length as the tRNAPYs-ribozymes hut placed downstream of tRNAval are 
much less inhibitory. The 50% level of inhibition demonstrated by the tRNAval 
functional and mutant ribozymes reflects some reduction in viral infectivity, but it does 
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not approach the level of inhibition of the tRNAPYs-based ribozymes. The low level of 
inhibition of viral infectivity could be the result of either ribozyme cleavage by the 
functional ribozyme or a block in initiation of reverse transcription by the mutant 
ribozyme. Most importantly, inclusion of the tRNA31-Ys-moiety results in up to 200-fold 
reduction in infectivity over the control, and 25- to 100-fold reduction in infectivity when 
compared to tRNAval chimeras (Fig. 8). This clearly demonstrates the importance and 
utility of the colocalization imparted by the specific binding of HIV RT to the tRNA31-Ys 
moiety of the chimeric RNAs. 
Detection of RNA in virions 
The above data also suggested that a percentage of the viral particles from the 293 
cells initially transfected contained ribozyme-specific transcript. To examine the quantity 
and types of RNA present in the virions isolated from 293 cells cotransfected with HIV 
and various tRNA-ribozymes, virions were pelleted, purified on Sepharose columns, and 
fractions were assayed for presence of p24 antigen. p24 peak fractions were pooled, and 
viral RNA was extracted and depleted for any contaminating cellular DNA. RT-PCR was 
performed on the viral RNA to detect packaged ribozymes and separated on acrylamide 
or agarose gels. Product purified from acrylamide gels was sequenced and the sequence 
verified the presence of tRNA LYs-rbz or tRNAPYs-mrbz (data not shown). Agarose gels 
were blotted, and probed with a ribozyme-specific probe. The results (shown in Fig. 9) , 
clearly demonstrate the presence of the tRNA-rbz in the virions produced from tRNAPYs-
rbz transfected 293 cells. The packaging of the tRNAPYs-ribozyme in virions also 
indicates that at least a portion of the chimeric transcripts are not 3'-end processed and 
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are localized to the cytoplasm in transiently transfected cells. It is not certain whether the 
nonprocessing tRNAValPBS-ribozyme is capable of nucleocytoplasmic transport. 
However, some cytoplasmic localization must occur in the transient cotransfection assay, 
as we have detected the inclusion of the tRNAValPBS-ribozyme in purified virions by 
RT-PCR (data not presented), consistent with our 50% inhibition using tRNAValPBS-
rbzs in the antiviral assay above. Since retroviruses are known to nonselectively package 
non-primer tRNAs (Jiang et al., 1992; Jiang et al., 1993), it is not surprising that we 
detected low amounts of the tRNAval chimera. Once packaged into the virion, the 
antiviral effect of the tRNAValPBS-ribozymes may be the consequence of their 
hybridization to the PBS region. 
Establishment of stable cell lines expressing tRNA3I-Ys-rbz 
We wished to determine if tRNA-ribozyme expression persisted in cell lines or if 
expression was toxic to the cell. We therefore transfected human 293 cells with the 
AGtRNA31-Ys-rbz driven from a U6+1 snRNA promoter incorporated into an Adeno-
Associated Viral Vector (AAV, Bertrand et al., 1997). Cells were selected on G418, 
allowed to expand, and clonally selected. Clones selected from pAAVU6+1AGtRNA31 'Ys-
rbz-transfected cells grew at the same rate as clones selected from pAAVU6+1 vector 
alone, indicating there was no toxicity from the plasmid or transcripts with or without the 
ribozyme. Total RNA was prepared from the G418 resistant clones and analyzed by 
Northern blot for the presence of AGtRNAPYs-rbz transcripts. Fig. 10 is an 
autoradiograph of a Northern blot probed with a radiolabeled oligonucleotide specific for 
the ribozyme moiety, and indicates the presence of intact transcript (lanes D5 and D6). 
Blots probed with an oligonucleotide specific for tRNA31-Ys confirmed equal amounts of 
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RNA were loaded (data not shown). This result demonstrates that transcription of this 
chimeric tRNA-ribozyme from the U6 snRNA promoter persists upon integration in 
stably transfected 293 cells. Furthermore, this tRNA-like molecule is not 3'-end 
processed as are wild-type tRNA precursor transcripts. 
DISCUSSION 
In this work, we have shown in vitro that a chimeric tRNA3LYs-ribozyme RNA cleaves 
its HIV-1 RNA target and is bound by HIV RT with an affinity similar to that of wild-
type tRNA314s. Previously, we reported that the AGtRNA31-Ys-rbz RNA is transcribed in 
vivo, generating an intact chimeric RNA which is localized cytoplasmically (Westaway et 
al., 1995). Interestingly, this chimeric dGtRNA31-Ys-rbz is not efficiently 3'-end processed 
as are most pre-tRNA transcripts, and the ribozyme moiety remains intact downstream of 
the tRNA molecule. This lack of apparent processing may be due in part to the 
overexpression of the chimera during transient transfections, the missing G near the B 
box of the tRNA, which could effect overall structure and hence recognition by 3'-end 
processing enzymes, or the fact that the CCA is already encoded in the DNA of the clone 
at the 3'-end of the tRNA at the junction between the tRNA and ribozyme. In eukaryotes, 
this CCA moiety is added post-transcriptionally after 3'-end processing. Alternatively, or 
in conjunction, the ribozyme structure could impede normal 3'-end processing. However, 
the cytoplasmic localization of AGtRNA31-Ys-rbz indicates that lack of apparent 3'-end 
processing does not interfere with nucleocytoplasmic transport. The cytoplasmic 
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localization also suggests that the tRNA31-Ys moiety of the tRNA-rbz is folding correctly, 
since nucleotide changes in tRNAs that greatly alter secondary and tertiary structures 
have been shown to interfere with nucleocytoplasmic transport (Tobian et al., 1985). This 
result is important in that the tRNA-rbz localizes to the cellular compartment where viral 
packaging begins. It is not known from which subcytoplasmic compartment the viral 
proteins recruit the tRNAPYs primer. It is also unknown whether this primer is recruited 
before aminoacylation, after aminoacylation and before recruitment by the translational 
machinery, or after the deacylated tRNA leaves the ribosome. The tRNA could be 
recruited in a deacylated state, or could be aminoacylated, and the amino acid removed 
during or after packaging. 
HIV RT activity of supernatants from 293 cells transiently transfected with tRNAPYs-
ribozymes and HIV proviral DNA is not affected by the presence of the tRNA-rbz. This 
suggests that the tRNA31-Ys-rbz either acts during or after viral packaging, and is 
ineffective in binding and cleaving viral InRNAs made prior to virion assembly. 
p24 antigen production in supernatants from T-cells infected with virions produced 
from 293 cells transiently transfected with tRNAPYs-ribozymes is reduced 5- to 200-fold 
over the controls. In addition, we have detected the presence of tRNA LYs-rbz in the 
population of virions packaged from the 293 cells. We have also observed that viral 
particles produced from 293 cells transfected with tRNAPYs-rbz and HIV proviral DNA 
have morphological defects when examined by electron microscopy (data not shown). 
The reduced infectivity of these virions is marked and reproducible. Ribozymes with a 
point mutation that abolish cleavage in vitro are also effective in reducing HIV virion 
infectivity, but are somewhat reduced in this capacity compared to the wild-type. The 
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most straightforward explanation for these results is that the tRNAPYs-mrbz may be 
acting as a decoy (i.e., binding RI and preventing necessary interactions with other HIV 
RNAs or proteins), or as an antisense RNA, blocking initiation of reverse transcription. In 
fact, the result with mutant ribozyme inhibition of viral infectivity supports the hypothesis 
that these chimeric tRNAs can be encapsidated and aligned on the primer binding site. 
The same holds true for the wild-type ribozyme, hut this does not preclude the possibility 
that wild-type ribozymes are cleaving the viral RNA as well. We have observed reduced 
levels of HIV RNA in virions produced from cells co-transfected with HIV proviral DNA 
and the chimeric AGtRNALys-rbz (data not shown). Nevertheless, the inhibitory effect of 
the mutant ribozyme suggests that the mechanism for the functional ribozyme could be a 
mixture of cleavage and antisense activities. Importantly, stable expression of the U6- 
driven AGtRNA31-Ys-rbz in 293 cells does not appear to be cytotoxic. The presence of the 
ribozyme prevents aminoacylation, thus the tRNA314s-rbz cannot interfere with the 
translation machinery. 
The results presented here demonstrate that chimeric tRNA31-Ys-rbz RNAs can be 
effective anti-HIV therapeutic agents. Their effectiveness is most probably the result of 
colocalization with the antiviral target RNAs via the normal packaging and primer 
selection pathways used for tRNAPYs. Recently, one group described anti-HIV inhibitory 
activity of an altered tRNAPYs primer which directs priming from the TAR region of 
HIV (Lu et al., 1997). It would thus appear that such an approach could also be used to 
direct a ribozyme to cleave at a site other than within the region adjoining the primer 
binding site. 
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The work described here is part of Our overall effort to utilize a ribozyme based gene 
therapy approach for the treatment and prevention of HIV infections. A strategic goal of 
this program is the simultaneous use of multiple ribozymes targeted to different regions 
of HIV RNA at different steps in the viral life cycle. The approach described in this study 
takes advantage of a critical part of the viral life cycle, virion assembly, to target a 
ribozyme to genomic virion RNA. It is anticipated that the chimeric tRNAPYs-rbz will 
complement the standard ribozyme targeting approaches to provide a complete 
intracellular immunity to HIV infection. This same approach can be used with other 
retrovirally caused diseases in both man and animals which use specific cellular transfer 
RNAs as primers for reverse transcription. 
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Figure 2. In vitro cleavage of IV substrate RNA by AGt 	3LYs-rbz and F iS-rbz. 
MW markers are indicated to the left of the diagram. Substrate (A) and two cleavage 
products (B and C) are indicated to the right. Lane 1, substrate alone, incubated in the 
presence of Mg+2. Lanes 2, 3, and 4: Substrate incubated with PBS-rbz, ZiGtRNA314s-rbz, 
or tRNALYs3, respectively, in the absence of Mg+2. Lanes 5, 6, and 7: Same as lanes 2, 3, 
and 4, in the presence of Mg+2. 
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Figure 3. tRNA3LYs and AGtRNA314s-rbz bind to HIV RT. Binding of tRNA314s or 
AGtRNA3LYs-rbz is specific for HIV RT. 
Lanes 1-4 contain radiolabeled tRNA314s; lanes 5-8 contain radiolabeled AGtRNA314s-
rbz. The type of RT added is labeled above the figure. S indicates the position of the 





1 2 3 4 
Figure 4. Native gel electrophoresis demonstrates competition of tRNA31-Ys and 
AG-tRNA314s-rbz complexed to HIV RT. 
Panel a; lanes contain 1 pmol radiolabeled tRNA31-Ys complexed with HIV RT. Panel b; 
lanes contain 1 pmol radiolabeled 6,GtRNA31-Ys-rbz complexed with HIV RT. Jr both 
panels: lane 1, no HIV RT; lanes 2 and 3, no competitor, with 1 pmol and 10 pmol HIV 
RT, respectively; lanes 4 and 5, 1 pmol HIV RT with 4 and 20 µM unlabeled tRNA31-Ys 
competitor, respectively; lanes 6 and 7, 1 pmol HIV RT with 4 and 20 µM unlabeled 
AGtRNA314s-rbz competitor, respectively. S indicates the position of the substrate, while 
Bl and B2 indicate two different migrations of bound complexes. 
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Figure 5. U6 snRNA promoter increases expression of tRNA-ribozymes. 
Two constructs, driven by either a tRNA31-Ys promoter (ptRNA314s-rbz) or fused 
downstream of the human U6 snRNA promoter (pU6tRNA314s-rbz) were transiently 
transfected into 293 cells and total RNA was analyzed by Northern blot with a U6 snRNA 
probe as a loading control (lanes I and 2) or a ribozyme-specific probe (lanes 3 and 4). 
Lanes 1 and 3 are from ptRNA314s-rbz transfected cells, and lanes 2 and 4 are from 
pU6tRNA31-Ys-rbz transfected cells. The arrow at the far right indicates where in vitro 
transcribed tRNAPYs-rbz migrates (not shown). 
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Figure 6. Flow chart of method for testing anti-HIV ribozymes for inhibition of 
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Figure 7. p24 antigen production from virions isolated from infected T-Cells. 
The T cell line CEMX174 was infected, in triplicate, with virions isolated from 
supernatants of three-thy post-transfected 293 cells transiently transfected with the 
constructs listed and proviral HIV DNA, using normalized HIV RT activity. T-cell 
supernatants were collected and assayed for p24 antigen @gimp. A day 6 post-infection 
timepoint is shown with p24 antigen levels for each of the viral populations used to infect 
the T cells. Corresponding mean values for each triple infection are shown above their 





Figure 8. Graph of p24 antigen production at day 7 as in Fig. 7, but for different 
viral populations used to infect the T cells. 
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Figure 9. RT-PCR of viral RNA isolated from 293 cells cotransfected with HIV 
proviral DNA and various tRNA-rbz constructs. 
RNA isolated from fractionated virions from supernatants of transfected 293 cells were 
subjected to RT-PCR using 5' and 3' primers specific for the tRNAPYs-rbz. Products 
were electrophoresed on an agarose gel, transferred to a nylon membrane and hybridized 
to a radiolabeled probe specific for the ribozyme. Lanes are RNA from cells transfected 
with: 1) pAGtRNA314s-rbz; 2) pU6tRNA31-Ys-rbz; 3) ptRNAValPBS-rbz; 4) 
ptRNAValPBS-mrbz; and 5) ptV5 (ptRNAVal). Lane labeled marker is a RT-PCR of in 
vitro transcribed tRNA314s-rbz as a size marker and positive control. ÷ and - indicate the 
presence or absence of AMV reverse transcriptase. Lanes 3-5 are negative, since PCR 





Figure 10. Northern blot analysis of total cellular RNA demonstrates nontoxicity 
and expression of AGMNA3LYs-rbz. 
Total cellular RNA isolated from stably transfected clonal cultures of 293 cells 
transfected with pAAVU6+1 vector alone (lanes B3 and A4), or 
pAAVU6+1AGtRNA314s-rbz (lanes D5 and D6) was resolved on an agarose 
formaldehyde gel, blotted and probed with a probe specific for the ribozyme moiety. Lane 
designated Marker is in vitro transcribed tRNA-rbz used as a size marker and positive 
control. 
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B. Expression of chimeric tRNALYs3- ibozymes under 
juxtaposed U6 snRNA gene and tRNA gene promoters in 
human cell cytoplasm and efficient HIV inhibition 
introduction 
Human immunodeficiency virus (HIV) is the causative agent of acquired immune 
deficiency syndrome (AIDS). In its life cycle, the HIV single-stranded RNA genome is 
reverse transcribed into double-stranded proviral DNA by reverse transcriptase (RT). 
Proviral DNA is then transported into the nucleus and integrates into the host 
chromosome. Like all retroviruses, HIV also employs one species of host tRNA as the 
primer for initiating the reverse transcription. The primer employed by HIV-1 is host 
native tRNA
Lys3 
 , which is packaged into virions from the cytoplasm during virion 
encapsidation by the action of the polyprotein Pr160Gag-Poi,  the precursor of RT (Mak 
et al., 1994, 1997). The nucleotide sequence at the 3' end of tRNALYs3 is complementary 
to 18 nucleotides of viral sequence near the 5' end of the RNA genome, called the primer 
binding site (PBS). During the initiation of reverse transcription, these 18 nucleotides are 
annealed to the HIV genome and prime the synthesis of the first strand of DNA. 
The interaction of HIV RT with host tRNALYs3 could potentially be exploited to 
bring RNA-based therapeutics including ribozymes, antisense RNAs and RNA decoys 
into the virions. Ribozymes are catalytic RNA molecules capable of cleaving target RNA 
molecules at specific sites. While ribozymes also function as antisense molecules, the fact 
that these can cleave and then recycle themselves to other target molecules provide an 
advantage over standard antisense molecules. 
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We attached a hammerhead ribozyme to the 3' end of the mature tRNALYs3 after the 
CCA tail. The ribozyme target is upstream of the PBS on the HIV-1 genome. Because 
tRNA genes possess internal RNA polymerase Hi promoters, such a construct should 
express chimeric tRNALY53-ribozyme transcripts at high levels from the internal tRNA 
promoter. The chimeric tRNA'-'Y 3-ribozyme was found to be catalytically active in vitro 
and bind to HIV-1 RT with an affinity similar to wild-type tRNA1-Ys3 (Westaway et al., 
1995, 1998). The chimeric tRNAL4s3-ribozyme could be detected inside the virions after 
being cotransfected with HIV proviral DNA into 293 cells. The HIV virions produced 
from the 293 cells were found to be less infectious than virions from control cells 
transfected with only HIV DNA (Westaway et al., 1998). 
One important aspect of the in vivo function of ribozymes is that they should be 
expressed at high levels to increase the ribozyme-to-substrate ratio to ensure maximal 
substrate inhibition (Cotten and Bimstiel, 1989). Therefore, higher level intracellular 
expression of chimeric tRNALYs3-ribozymes is essential and is expected to enhance the 
inhibition of viral replication by the ribozymes. In addition, it is also expected that a 
higher level of expression of the chimeric tRNALYs3-ribozymes would lead to more 
incorporation into virions, and concurrently less incorporation of endogenous tRNALYs3. 
This expectation is based upon the suggestion of a limited number of molecules of 
Pri60Gag-P°1 for interacting with the tRNALYs3 (Huang et al., 1994). 
Transfer RNAs including tRNAMet and tRNAVal have been widely used in gene 
therapy approaches as in vivo expression cassettes to produce a high level of short 
therapeutic RNA molecules, such as ribozyme and antisense molecules. Among many 
characteristics of tRNA expression cassettes, the most important advantage is that they 
produce short RNA molecules at high efficiency. They possess internal RNA polymerase 
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III promoters and can express ribozymes at levels at least an order of magnitude more 
than RNA polymerase II (Poi II) promoters (Cotten and Bimstiel, 1989). 
While expression of the chimeric tRNA1-'Ys3-ribozymes under the tRNALYs3  
promoter is effective in HIV inhibition (Westaway et al., 1998), our goal has been to 
increase the expression level further. The human U6 small nuclear RNA (snRNA) is a 
very abundant species of RNA involved in spliceosome formation during pre-mRNA 
splicing, reaching as high as 0.4-0.5 X 106 copies per cell (Sauterer, 1988; Weinberg and 
Peuman, 1968). The U6 promoter drives transcription of short RNA molecules at levels 
higher than expression from tRNA promoters (Heves et al., 1996). Both U6 and tRNA 
promoters belong to the Poi III promoter class and transcripts from these two promoters 
do not have a 3' polyA tail added after transcription as do mRNA transcripts from RNA 
polymerse II promoters. However, one important difference exists between the U6 and 
tRNA promoters— the U6 promoter is positioned upstream of its structural gene, while 
the tRNA promoter is intragenic, embedded inside the structural gene. This difference 
makes it possible to juxtapose these two Poi III promoters in tandem as an expression 
cassette for enhancing the expression level of RNA-based molecules. 
In an attempt to enhance the expression level of the ribozymes and hence boost the 
HIV inhibition, we adjoined the U6 promoter upstream of the chimeric tRNA1-Ys3-
ribozymes. In these constructs, two promoters are connected in tandem, one extragenic 
U6 promoter and another intragenic tRNA promoter. Using combinations of different 
promoter elements of both U6 and tRNA promoters (A and B box without the rest of the 
tRNA gene introduced into the coding sequence ofXenopus U6 gene), Parry and Mattaj 
(1990) demonstrated that there could be different interactions between the two promoter 
elements. However, the feasibility of using juxtaposed U6 extragenic and tRNA 
intragenic promoters as an expression cassette for expressing short therapeutic RNAs has 
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never been tested in mammalian cells. There could be additive, synergistic or 
antagonistic effects on the expression level. 
Another factor that is important in determining the feasibility of using tRNA or U6 
promoters in expressing short genetic materials like ribozymes for therapeutic inhibition 
of HIV is that they have to be exported to the cytoplasm, where they can colocalize with 
their target and be packaged into virions. Despite reports of nuclear retention of 
transcripts expressed from the U6 promoter, it is likely that the nuclear retention is a 
function of the transcripts per se rather than a function of the promoter. With tRNALYs3  
as part of the chimera, we expect that the tRNA moiety could facilitate the export of the 
chimeric molecules expressed from the dual U6/tRNA promoters. The tRNA moiety of 
the chimera is expected to retain the tRNA secondary and tertiary structure, while a CCA 
appended to the 3'end of the tRNALYs3 also helps to mimic the mature tRNA 3'-end. 
Therefore, the tRNA moiety of the chimera is expected to facilitate the export of these 
transcripts into the cytoplasm. 
We demonstrated that juxtaposing the U6 snRNA promoter and tRNA promoter 
could result in higher levels of expression of chimeric tRNALY53-ribozymes than that 
obtained from the tRNA promoter alone. Additionally, the transcripts can be transported 
to the cytoplasm. These constructs were shown to inhibit HIV-1 infectivity effectively. 
The hybrid U6/tRNA expression cassette can be valuable in applied research using RNA-
based therapeutics and could contribute to basic research in RNA polymerase III 
promoters as well. 
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Results 
Design of chimeric tRNA-ribozymes under intragenic tRNA promoter and 
U6 snRNA promoter 
tRNA genes have intragenic promoter elements, called the A and B boxes (Fig. 1A). 
tRNA expression cassettes (Fig. 1C) have been widely used for expressing RNA-based 
therapeutics including chimeric tRNA-ribozymes. Different anti-HIV chimeric 
tRNALYs3-ribozymes, pWW, pMW, pWM, pMM and pAGTRz were designed (Fig. 2). 
The 3' 18 nucleotides of tRNALYs3 are complementary to the HIV-1 primer binding site 
(PBS). The hammerhead ribozyme targeting 8 nucleotides upstream of the PBS is fused 
to the 3'end of the tRNALYs3 gene. 
Specific single mutations in the B Box of the tRNA (GCTACAAGTCC instead of the 
wild type B box GGTTCAAGTCC) were shown in vitro to abolish transcription from the 
tRNA intragenic promoter (Murphy et al., 1983). The sequences of the chimeric tRNA-
ribozymes have 33 nucleotides of homology with the sequences of HIV-1 and this could 
result in inhibition of HIV replication through an antisense effect. To compare if the 
resulting inhibition of HIV-1 was due to ribozyme cleavage or an antisense effect, we 
introduced a mutation in the catalytic core of the ribozyme moiety (Fig. 2), which would 
abolish the ribozyme activity of the transcripts (Ruffner et al., 1990). 
Different constructs with different combinations of the wild type and mutant forms of 
the tRNALY53  and ribozyme were synthesized and cloned (Fig. 1.B). These were 
synthesized by PCR from synthetic oligonucleotides and cloned between the Sall and 
EcoRI sites of pBluescipt II SK, in between the T7 and T3 promoters. These include 
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Figure 1. Structure of the tRNA gene, the human U6 snRNA gene, and the tRNA 
expression cassette or the hybrid U6/tRNA promoter expression cassette driving the 
expression of chimeric tRNA-ribozyme sequence. 
(A) The tRNA gene has intragenic promoter elements, the A and B box, for driving the 
expression of tRNA molecules. (B) The human U6 snRNA gene has an upstream distal 
sequence enhancer (DSE), proximal sequence element (PSE) and TATA box as promoter 
elements. (C) The tRNA expression cassette is widely used for the expression of 
ribozymes. Our constructs pWW, pMW, pWM and pMM use this cassette. (D) The 
hybrid U6/tRNA expression cassette, i.e., the human U6 snRNA promoter (Bertrand et 
at, 1997) adjoined upstream of the tRNA promoter, is developed here for expressing the 
ribozyme sequence. The constructs in this series include pU6WW, pU6MW, pU6WM 
and pU6MM. The structural sequence of the U6 snRNA is not included. However, the 
whole sequence of the tRNA gene is incorporated and the transcripts would incorporate 
the tRNA sequence and the ribozyme sequence in a chimeric molecule, as in the tRNA 
expression cassette. (A-D) All the genes and expression cassettes use a run of Ts as the 
termination signal. 
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Figure 2. Structure of the chimeric tRNALY53-ribozymes and their proposed 
interaction with the HIV genome RNA. 
The chimeric tRNA''Y 3-ribozymes are shown base-paired to the flanking sequence of 
the AUC cleavage site indicated on the HIV RNA. The 3' end 18 nt of the tRNA moiety 
is complementary to the primer binding site (PBS) of HW. The ribozyrnes target 8 nt 
upstream of the PBS. The 5 uridine residues at the 3' end of the ribozyme serves as an 
RNA polymerase III terminator. The G*A mismatch at the end of the ribozyme/HIV 
RNA duplex was introduced to prevent premature transcription termination, because the 
perfectly matched ribozyme sequence would have a stretch of four uridines. The wild 
type sequence of tRNA and ribozyme is present in the WW construct. The G-to-A change 
in the catalytic core of the ribozyme, present in the WM and MM constructs (Westaway 
et al., 1998) is inactive for cleavage in vitro (see text). The U to A and G to C changes in 
the B box of the tRNA sequence, present in MW and MM constructs, were shown to 
abolish transcription from the tRNA promoter in vitro. One deletion in the PIT stem, 
immediately upstream of the B box, is present in the AGTRz as described previously 
(Westaway et al., 1998). All the constructs in the tRNA expression cassette series, WW, 
MW, WM, MM and AGTRz, are also cloned under the U6 promoter, giving rise to the 
U6/tRNA expression cassette series U6WW, U6MW, U6WM, U6MM and U6AGTRz. 
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pWW, pMW, pWM and pMM. Another construct named pAGTRz has a single G 
deletion in the TWC stem loop junction, immediately upstream of the B Box of the tRNA 
gene. 
U6 snRNA is an abundant RNA in eukaryotic cells (Fig. 1B). The U6 snRNA 
promoter is extragenic. Therefore, we could place our chimeric tRNA'Y 3-ribozymes 
downstream of the U6 snRNA promoter and attempt to drive expression of tRNALY53-
ribozymes by two promoters in tandem (Fig. 1.D). Only one nucleotide from the structural 
U6 RNA gene was included downstream of the U6 promoter, excluding the capping 
signal, which is important for nuclear localization of the U6 snRNA (Good et al., 1997). 
These constructs are named pU6WW, pU6MW, pU6WM and pU6MM and pU6AGTRz. 
Enhanced expression of chimeric tRNALYs3-ribozymes under the hybrid 
U6/tRNA promoter 
One important aspect for enhancing the efficiency of a therapeutic ribozyme is the 
expression level. The higher the expression level, the higher the ribozyme to substrate 
ratio, and the more effective the ribozyme targeting. Earlier studies showed that the 
chimeric tRNALYs3-ribozymes could be packaged into HIV virions during encapsidation 
and subsequently inhibit HIV infectivity (Westaway et al., 1998). We expected that if we 
increased the intracellular levels of expression of the chimeric tRNALYs3-ribozymes, 
more copies of these molecules would he incorporated into the virions during virion 
encapsidation, and consequently lead to more efficient inhibition of HIV-1. This was 
suggested by a study which showed that each virion contains 8 copies of tRNALYs3 and 
the total number of copies of tRNALYs3, tRNALysl  and tRNALYs2 was fixed at 20 
copies per virion (Huang et al., 1994). When human cells were transfected with a plasmid 
containing both HIV proviral DNA and a human tRNALYs3 gene, which would largely 
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increase cytoplasmic concentration of tRNALYs3, the tRNALYs3 copies incorporated 
into virions more than doubled (from 8 to 17 copies). However, the total number of 
tRNALYs isoacceptors remained at 20 copies with a concurrent chop in the copy numbers 
of tRNALYs 1 2  from 12 to 3 copies. This was suggested to be due to either limited space 
ag-Poi 
in the virions or a limited number of molecules of Pri 60
G  
	, which is responsible for 
recruiting and packaging the tRNALYs3 primers (Huang et al., 1994). Therefore, it can 
be inferred that if we increase the levels of cytoplasmic expression of the chimeric 
tRNALY53-ribozymes, we should be able to increase packaging of the chimeric tRNA-
ribozymes into virions, thereby enhancing the inhibition of HIV replication. 
It was therefore of interest to compare the expression levels of tRNA promoter driven 
with levels from juxtaposed U6 promoter / tRNA promoter driven transcription. There 
was the possibility that the promoter elements present in the intragenic tRNA promoter 
would compete or interfere with the upstream promoter elements of the U6 gene (Parry et 
al., 1990). Therefore we sought mutations in the B box of the tRNA which could 
decrease this interference by decreasing or eliminating transcription from this promoter. 
each other in their interactions with the transcription machinery We began by comparing 
the relative abundance of transcripts from the construct with @NM, pMM and pU6MW) 
and without (pWW, pWM and PU6WW) the mutations in the B Box. 
The constructs harboring the tRNA promoter alone or the adjoining U6 and tRNA 
promoters were transiently transfected into 293 cells. A plasmid pTKGH for expressing 
growth hormone was cotransfected to normalize transfection efficiencies. After 48 hours, 
total RNAs were isolated and analyzed by Northern hybridization. The ribozymes were 
detected using a probe specific for the ribozyme sequence (Fig. 3A). The membrane was 
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RNA loading (data not shown). Quantitation of the expression levels (Fig. 3B) was 
carried out by Phosphoun* ager analysis. 
Expression from the chimeric tRNA ribozymes with mutant B box, i.e., MW and 
MM, was the lowest (Fig. 3A, lanes 4, 6) but not totally absent, which was different from 
expectations. Little or no expression from tRNAs with single mutations in the B box was 
demonstrated in in vitro assays (Murphy et al.). The presence of the U6 promoter 
upstream of the chimeric tRNA-ribozymes enhanced the expression of the transcripts by 
nearly 3 fold in U6WW (Fig. 3A, lanes 1 vs 3) and by almost 10 fold in U6MW (Fig. 3A, 
lanes 2 vs 4). The highest expression level is seen in U6MW in which the U6 promoter 
was adjoined upstream of the tRNA moiety with mutations in the B box, even higher than 
expression from U6WW in which the tRNA with wild a type B box was joined 
downstream of the U6 promoter (Fig. 3A lanes 1 and 2). The difference in expression 
between U6MW and U6WW is nearly 2 fold (Fig. 3C, ratio c). Compared with the 
expression from WW (wild type tRNA-ribozyme without the U6 promoter), the construct 
U6MW yielded an expression level approximately 4 times higher. 
Subcellular localization of the tRNALYs3-ribozyme transcripts expressed 
from the tRNA promoter alone or the U6 and tRNA promoters in tandem 
For ribozymes to work inside cells, they have to be able to colocalize with their target 
RNA molecules (Bertrand et al., 1997; Good etal., 1997; Sullenger et al., 1993). It is 
known that endogenous tRNAs are transcribed in the nucleus and exported into the 
cytoplasm while endogenous U6 snRNA remains exclusively in the nucleus (Fig. 4A). 










and structure, we expected that our chimeric tRNALY53-ribozyme transcripts would 
localize in the cytoplasm. Since our U6 driven tRNA1-'Ys3-ribozymes do not contain any 
U6 snRNA localization signals, transcription from U6 should not affect intracellular 
localization of a heterologous gene product. 
The intracellular localization of the chimeric tRNA-ribozymes transcripts were 
detected by fluorescent in situ hybridization. The probes were antisense riboprobes 
produced and labeled with digoxigenin by in vitro transcription from DNA fragments 
containing the T3 promoter. A probe specific for the ribozyme moiety with no sequence 
complementarity with the tRNALY53 was used to detect the transcribed tRNALYs3-
ribozymes (Fig. 4 B, C, D). Specific probes for the U6 snRNA and tRNALYs3 were 
employed to detect the intracellular localization of these two endogenous RNA species as 
nuclear and cytoplasmic localization controls (Fig.4 A). 293 cells were transiently 
transfected with the constructs, fixed after 48 hours and then subjected to in situ 
hybridization. The probes were subsequently detected by FITC labeled antibodies against 
the digoxigenin-11-dUMP tag. The slides were counterstained with propidium iodide to 
stain the nucleus red. 
The lower panels of Fig. 4A show the intracellular localization of endogenous U6 
snRNA. In agreement with one previous report (Good et cd., 1997), the U6 snRNAs were 
found in large numbers of evenly distributed punctate loci outside the nucleoli, shown as 
hollow red spots. Another report showed that U6 stiRNAs were localized to small 
numbers of punctate loci only (Carmo-Fonseca et cd., 1992). Endogenous tRNALYs3 was 
shown to be localized exclusively to the cytoplasm (Fig. 4A upper panels). Expression of 
AGTRz was found to be cytoplasmic (Fig. 4B), as reported previously by nuclear-
cytoplasmic fractionation (Westaway et al., 1995). This is in agreement with most reports 
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about cytoplasmic localization of transcripts from tRNA expression cassettes (see 6ne 
exception in the discussion). Chimeric tRNALYs3-ribozymes expressed under the U6 
promoter (U6MW and U6WW) were found to be localized homogeneously in both the 
nucleus and cytoplasm (Fig. 4 C, D). 
Chimeric tRNA-ribozyme mediated inhibition of HIV-1 corresponds with 
tRNA-ribozyme expression levels 
We previously demonstrated that the chimeric tRNA-ribozymes can inhibit HIV-1 by 
virion encapsidation (Westaway et al., 1998). Here, we checked and compared the 
efficiency of these chimeric tRNA-ribozymes expressed under the hybrid U6/tRNA 
promoter for their ability to inhibit HIV-1 infectivity. The fact that these transcripts can 
be detected in the cytoplasm suggests that they should be able to inhibit HIV-1 by being 
packaged into the virions from the cytoplasm (Westaway et al., 1998). The level of HIV 
inhibition should correspond with their expression levels since the higher the level of 
expression, the more competitive they would be in getting packaged into the virions. If 
HIV-1 infectivity is being reduced by the transcripts, it is an indirect indication that the 
transcripts have been exported into the cytoplasm. We also wanted to compare chimeras 
with wild type versus mutant ribozymes with respect to HIV-1 inhibitory activity. If the 
constructs with mutant ribozyme exhibit HIV inhibition, this is likely to be due to an 
antisense or a decoy effect in which the tRNALYs3 moiety competitively interacts with 
Gag-Pol 
reverse transcriptase or its precursor Prl 60 	during reverse transcription or 
encapsidation. 
Human 293 cells were cotransfected with HIV-1 proviral DNA and plasmids which 
can express tRNALYs3-ribozymes under the U6 promoter, or a negative control plasmid 
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pTZU6+1 (Bertrand et al., 1997), which has the U6 promoter but lacks any chimeric 
tRNALYs3-ribozyme sequences. Because these chimeric tRNA-ribozymes have been 
shown to work by incorporation into virions (Westaway et al., 1998), the virions 
produced from the supernatant of these cotransfections are expected to have reduced 
replication capability during reinfection of other CD4 + cells. Because 293 cells are CD4 
negative, virions produced from these cotransfected 293 cells do not reinfect neighboring 
cells. We collected supernatants that contain virions that may have packaged chimeric 
tRNALYs3-ribozymes and assayed for RT activity. No significant difference in RT 
activity was observed in these samples compared with that from the pT7U6+1 vector 
contr) ol, suggesting that little if any ribozyme inhibition occurred in the cytoplasm prior to 
encapsidation. We then used viral stocks prepared from the supernatant, which were 
equalized for RT counts, to reinfect CEM cells, which are CD4 positive. On day 6 and 
day 7, the p24 antigen levels from the supernatant were assayed and compared (Fig. 5). 
The best inhibition of HIV-1 p24 level was observed in U6MW, the construct with 
highest intracellular expression level. There was a 14-20-fold reduction of p24 level on 
day 7 and day 6 respectively compared with that of the pTZU6+1 vector control. There 
was a 5-6-fold p24 reduction when U6WW was used. The constructs with mutant 
ribozymes also showed HIV-1 inhibition. For U6MM, p24 level showed a reduction by 3 
to 4-fold on day 7 and day 6 respectively. This inhibition is presumably due to an 
antisense or decoy effect. The mutant tRNALY53-ribozyme could anneal to HIV RNA 
and inhibit initiation of replication by an antisense effect. The mutanttRNALYs3- 
ag-Pol 
ribozyme may also interact with Pr160
G 	
and interfere with packaging of endogenous 
tRNALYs3, or bind to RI inside virions and hinder the interactions of RI with native 
tRNALYs3 and pm. There is a 5-fold difference in HIV inhibition when U6MW (with 
wild type ribozyme) and U6MM (with mutant ribozyme) are compared. Because they 
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Figure 5. HIV inhibition by chimeric tRNALYs3-ribozymes expressed from the 
hybrid U6/tRNA promoter expression cassettes. 
293 cells were cotransfected with HIV-1 pNI4-3 proviral DNA and chimeric 
tRNA14s3-ribozyme constructs containing hybrid U6/tRNA promoter cassettes. 
Supernatants were collected and measured for RT counts. Supernatants with equalized 
RT counts were then used to infect CEM cells. After 6 and 7 days, p24 levels in the 
media of the CEM cells were measured and compared. 
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have the same promoter elements, their expression levels in vivo should be the same. This 
observation suggests a significant action of ribozyme cleavage activity on the HIV RNA 
target, which most likely occurs in the virions (Westaway et al., 1998). 
Discussion 
We reported that anti-HIV chimeric tRNALY53-ribozymes could be detected inside 
the virions obtained from cells cotransfected with HW DNA and the chimeric tRNA-
ribozyme constructs and the virions were found to be defective with reduced infectivity 
in subsequent infection assays (Westaway et al., 1998). During encapsidation of HIV-1 
virions, endogenous tRNA1 Ys3 molecules are recruited from the host cytoplasm by 
interacting with Pr160gag-pol, the precursor of reverse transcriptase (Mak et al., 1994). 
In the chimeric constructs, the ribozymes were fused to the 3' end of tRNALYs3 and 
presumably brought into HIV virions during encapsidation through interactions with 
Pr 1 
60Gag-P01 
 . It should be noted that these chimeric tRNALY53-ribozymes were found to 
have binding affinities to reverse transcriptase similar to wild type ti NALYs3 (Westaway 
et al., 1998). in an effort to enhance the expression of the chimeric ribozymes and hence 
improve their competitiveness with endogenous tRNALYs3 for packaging into HIV 
virions, we cloned the chimeric tRNALYs3-ribozymes under the human U6 snRNA 
promoter. We studied the expression of anti-HIV chimeric tRNALY53-ribozymes from 
the juxtaposed U6 promoter and tRNA promoters, the intracellular localization of the 
transcripts and the effectiveness of these constructs in HIV inhibition. 
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The feasibility of using such an approach for expression of short RNAs from 
juxtaposed U6 and tRNA promoters depends upon whether or not there is promoter 
interference. There may be steric hindrance between factors bound to the U6 promoter 
and tRNA promoter elements (Parry et al., 1990; Fig. 1D). For the tRNA promoter, 
transcription factor TFITIC recognizes the B box and binds to a region spanning both the 
B and A box. This binding enables TRIM, the positioning factor, to bind to a sequence 
surrounding the startpoint. One component of TRIM, the TATA Binding Protein (TBP), 
is responsible for directly interacting with RNA polymerase III. For the upstream U6 
promoter, the TATA element is important for determining the initiation site. TATA is 
bound by a factor that contains the TBP, the subunit that actually recognizes the 
sequence. These proteins specifically recruit RNA polymerase III. For both tRNA and U6 
promoters, the TBP and its associated proteins help to correctly position RNA 
polymerase III at the startpoint. When the U6 promoter is adjoined upstream of the tRNA 
gene, there could be some steric hindrance caused by the positioning of these 
transcription factors within close proximity to each other. Such hindrance may 
compromise the effectiveness of such an expression system. Nevertheless, it is also 
possible that in our constructs such hindrance either does not occur or is not a significant 
factor in transcriptional efficiency from each of the two promoters. 
Parry and Mattaj (1990) introduced just the consensus A and B boxes of a tRNA gene 
into the coding sequence of a Xenopus U6 snRNA gene and studied the effect on 
transcription. The constructs were microinjected into Xenopus oocytes and transcription 
levels were studied by RNA isolation and primer extension. When both an A and a B box 
were inserted into the U6 snRNA gene and combined with the complete U6 promoter, 
with 26 nucleotides as the distance between the TATA element of the U6 promoter and 
the A box of the tRNA promoter, the resulting construct was transcriptionally inactive. 
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This antagonistic consequence was thought to be due to a steric hindrance that could 
block transcription initiation. When the TATA element-A box distance was increased to 
33 or 42 nt, the constructs were strongly transcribed (Parry et al., 1990). In our study, the 
whole tRNA sequence with its internal A and B box was appended to the end of the U6 
promoter. The TATA element-A box distance is 36 nucleotides. The results obtained in 
Xenopus oocytes are in agreement with our results and our constructs are able to initiate 
transcription and show high level expression. 
The second problem that may potentially undermine the use of juxtaposed Pol III 
promoters is the intracellular localization of the transcripts. In order for ribozymes to 
work, they have to be able to colocalize within the same cellular compartment as their 
target (Bertrand et al., 1997, Sullenger et al., 1993). Because HIV encapsidation occurs 
in the cytoplasm, the expressed tRNALYs3-ribozymes have to be exported to the 
cytoplasm for them to be effective in competing for packaging into virions. We 
engineered the tRNALY53-ribozymes such that they have a CCA at the end of the tRNA 
moiety. The added CCA should make the tRNA14s3-ribozymes mimic mature tRNA and 
therefore evade the action of the 3' processing endoribonuclease (3'-tRNase) which is 
responsible for the 3'-processing of pre-tRNAs (Mohan et al., 1999). Computer modeling 
also predicts that the tRNA moiety of the chimeric tRNA1-'Ys3-ribozymes would maintain 
all the secondary structure and properties of the mature tRNA, but aminoacylation can 
not occur due to the presence of the ribozyme at the 3' end. These native structural 
properties are likely to assist in recognition by the tRNA export system and facilitate 
export of the chimeric ribozymes. 
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U6 and tRNA promoters enhance expression when placed in tandem 
U6 snRNA promoter and tRNA promoters can drive the expression of small RNA 
molecules individually. In this research, we studied the juxtaposition of the extragenic U6 
snRNA and intragenic tRNA promoters in expressing chimeric tRNALY53-ribozymes 
targeting HIV-1 PBS for therapeutic purposes. It was found that the dual U6/mutant 
tRNA promoter in U6MW gave the highest levels of expression. Why is expression from 
this construct higher than expression from the U6 promoter upstream of the wild type B 
box (U6WW)? There are two possibilities. First, in pU6MW the mutations in the B box 
are in the PPC loop and T stem. Changes in this loop or reduced base-pairs in the T 
stem have been reported to reduce 3' processing of tRNA molecules by the 3' processing 
endoribonuclease (3'-tRNase; Nashimoto, 1996 and Nashimoto et al., 1999). A second 
possibility is that there are antagonistic interactions between promoter elements when the 
wild type B box is used. In other words, transcription factors bind to the different 
promoter elements in both the U6 and tRNA promoters. This may lead to steric 
hindrance of transcriptional initiation in one of the two promoters. Since transcript levels 
from U6MW were greater than those observed from U6WW (Fig. 2), and the only 
difference between these two constructs lies in the tRNA promoter which harbors two 
point mutations in the B box, there may be less promoter interference with this construct. 
However, it is also possible that the transcripts with the mutant B box are more stable or 
are 3'-processed to a lesser extent than those with a wild type B box. This could also 
contribute to the higher intracellular level of U6MW over U6WW. 
Subcellular localization of the chimeric tRNAL"3-ribozymes 
After being transcribed in the nucleus, the chimeric tRNALYs3-ribozymes expressed 
under any promoter have to be exported to the cytoplasm for them to function in 
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inhibition of HIV replication. For a ribozyme utilizing the tRNALYs3 as a carrier to get 
packaged into the virions, this requirement is essential. 
Exportin-t was recently identified as a receptor responsible for mediating the export 
of tRNAs from the nucleus to the cytoplasm (Arts et al., 1998a, Kutay et al., 1998). 
Exportin-t was found to shuttle rapidly between the nucleus and cytoplasm and binds 
tRNA in a RanGTP-dependent manner. Ran binds GTP, but the GTP-bound form can 
change to a GDP form by GTP hydrolysis and nucleotide exchange. This is catalyzed by 
the GTPase activating protein RanGAP1 that is only present in the cytoplasm. Thus, 
RanGTP is depleted from the cytoplasm. In the nucleus, RanGTP is generated by the 
nucleotide exchange factor RCC1. Therefore, RanGTP is thought to exist in higher 
concentration in the nucleus than in the cytoplasm. This gradient leads to loading of 
tRNA in the nucleus and after passing through the nuclear pore complex, unloading in the 
cytoplasm. It was recently reported that the correct tRNA shape and the TwC loop are 
critical for exportin-t binding (Lipowsy et al., 1999; Arts et al., 1998b). 
There are reports which showed that small RNA molecules including ribozymes 
expressed from a tRNA gene can be expressed and localized in the cytoplasm (Koseki et 
al., 1999; Byes et al., 1996; Westaway et al., 1995; Gebhard et al., 1997). We 
demonstrated in this work that expression of chimeric tRNALYs3-ribozymes under a 
tRNA promoter alone or a juxtaposed U6 external and tRNA internal promoter both lead 
to detection of transcripts in the cytoplasmic compartment (Fig. 4), where they are 
available for encapsidation into HIV virions. 
Constructs with deletions involving the 3' terminal regions up to +62 in the coding 
sequence of the human tRNAMet gene were created to produce an unprocessed co- 
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transcript of tRNA and downstream sequences (Adeniyi-Jones et al., 1984). There have 
been reports of nuclear localization for transcripts expressed from such a tRNAMet 
promoter with the 3' sequence deleted after the B box (Good, 1997; Koseki et al., 1999). 
Another study showed 70% nuclear and 30% cytoplasmic localization from the same 
tRNAMet cassette (Du et al., 1998). Yet another report showed cytoplasmic expression 
from this cassette (Gebhard et al., 1997). While there was not a consensus when the 
3'deleted tRNAMet cassette was used, there seems to be an agreement when the whole 
tRNA sequence is used (lives etal., 1996; Koseki etal., 1999; Westaway et al., 1995 and 
this study). As suggested by recent findings in tRNA transport (Lipowsky et al., 1999), 
the correct tRNA shape is important for export through the exportin-t/RanGTP pathway. 
In 3' - deleted tRNAMet, the tRNA molecule is not able to maintain its shape and nuclear 
retention makes more sense, which is in agreement with most reports (Good, 1997; 
Koseki et al., 1999; Du et al., 1998). 
As suggested by computer modeling, the tRNA moieties in chimeric tRNALYs3-
ribozymes are expected to maintain their wild type tRNA shape. In addition, the 
expressed chimeric tRNALYs3-ribozyme transcripts are expected to maintain a mature 5'-
end, while the fate of the 3'-end deserves further study. With a CCA inherently expressed 
from the genes, we expect that the 3'end is going to be stable because it was shown that 
mature tRNA containing the 3' terminal CCA is not a substrate for 3'-tRNase, the enzyme 
responsible for the 3' processing of pre-tRNAs (Mohan et al., 1999). At least a significant 
proportion of our chimeric tRNALYs3-ribozyme remains intact (Fig. 3A) and a large 
proportion of these intact molecules can be exported into the cytoplasm (Fig. 4), evading 
the 3' processing which normally occurs in the nucleus. 
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It was reported that tRNAs lacking the CCA at the 3' end are much less efficient in 
exportin-t/RanGTP binding and therefore have deficient export (Lipowsky et al., 1999). 
Although unremoved 3' extensions decrease affinities of tRNAs with exportin-t/RanGTP 
(Lipowsky et al., 1999), it is possible that the decreased binding could be due to the 
absence of CCA in these tRNAs. Therefore, it is possible that tRNAs like the chimeric 
tRNAL4s3-ribozymes with CCA at 3'end of tRNA and with ribozyme as a 3' trailer after 
the CCA could still bind exportin-t and get exported into the cytoplasm. There have been 
several reports that transcribed tRNAs with 3' trailers for therapeutic purposes expressed 
from tRNA cassettes could be exported to the cytoplasm (Koseld et al., 1999; lives et al., 
1996 and this study). 
Aminoacylation of tRNA before export has been recently suggested to be a 
mechanism of proofreading for tRNAs (Lund & Dahlberg, 1998). Nevertheless, 
nonacylated tRNAs have been shown to bind exportin-t efficiently (Arts et al.,1998a, 
1998b, Lipowsky et al., 1999) and there have been reports showing that 
nonaminoacylated or poorly aminoacylated tRNAs can be exported efficiently (Lipowsky 
et al., 1999; Arts et al., 1998b). The chimeric tRNALYs3-ribozymes cannot be 
aminoacylated due to the presence of the ribozyme at the 3' end but this obviously did not 
abolish the export of these transcripts. 
There is evidence which suggests that tRNAs may get exported through exportin-t 
independent pathways (reviewed in Wolin and Matera, 1999 and Simos and Hurt, 1999). 
It is possible that the chimeric tRNALYs3-ribozymes may get exported through these 
pathways that are yet to be defined. 
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Short RNA transcripts (a stem loop structure, an antisense, a ribozyme, or an RNA 
aptamer) expressed under the U6 promoter with little or no U6 structural sequence, were 
found to be retained in the nucleus (Bertrand et al., 1997; Good et al., 1997). Our results 
demonstrate that the chimeric tRNA1-'Ys3-ribozymes expressed under the U6 promoter 
can be detected in the cytoplasm (Fig. 4). The promoter used was the same as one of the 
promoters used in Bertrand and Good's papers. The difference in subcellular localization 
is likely to be due to the nature of the transcripts, with tRNA characteristics helping to get 
the transcripts exported into the cytoplasm. There could be arguments that the 
cytoplasmic localization of transcripts from the dual U6/tRNA promoter could be a result 
of high level expression due to overwhelming expression from transient transfection that 
exceeds the nuclear transport pathway capacity of the nucleus, allowing the transcripts to 
"leak" from this compartment. However, this is unlikely because transcripts from several 
constructs which were expressed at levels of up to I million copies per cell did not leak 
out of the nucleus (Good et al; 1997). 
Efficient HIV inhibition 
The importance of intracellular colocalization of ribozymes with their targets has 
been well established (Sullenger and Cech, 1993; Bertrand et al., 1997). When expressed 
under the hybrid U6/tRNA promoter, the level of expression of the chimeric tRNALYs3-
ribozymes increases greatly (Fig. 3), while the cytoplasmic export of the transcripts is 
maintained (Fig. 4). It is therefore conceivable that the increased expression would lead 
to increased packaging of the tRNALYs3-ribozymes, and resultant increased inhibition of 
HIV infectivity. As can be seen in Fig. 5, the inhibition levels corresponded well with 
the relative levels of expression of the various constructs. Antisense molecules or 
ribozymes expressed under the U6 promoter alone with no tRNA sequence have been 
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found to be retained in the nucleus and showed no inhibition of HIV gene expression 
(Good et cd., 1997). Therefore, our findings once again highlight the importance of high 
level expression and intracellular colocalization of RNA therapeutics with their targets. 
Constructs with active ribozyme moieties in the chimeric tRNALY53-ribozyme 
(pU6WW and pU6MW) showed stronger inhibition of HIV than constructs with inactive 
ribozyme moieties (pU6WM and pU6MM; Fig. 5), demonstrating an advantage of the 
ribozyme over an inert antisense. The chimeric tRNALY53-ribozymes can be packaged 
into the virions (Westaway et al., 1998), therefore the ribozymes are highly colocalized 
with their targets inside a very limited space within the virions. This contributes to a 
greater probability for the ribozymes to interact with their targets. 
General considerations 
RNA polymerase III promoters have been widely used in expressing short therapeutic 
molecules. These include human tRNA genes (tRNA Met, e tRNAVal, tRNALys), human 
U6 small nuclear RNA genes, and adenovinis-associated RNA 1 (Ad VA1) gene 
promoters. There were many reports of using tRNAVal, tRNAMet and tRNALYs for 
driving the transcription of small RNAs including ribozyrnes, antisense molecules and 
RNA decoys. Despite the finding that the presence of a 3' trailer leads to decreased 
affinity with exportin-t (Lipowsky et al., 1999) as discussed previously, several studies 
showed that the transcripts from the tRNA promoter with a 3' trailer can lead to 
cytoplasmic localization of transcripts. Although it was found that the U6 promoter led to 
higher level expression than tRNA promoters (Heves et al., 1996), there were far fewer 
reports in using the U6 promoter for RNA expression presumably due to the nuclear 
localization of U6 snRNA and the finding that heterogeneous transcripts expressed from 
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the U6 promoter were also localized to the nucleus (lives et al., 1996; Bertrand_et a .9 
1997; Good et cd., 1997) and would not colocalize with mRNA or viral RNAs. 
The finding that expression from juxtaposed U6 and tRNA promoters can be used to 
express small therapeutic RNAs at high levels has meaningful implications for 
developing expression cassettes for therapeutic RNA molecules (ribozymes, antisense 
molecules and RNA aptamers). Besides the advantage of higher levels of expression, 
transcripts expressed from juxtaposed U6 and tRNA promoters have the tRNA structure 
as part of the chimera. When properly designed, the properties of the tRNA important for 
export can be reasonably well preserved in the chimera and export of the chimera can be 
facilitated and ensured by the presence of tRNA as a part of the structure. Therefore, it is 
worthwhile to test the feasibility of juxtaposing the U6 promoter with other useful tRNA 
expression systems such as tRNAVal or tRNAMet, which have been and are presently 
utilized for expressing therapeutic RNAs. These two RNA species are more abundant 
than tRNALYs (in vitro transcription experiments in human cell extract demonstrate a 
much higher level of transcription for tRNAVal than for tRNALYs3, Shawn Westaway, 
personal communication). 
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C. Transcription, stability and processing of chimeric 
tRNALP3-ribozymes 
Introduction 
Ribozymes are catalytic RNAs which can catalyze the endoribonucleolytic cleavage 
of RNA molecules (Cech, 1987). Upon formation of a complex with their complementary 
target RNA molecule, they catalyze the degradation and inactivation of the target RNA 
via a cleavage reaction. The hammerhead ribozyme, the smallest ribozyme identified 
(Guerrier-Takada et al., 1983; Kruger et al., 1982), has shown great potential in 
inhibiting specific gene functions. Hammerhead ribozymes have been designed to cleave 
a variety of target RNAs. Diseases with undesirable expression of RNAs such as 
malignant disorders, viral infections and genetic diseases are amenable to the actions of 
ribozymes (reviewed in Kiehntopf et al., 1995a and 1995b; Phylactou et al., 1998; 
Couture and Stinchcomb, 1996). 
RNA polymerase III promoters have been widely used in expressing RNA-based 
therapeutics including ribozymes, antisense molecules and decoys. Advantages of Poi III 
promoters over Poi II promoters include 1) RNA Pol III transcribed transcripts are more 
abundant than poly(Ar RNAs transcribed from Pol II promoters (Palmer et aL, 1990), 2) 
most RNA Poi HI-transcribed genes are ubiquitously expressed in many cell types and 3) 
Pol III transcripts are short and avoid the possibility that the ribozyme activity may be 
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masked in a long transcript. The RNA polym erase III promoters that have been used 
include the human U6 small nuclear RNA gene promoter, adenovirus-associated RNA 1 
(Ad VAI) gene promoter and tRNA gene promoters. tRNA gene promoters including 
tRNAmet and tRNAval  are the most commonly employed Poi III expression cassettes in 
the literature. The level of expression from the Poi III system is at least one order of 
magnitude higher than that obtainable from Poi II systems (Cotten and Bimstiel, 1989). 
While native tRNA molecules are small (around 75 bp), they are transcribed as 
precursor tRNAs and go through complex maturation processes including 5' processing, 
3' processing, splicing (for some tRNA species), base modifications, CCA addition, 
aminoacylation and export into the cytoplasm. Eukaryotic pre-tRNAs are 5' processed by 
RNase P, 3' processed by the 3' processing endoribonuclease (3' tRNase), and exported 
through interaction with the tRNA export machinery with exportin-t as the export 
receptor (Arts et al., 1998a, Kutay et al., 1998). A CCA sequence is added to the 3' end 
of the tRNA molecule before it is exported. ecause the tRNA promoters are intragenic, 
the transcripts produced from our tRNA expression cassettes are chimeric molecules with 
the tRNA as part of the RNAs. The exogenous RNA sequences in the tRNA chimerics 
should not be easily processed from the tRNA molecule. The chimeric transcripts should 
also be exported into the cytoplasm because the great majority of RNA therapeutics 
target cytoplasmic molecules. However, it has been reported that expression of 
exogenous sequences under a tRNA promoter allowed the liberation of the expressed 
molecule as a separate molecule upon tRNA processing (Lee et al., 1995). Attempts to 
enhance the stability of the chimeric transcripts (Adeneyi et al., 1984; Cotten and 
122 
Bimstiel, 1989; Koseki et aL, 1999) led to cytoplasmic (Koseki et al., 1999), or nuclear 
localization of the transcripts (Good et al., 1997; Bertrand et al., 1997; Koseki et al., 
1999; Cotten and Bimstiel, 1989) when the tRNA expression cassette was modified. 
Nuclear localization of the transcripts when the target molecules are cytoplasmic would 
certainly greatly discount the effectiveness of these RNA-based therapeutics. 
Because tRNA promoters are widely used in RNA-based gene therapy endeavors, 
studies on proper tRNA expression cassette design should be undertaken to achieve high 
level expression of stable transcripts with proper subcellular localization before using the 
promoters in practical applications. We developed effective anti-HW chimeric tRNAL1s3-
ribozymes, in which a ribozyme targeting immediately upstream of the primer binding 
site of HIV genome was fused to the 3' end of tRNAL1s3. When expressed under the 
tRNALYs3  promoter in cells cotransfected with HIV proviral DNA, the chimeric tRNALYs3-
ribozyme can be encapsidated into virions and reduce the infectivity of those virions 
(Westaway et al., 1998). We also developed a U6/tRNA expression cassette, in which the 
human U6 snRNA is adjoined upstream of the tRNALYs3 promoter for expressing the 
chimeric tRNALYs3-ribozymes. The hybrid U6/tRNA Poi III promoter cassette expresses 
the chimeric tRNALYs3-ribozymes at much higher levels than expression from the tRNA 
promoter alone. The transcripts were exported into the cytoplasm and enhanced inhibiting 
activity against HIV was observed (Chapter III, Part B). 
To investigate further the feasibility of using such chimeric U6 and tRNA promoters 
in tandem for transcribing ribozyrnes or other tRNA chimerics for practical applications, 
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we first studied the transcripts made from such constructs and compared them with 
transcripts expressed from the tRNALYs3  promoter alone. We found the major species of 
transcript is intact and is the same size regardless of promoter used. The relative level of 
expression of these transcripts was demonstrated to be close to that of endogenous 
tRNALYs3  in the construct with the highest expression level. 
The effects of several modifications of chimeric tRNALys3-ribozyrne structure on the 
stability of transcripts and the effect of increased stability upon inhibition of HIV 
infectivity were also studied. With an increased understanding of tRNA export and tRNA 
processing, more optimal designs for increasing stability and directing proper 
intracellular localization are becoming realities. According to recent developments in 
tRNA export and 3' processing of tRNA (Arts et al.,1998a and 1998b; Kutay et aL, 
1998; Lipowsy et al., 1999; Nashimoto et al., 1996; 1997; 1999 ), we hypothesized that 
several modifications in tRNA structure, including an encoded CCA in between the 
tRNA and the ribozyme, PFC loop mutations and a deletion of one G in the T stern could 
lead to an increase in the steady-state level while retaining the export property of the 
transcripts. We expect these changes to increase the stability of the intact transcripts 
because similar changes were reported to greatly reduce the action of the 3' processing 
endoribonuclease (3' tRNase) (Nashimoto et al. , 1996; 1997; 1999). One construct with a 
deletion in the T stem led to increased stability of transcripts in cell extracts and this 
chimeric tRNALYs3-ribozyme showed better inhibition of HIV infectivity. 
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Results 
Construction of chimeric tRNALYs3-ribozymes expressed under different 
promoters 
We reported that chimeric tRNA1 Ys3-ribozymes could effectively inhibit HIV 
infectivity by virion encapsidation (Westaway et al., 1998). In these constructs, 
hammerhead ribozymes were fused to the 3' end of the tRNALYs3. As in native tRNALYs3, 
18 nucleotides at the 3'end of the tRNA moiety of the chimera are complementary to the 
HIV-1 primer binding site (PBS). These ribozymes target immediately upstream of the 
PBS of the HIV genome. 
In this study, several constructs with different modifications in the tRNALYs3 moiety 
of the chimeric constructs were studied. One construct named pWW contains a functional 
(wild type) ribozyme fused downstream of the wild type tRNALYs3 sequence (Fig. 1A). 
Another construct has mutations in the B box of the tRNALYs3 promoter. In replace of the 
wild type B box sequence (GGTTCAAGTCC), two mutations were introduced and gave 
rise to the sequence GCTACAAGTCC (Fig. 1B). This construct is named pMW, 
denoting mutant (M) tRNA and wild type ribozyme (W). The mutations were reported to 
abolish transcription from the tRNA internal promoter during in vitro experiments 
(Murphy et al., 1983). Although we found that these mutations significantly reduce 
expression in mammalian cells (293 cells), they did not completely eliminate 
transcription of the chimeric tRNALYs3-ribozymes (Chapter III, Part B). Another chimeric 
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box of the tRNA sequence in the T stem (Fig. 1C), and has been described previously 
(Westaway et al., 1998). 
As mentioned earlier, the chimeric tRNAL1s3-ribozyme transcripts may be subject to 
3' processing by the 3' processing endoribonuclease. The 3' trailer of mammalian pre-
tRNA is removed by the 3' processing endoribonuclease (3' tRNase) which cleaves the • 
RNA immediately downstream of the discriminator nucleotide (the unpaired nucleotide 
3' of the last base pair of the acceptor stem), onto which CCA residues are added to 
produce mature tRNAs. The CCA sequence is required for aminoacylation. We 
hypothesized that several modifications in these chimeric tRNAL1s3-ribozyme constructs 
could reduce the processing of the transcripts. First, a CCA sequence is inserted in 
between the tRNALYs3  and the ribozyme sequence in our design of chimeric tRNALYs3-
ribozymes to make these mimic the end of mature tRNA. It was reported that tRNAs with 
a 3' trailer composed of CC, CCA or CCA plus one or two nucleotides were not 
processed by the 3' processing endoribonuclease at all and tRNAs with a 19 nt 3' trailer 
beginning with CCA were processed at very low efficiency only (Nashimoto, 1997; 
Nashimoto et al., 1999). Second, it was reported that changes or deletions in the TWC 
loop could reduce the cleavage efficiency by 3' tRNase(Nashimoto, 1996 and Nashimoto 
et al., 1999). Transcripts from MW have two point mutations located in the TTC stem 
and loop (Fig. 1B) and therefore could have reduced 3' processing and increased 
stability. Third, one and two base- pair deletions in the T stem were poorly processed by 
3' tRNase (Nashimoto et al., 1999). pAGTRz with a deletion of one G in the T stem 
immediately 5' of the B box would have one less base-pair in the T stem (Fig. 1C) and 
129 
should theoretically reduce the 3' processing of the transcripts. In pMW, the upstream 
mutation would also result in one less base-pair in the T stem and could also reduce the 
processing of the transcripts (Fig. 1B). 
Chimeric tRNALYs3-ribozyme genes with restriction sites for adapting into cloning 
vectors were synthesized from different oligonucleotides as described previously 
(Materials and Methods, Chapter II). The chimeric tRNALYs3-ribozymes were subcioned 
into another vector pTZU6+1, downstream of the human U6 snRNA promoter and these 
gave rise to the constructs pU6WW, pU6MW and pU6AGTRz (Fig. 1A, B, C). The U6 
promoter was shown to enhance expression of the chimeric tRNALYs3-ribozymes, with the 
highest expression level in p16MW (Chapter III, Part B). The same ribozyme sequence 
without the tRNA sequence was directly cloned into 0713'6+1 vector under the U6 
promoter, giving rise to pU6Rz (Fig. 1D and see Materials and Methods, Chapter II). 
This construct would allow the comparison of the stability of the ribozyme with or 
without the tRNA structure as part of the molecule, an important study only made 
possible by the use of an upstream U6 promoter. This construct also allows the 
comparison of expression levels from the hybrid U6/tRNA promoter and the U6 promoter 
alone. The gene structure of the hybrid U6/tRNA promoter driving the expression of the 
chimeric tRNALYs3-ribozymes is depicted in the lower panel of Fig. 1E. The gene 
structure of human U6 siiRNA gene with promoter elements and structural gene sequence 
is shown in the upper panel of Fig. lE for comparison. 
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To make stable cell lines and to study the stability of these chimeric ribozymes in 
these stable cell lines, we subcloned the chimeric tRNALYs3-ribozymes into an adeno-
associated virus (AAV) vector with a neo gene. These constructs were termed 
pAAVU6WW, pAAVU6MW, pAAVU6WM and pAAVU6AGTRz. These were 
transfected into 293 cells and stable cell lines expressing these chimeric tRNALYs3-
ribozymes under the dual U6/tRNA promoter were made by selection with G418. 
Qualitative differences in transcripts from the tRNA promoter alone and 
from the hybrid U6/tRNA promoters 
Previously, quantitative comparisons of expressions under tRNA promoters (pWW 
with wild type B box and pMW with mutant tRNA B box) and hybrid U6/tRNA 
promoters (WW and MW under the U6 promoter without the U6 structural gene 
sequence) were conducted (Chapter III, Part B). It was found that the construct pMW 
with the mutant tRNA B box led to decreased (not abolished) expression compared with 
the construct pWW with the wild type tRNA B box. However, expression from hybrid 
U6/mutant tRNA promoters in the construct pU6MW led to much higher expression than 
that obtained from the hybrid U6/wild type tRNA promoters in the construct pU6WW. 
This apparent paradox was explained in terms of steric interference caused by the binding 
of transcription factors to the U6 and tRNA promoters, with stronger interference 
between the wild type tRNA promoter and the U6 promoters. It was also suggested that 
the transcripts from pU6MW could be more stable due to mutations in the TwC stem 
which could lead to decreased processing by the 3'- tRNase. However, the interference 
between the U6 and tRNA promoters was just inferred from the quantitative difference in 
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expression levels (Chapter III, Part B; Parry et al., 1990). In addition to the quantitative 
difference in expression, the steric interference from the two promoters could also result 
in qualitative changes in the initiation sites of the transcripts. 
One of the objectives in this paper is to study the qualitative difference of the 
transcripts from the tRNA promoter alone and from the hybrid U6/tRNA promoters. 
Different constructs with different promoter elements including pMW, pWW, pU6MW 
and pU6WW, were employed,. They were transiently transfected into 293 cells and after 
48 hours, total cellular RNAs were isolated and purified. The total RNAs were then 
separated on a 6% denaturing polyacrylamide gel and subsequently electroblotted onto a 
nylon membrane. The membranes were then probed with an oligo specific for the 
tRNA(Fig. 2A). Following hybridization with the tRNA probe, the membrane was 
stripped and reprobed with a ribozyme-specific probe (Fig. 2B). 
The tRNA-ribozyme is not present in the mock-transfected cells (lane 5, Fig. 2A and 
2B). In constructs with tRNA promoters, i.e., pMW and pWW, there are differences in 
the amount of transcripts. In the tRNA promoter with mutant B box, there is a transcript 
Xi, which is similar in size to the in vitro transcribed chimeric tRNA-ribozyme (Fig. 2B, 
lane 1 and lane 61 ) and another transcript X2 initiated about 60 bp upstream of X1 . In 
I  In vivo expressed chimeric ribozymes have extra 5' sequences (6 bp restriction site). In lane 6, in vitro 
transcribed RNAs are used as RNA markers. The template for the chimeric ribozyme is a PCR product that 
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pWW the transcripts Xi and X2 are similar in size with those expressed from pMW (Fig. 
2B, lane 2). There exists yet another transcript X3 initiated about 5-6 bp downstream of 
the Xl, which is expressed from the pWW but absent in transcripts from pMW (Fig. 2B, 
lanes 1 and 2). 
In constructs with hybrid U6/tRNA promoters, U6MW and U6WW (Fig. 2, lanes 3 
and 4), the major transcript X1 expressed from pU6MW and pU6WW are similar in size 
to those expressed from pMW and pWW (Fig. 2B, cf. lanes 3 and 4 with lanes 1 and 2). 
The transcript X3 from pU6WW is similar with the X3 transcript in WW (Fig. 2B, cf. 
lane 4 with lane 2). However, the upstream minor band X2 was shifted about 15 bases 
downstream (Fig. 2B, cf lanes 3 and 4 with lanes 1 and 2). Because the ribozyme probe is 
complementary to the 3' end of the transcript, the change in size is most probably due to 
a downstream shift of the 5' initiation site. This could be the result of interference 
between the transcription factors bound to the U6 and the tRNA promoter elements (Fig. 
1E). In U6WW, another transcript X4 that is about 5 bases shorter than X2, is present 
below X2 (Fig. 2B lane 4). However, despite the interference that results in downstream 
initiation of a minor species of transcript, the two promoters enhance total expression 
when utilized in constructs such as pU6MW and pU6WW (Chapter III, Part B). 
The X1 and X3 doublet present in pWW and pU6WW could be the result of 
differential initiation from transcription complexes bound to U6 promoter elements and 
tRNA promoter elements. If this is true, it may be a manifestation of interference between 
the two promoters and could explain the lower level of expression in U6WW compared 
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with U6MW (see Chapter III, Part 13). The mutations in the B box may lead to different 
positioning of the transcription complex that does not allow interference between U6 and 
tRNA promoter elements and as a result only one major band is visible. On the contrary, 
there is a possibility that the mutations in the B box could favor synergism between the 
U6 and tRNA promoters (transcription complexes bound to the two promoters 
synergistically initiate from the same site). Alternatively, the shorter one of these two 
bands could be the result of processing by the tRNA 5' processing enzyme RNase P. The 
mutation in the B box could possibly interfere with the processing by RNase P, resulting 
in the absence of the smaller band X3 of the doublet in lane 1 of Fig. 2B. 
In the tRNA probed gel (Fig. 2A), a transcript of more than 40 bp is present. This 
could be a prematurely terminated transcript due to the presence of a run of four U's in 
the anticodon loop of the tRNA moiety (Fig. 1). This string of U's may constitute a weak 
Poi III termination signal (four Ts in the tRNALYs3 gene). The band is also faintly visible 
in the mock transfected sample (Fig. 2A). 
Relative intracellular levels of chimeric tRNALP3-ribozymes and 
endogenous tRNALYs3 and increased stability of transcripts with mutations 
in P.M stem-loop 
It was reported that HIV virions recruit tRNALYs3 from the cytoplasm by the 
interaction of the precursor of reverse transcriptase, Pr160Gag-mpolyprotein with 
tRNALYs3 (Mak et al., 1994). tRNA'' and tRNALYs2 are also packaged into HIV virions. 
Because of the limited space inside the virions or the limited number of molecules of 
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Pr160Gag-po1,  the number of molecules of tRNAs incorporated into the virions is limited 
(Huang et al., 1994). It has been shown that in cells cotransfected with HIV proviral 
DNA and a human tRNALYs3 gene, there is a large increase in the amount of cytoplasmic 
tRNALYs3 packaged into the virions with a concomitant decrease in the amount of 
tRNALYsl and tRNALYs2 packaged, while the total amount of tRNALYs molecules remains 
the same (Huang et al., 1994). As we previously demonstrated, our chimeric tRNALYs3-
ribozymes get packaged into the HW virions (Westaway et al., 1998). Therefore, it can 
be expected that if we increase the intracellular expression level of chimeric tRNALYs3-
ribozymes, the copy numbers of the chimera would increase while the number of 
-cRNALYs3 packaged should decrease. 
The intracellular expression levels of chimeric tRNAL1s3-ribozymes are compared 
with the level of intracellular tRNALYs3 in the transient transfection assay. 293 cells were 
transfected with different chimeric tRNALYs3 ribozyme constructs and the levels of 
expression of the chimeric tRNALYs3-ribozymes and the level of tRNALYs3 were 
determined by Northern hybridization with a probe specific to the tRNALYs3, which detect 
both chimeric tRNALYs3-ribozymes and tRNALYs3. Because the chimeric tRNALYs3-
ribozymes can be processed to tRNALYs3 size (see later in Fig. 5), the tRNALYs3 band 
could be from native tRNALYs3 and processed tRNALYs3-ribozyme. The result is shown in 
Fig. 2A. The levels of chimeric tRNALYs3-ribozymes are compared with the tRNALYs3 
level in the same sample by getting a chimeric tRNALYs3-ribozyme to tRNALYs3 ratio (tc/t 
ratio; tc stands for tRNA chimeric and t stands for tRNA; Table 1). Because the tc/t ratio 
is obtained from two molecules within the same sample, no loading control is necessary. 
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tch ratio analysis (Relative volumes of different bands) 
Samples  tc/t ratio (Chimeric tRNA-ribozyme bands/tRNA band) ' 
MW  0.57 - WW  0.28 , ... U6MW  0.74 
U6VVW  0.21 
Mock transfected S 	 Not Applicable 
Table 1. tc/t analysis for evaluating chimeric tRNALYs3-ribozyme transcript stability 
and assessing relative chimeric tRNALYs3-ribozyme expression levels. 
tc stands for tRNA chimeric and t stand for tRNA. Because chimeric tRNA-ribozymes 
(or other tRNA chimerics fused to the 3' end of tRNA) can be processed to the size of 
tRNA (Fig. 7), more stable transcripts would have a higher tc/t ratio. 
Summary of interpretation of tc/t analysis: 
• Transcripts with equal stability and equal promoter strength should have the same Wit 
ratio. 
• Unstable transcripts with strong or weak promoter: low tc/t ratio. 
• Stable transcripts with weak promoter: higher tc/t ratio than unstable transcripts. 
• Stable transcripts with strong promoter: even higher tc/t ratio. 
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The ratio represents the relative amount of intracellular levels of chimeric tRNALYs3-
ribozyrnes compared with tRNALYs3 and a higher ratio is advantageous because it could 
lead to more molecules of chimeric tRNALYs3-ribozymes getting competitively packaged 
into the virions. It can be seen in U6MW that the level of chimeric tRNALYs3-ribozyme 
can be very close to the level of tRNALYs3 (a tc/t of 0.74), although a portion of the 
tRNALYs3 band may come from the processed chimeric tRNAL4s3-ribozyme. 
A higher tc/t ratio could also be a reflection of the stability or 3' processibility of the 
chimeric tRNALYs3-ribozyme transcripts. An increased Wit ratio could be due to decreased 
processing or degradation of the transcripts or increased promoter strength. Significantly 
higher tc/t ratios were observed in MW (a tc/t of 0.57) and U6MW (0.74) and very low 
ratios in WW (0.28) and U6WW (0.21). In MW, the increased ratio could not be the 
result of promoter strength change, because the mutations in the B box in the construct 
would result in a weaker promoter (Chapter III, Part B; Murphy et al., 1983). However, 
in U6MW, a much stronger promoter (the U6 promoter upstream of the mutant tRNA 
promoter) in the presence of stable transcripts (essentially the same transcripts as MW) 
does increase the tc/t ratio even further, indicating a role of both higher stability and 
higher promoter strength for the highest expression level of U6MW among these 
constructs (Chapter 1111, Part B). The Wit ratio of WW is much lower than that of MW, 
despite of the fact that WW has a much stronger promoter than MW (Murphy et al., 
1983). This could explain why the intracellular level of MW could reach a comparable, 
albeit lower level than WW (Chapter III, Part B). However, increased promoter strength 
in the face of unstable or easily processed transcripts is not likely to increase the Wit ratio 
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because the increased tRNA chimeric (tc) transcripts would rapidly be converted to tRNA 
(0 size. This is observed in U6WW; it has a stronger promoter than WW (Chapter III, 
Part B) but only has a tc/t ratio similar to that of WW. it can be concluded that the 
mutations in the B box of MW and U6MW result in somewhat more stable transcripts. 
Intracellular stability of transfected chimeric tRNALYs3-ribozymes in 
transient transfection analysis 
The ribozyrne structures were fused to the 3' end of the tRNA sequence. We included 
a CCA sequence at the 3' end of the tRNA sequence in between the tRNA and the 
ribozyme sequence. In prokaryotic cells, this sequence is encoded in the tRNA gene, 
while in eukaryotic cells this sequence is added to the 3' end of the tRNA by the CCA-
adding enzyme after 3' end processing (Deutscher, 1990). We expect that this sequence 
could help to stabilize the tRNA-ribozyme structure because the transcripts made this 
way would mimic the mature tRNA structure. 
It has been reported that mature tRNA with added CCA (tRNA-3'+ CCA) is not a 
substrate for YARNase. The 3'-tRNase is not inhibited by excess tRNA+CCA, ensuring 
that the 3'-tRNase can remain free to process precursor tRNAs with 3'end trailers and 
tRNAs can progress to aminoacylation. it was postulated that the active site of 3'-tRNase 
might have a poor fit with tRNA+CCA (Mohan et al., 1999; Nashimoto, 1995). If this is 
the case, we expect that the tRNA+CCA structure could possibly enhance the stability of 
the ribozymes. 
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In order to study the contribution to stability of the tRNA±CCA structure in the 
chimeric tRNAL1s3-ribozymes, we used constructs in which the chimeric tRNALYs3-
ribozymes are inserted under the U6 promoter as well as a construct containing the 
ribozyme without the tRNA structure, also under the U6 promoter. We also wanted to 
examine if the mutations in the B box, which are present in pU6MW, have any effect on 
the stability of the transcripts. Two assay systems were used for analyzing the 
intracellular stability of the transcripts. 
In the first system, 293 cells were transiently transfected with pU6WW, pU6MW, 
pU6AGTRz and pU6Rz. To normalize for transfection efficiency, a non-related reference 
growth factor expressing plasmid pTKGH was cotransfected with constructs expressing 
chimeric tRNALYs3-ribozyrnes. After 48 hours, transcription was halted by adding 
actinomycin D to the culture medium. Total RNA was isolated at different time points. 
The RNA samples were then subject to Northern hybridization and analyzed for half-
lives (Fig. 3 A, B). The endogenous U6 snRNA level was monitored as a loading control 
since its half-life is known to be 16-24 h (Sauterer et al., 1988; Terns et al., 1993; 
Noonberg et al., 1994). The loading was normalized according to the half-life-adjusted 
native U6 level. The half-lives of U6WW, U6MW, U6AGTRz and U6Rz were shown to 
be approximately 25 to 50 minutes (Fig. 3C) . The use of a U6 promoter driven ribozyme 
sequence without the tRNA sequence allowed comparison of the stability of the chimeric 
tRNALYs3-ribozyme transcripts with stand-alone ribozyme transcripts. It was found that 
the half life of the stand-alone ribozyme is about 63 min (Fig. 3C). 
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Figure 3. Stability of ribozyme and chimeric tRNALYs3-ribozymes in transiently 
transfected 293 cells. 	- 
The half-lives of the ribozyme or chimeric ribozyme transcripts are determined by 
transiently transfecting 293 cells with different constructs (pU6WW, pU6MW, 
pU6AGTRz and pU6Rz). After 48 hours, transcription was halted by adding actinomycin 
D. Total RNA samples were isolated at different time intervals and the RNA samples 
were then analyzed and quantitated by Northern hybridization with ribozyme a specific 
probe. 
A. Determination of half-lives of transcripts from pU6WW and pU6MW (Northern 
hybridization with a ribozyme specific probe). 
B. Determination of half-lives of transcripts from pU6AGTRz and pU6Rz (Northern 
hybridization with a ribozyme specific probe). 
C. The half-lives of the transcripts from different constructs were calculated and 
compared from quantitation of the ribozyme RNA levels remaining at different time 
points. Values indicate percent intact RNA remaining compared to time 0. 
Quantitation involves normalization of transfection efficiency and normalization of 
loading variations with U6 snRNA level probed with a U6 snRNA specific probe 
(data not shown). Half life of U6 snRNA was taken into account. 
Note: Although the half-life of the U6Rz is a bit longer than the other chimeric 
transcripts, the intracellular level of U66,GTRz is much higher than that of U6Rz (B) 
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Intracellular stability of chimeric tRNALYs3-ribozymes in stable cell lines 
expressed under the U6ARNA promoters 
In the second assay, the stability of the transcripts from U6WW, U6MW and 
U6AGTRz were analyzed under more natural, intracellular conditions in stable cell lines. 
Cell lines stably expressing U6WW, U6MW and U6AGTRz were established and we 
determined the half-life of the transcripts by halting intracellular RNA polymerase III 
transcription with actinomycin D. Endogenous U6 snRNA levels were monitored and 
used as a loading normalization control. The half-lives of the transcripts were determined 
to be similar with those obtained from transient transfections (Fig. 4). These results 
indicate that the absolute increase in chimeric tRNALYs3-ribozyme steady-state levels do 
not affect our half-life determinations, indicating a first-order process of transcript 
degradation. 
One deletion in the TtpC stem increases the stability of the chimeric 
tRNALYs3-ribozyme in cell extract 
The construct with a deletion in the TwC stem (AG) may have increased resistance to 
3' processing due to the involvement of the stem in interaction with 3' processing 
endoribonuclease (3'-tRNase; Nashimoto et al 1999). We further compared the stability 
of transcripts from the AGTRz tRNA-ribozyme with transcripts from WW tRNA-
ribozyme in cell extracts that harbor tRNA processing activities. The cell extract was 
prepared from 293 cells as described in Materials and Methods. In vitro transcribed 
chimeric tRNALYs3-ribozyrne transcripts from AGTRz and WW were incubated with the 
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Half-lives of chimeric tRNALYs3-ribozymes 
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Figure 4. Stability of chimeric tRNALYs3-ribozymes in stable transformants. 
Transformants stably expressing U6WW, U6MW and U6AGTRz were obtained by 
transfecting 293 cells with pAAVU6WW, pAAVU6MW and pAAVU6AGTRz and 
selecting clones with G418. The half-lives of the chimeric tRNALYs3-ribozyme transcripts 
are determined by halting transcription by adding actinomycin D. Total RNA samples 
were isolated at different time intervals. The half-lives of the transcripts from different 
constructs were then calculated and compared. Values indicate percent intact RNA 
remaining compared to time O. 
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cell extract for 30 minutes. The AGTRz transcripts (147-149 bps) are longer than the 
WW transcripts (121-123 bps) because longer 5' polylinker sequence is present in the 
pAGTRz construct (Fig. 5 lanes 2-4 vs. lanes 5-6). As suggested elsewhere, the in vitro 
system exhibits relatively slow processing kinetics (Adeniyi-Jones et al., 1983) and this 
allowed us to analyze the stability and processing of transcripts from different constructs. 
It can be seen that part of the pWW transcripts were processed to the approximate tRNA 
\ size (both ends processed, about 75 bps) and pAGTRz transcripts were processed to 3' 
processed size (104-106 bps) only (and it can be seen that the transcripts from AGTRz 
have markedly reduced processing than transcripts from WW (compare lanes 5, 6 with 
lanes 2, 3 in Fig. 5). 
Increased stability resulted in stronger HIV inhibition 
Since transcripts from AGTRz show increased resistance to 3' end processing, we 
subdoned this ZIGTRz sequence under the U6 promoter in a dual U6/tRNA promoter 
design to maximize the intracellular level of the chimeric tRNALYs3-ribozyme. The anti-
HIV effect of the construct pU6AGTRz was compared with that of pU6MW. 
293 cells were cotransfected with proviral HIV DNA and chimeric tRNALYs3-
ribozyme constructs (pU6MW, pU6AGTRz and pU6Rz). The infectivity of the 
supernatant with normalized RT counts was then checked as described before (Westaway 
et al., 1998). The results showed that the AGTRz transcript expressed under the dual 
'MARNA promoters had the highest HIV inhibition activity (Fig. 6). The inhibition is 
stronger than that obtained with pU6MW, in accordance with the increased resistance of 
148 
Sample Marker WW WW WW AG AG AG tRNA tRNA tRNA 
Extract 	 — 
2 3 4 5 6 7 8 9 10 
Figure 5. Processing of chimeric tRNA-ribozymes in cell extract. 
Cell extract with tRNA processing activity was isolated from 293 cells as described in 
Materials and Methods. Chimeric tRNALYs3-ribozymes (WW and AGTRz) and tRNALYs3  
were transcribed and labeled with [a-32P]UTP by in vitro T7 transcription using 
linearized plasmids as templates. The transcripts were then incubated with (-1--) or without 
(-) cell extract in a 3'-end processing buffer (see Materials and Methods). The processing 
reactions were then separated on a 10% denaturing acrylamide gel. 
AG: AGTRz tRNA: tRNALYs3. 
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pli6WW pU6AGTRz pU6Rz pTZU6+1 
Figure 6. Inhibition of HIV infectivity by chimeric tRNALYs3-ribozymes. 
293 cells were cotransfected with proviral DNA, anti-HIV ribozyme constructs (pWW, 
pMW, pU6WW, pU6MW, pU6AGTRz, pU6Rz) or a vector control pTZU6+1. 48 hours 
later, supernatants were collected and the RT activity was assayed. CEM cells were 
infected with the supernatants from the transfection with equalized RT counts. The p24 
level in culture media from these infections were assayed and compared after six and 
seven days. 10 jig anti-HIV ribozyme and I jig proviral DNA were used. 
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transcripts from pU6AGTRz to 3' end processing. Interestingly, the ribozyme expressed 
under the U6 promoter alone exhibits same HIV inhibition effect, which may be mediated 
prior to HIV encapsidation. 
Discussion 
Ribozymes are potentially powerful tools for suppressing the expression of specific 
genes. They can be engineered to cleave other RNA molecules with high specificity 
(Haseloff et al., 1988; Uhlenbeck, 1987) and are therefore not likely to interfere with 
normal cellular functions. They also have the advantage of being less immunogenic than 
protein-based therapeutics. In addition to an antisense effect, ribozymes have additional 
benefits in that they can cleave the target and recycle to cleave additional molecules. 
The successful development of a suitable expression cassette is one major challenge 
related to the use of RNA-based molecules including ribozymes, antisense RNAs, decoy 
RNAs and aptamers as therapeutic agents. tRNA promoters have been popularly used in 
the expression of different RNA-based therapeutics. However, the transcripts expressed 
from these cassettes can be subject to the action of the tRNA 3' processing 
endoribonuclease (3'-tRNase) and the stability of these transcripts inside cells becomes 
crucial for their practical use in intracellular immunization. 
Despite the popularity of tRNA expression cassettes, relatively little is known about 
the intracellular characteristics of the expressed transcripts. We previously demonstrated 
that an anti-HIV chimeric tRNALYs3-ribozyme cassette could be placed under the human 
U6 snRNA promoter, resulting in a much higher expression level than that from the 
151 
tRNALYs3 promoter alone (Chapter III, Part B). Here, we qualitatively studied the 
transcripts from the tRNA promoter alone or dual U6/tRNA. Intact chimeric tRNALYs3-
ribozymes expressed from the tRNA expression cassette and U6/tRNA expression 
cassette were detectable in cells. The lower level of expression when the wild type B box 
rather than the mutant B box of tRNA was put under the U6 promoter could be due to 
stronger interference between the wild type B box and the U6 promoter. Differences in 
resistance to 3' end processing could also contribute. Transcription factors bound to the 
different promoter elements of the two promoters (Fig. 1E) could sterically interfere with 
each other. 
In this study, we analyzed the effect on resistance to 3' end processing of CCA at the 
3' end of tRNAs harboring mutations in the B box or a deletion of one G residue in the 
PIT stem. As mentioned in the introduction, the presence of the CCA at the end of 
tRNA molecules causes inefficient cleavage by the 3' processing endoribonuclease 
(Nashimoto, 1997 and Nashimoto et al., 1999). The constructs pU6WW, pU6MW, 
pU6AGTRz all have CCA encoded between the tRNA and the ribozyme sequence. The 
construct pU6AGTRz has a deletion of one G immediately 5' of the B box in the T stem 
and this deletion would lead to one reduced base-pair in the T stem, which could in turn 
lead to reduced processing by 3' tRNase (Nashimoto et al., 1999). The construct pU6MW 
has two base mutations in the B box present in the T stem-loop. The 5' mutation could 
also result in one less base pair in the PPC stem and the 3' mutation is in the TIPC loop. 
Changes in this loop were also reported to reduce the processing activity of 3' tRNase 
(Nashimoto, 1996 and Nashimoto et al., 1999). One advantage of the U6/tRNA dual 
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promoter system is that the sequence of the B box can be changed to achieve higher 
stability of the construct and the expression level is not likely to be affected since the U6 
promoter predominates due to lack of promoter interference. 
As reported in the literature, modifications in the tRNA expression cassette could lead 
to nuclear retention of the transcripts. Constructs with a deletion of the last ii bases of 
the human tRNAmet gene were developed to produce an unprocessed co-transcript of 
tRNA and downstream sequences (Adeniyi-Jones et al., 1984). This is probably because 
• the deletion would lead to 'disrupted base-pairs in the acceptor stem and T stem which are 
recognized by 3'-tRNase (Nashimoto, 1999). Nevertheless, transcripts from the 3' 
deleted cassette were found to remain in the nucleus in two studies (Good et al., 1997; 
Koseki et al., 1999) probably as a result of disrupted secondary and tertiary structure of 
the tRNA recognized by the export machinery (Lipowsy et al., 1999; Arts GJ et al., 
1998b). Therefore, stability is increased but cytoplasmic export of the transcripts is 
sacrificed. Another interpretation is that nuclear retention enhances stability. For most 
gene inhibition applications of ribozymes, cytoplasmic export of the transcripts is 
essential. Ribozymes retained in the nucleus can only be used against a very narrow 
range of targets such as splice sites, introns or polyadenylation signals and would not be 
desirable where the RNA to be cleaved is quickly exported to the cytoplasm. Our 
constructs would maintain the secondary structure and overall shape of the tRNA and we 
expect that the transcripts would have a reasonable chance of being transported into the 
cytoplasm. 
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In the half-life determination assay, the half-life of the transcripts from pU6WW, 
pU6MW and pU6AGTRz were found to range from 25 minutes to 50 minutes (Fig. 3). 
These are somewhat shorter than the half-life of the ribozyme transcript without the 
tRNA moiety (about 63 minutes). However, the overall intracellular level of transcripts 
from the dual U6/tRNA cassettes (U6WW, U6MW and U6AGTRz) are much higher than 
the level of the ribozyme alone expressed from the U6 promoter (Fig. 3B). The half-lives 
of these are sufficiently long, in the context of the strong U6/tRNA expression cassette, to 
give rise to very high intracellular level of the chimeric tRNALYs3-ribozymes (Chapter III, 
Part B). The intracOular chimeric tRNALYs3-ribozyme level is comparable to that of 
tRNALYs3 sized band in U6MW (Fig. 2A and Table 1) although tRNAILYs3 sized band 
could be native tRNALYs3 or be from 3'-processed chimeric tRNALYs3-ribozyme. This 
stability in combination with the high level expression could make the chimeric 
tRNALYs3-ribozyme transcripts competitive for packaging into the HIV virions, 
contributing to their efficient HIV inhibition. Once inside the virions, these should 
function efficiently, because they are highly colocalized with their substrate. In addition, 
they should remain intact, because the 3' processing endoribonuclease and other 
processing enzymes are not specifically packaged into virions. In other words, the 
tRNALYs3 expression cassette is advantageous in that the tRNALYs3 moiety of the chimeric 
tRNALYs3-ribozymes facilitates the colocalization of the ribozyme with its target not only 
for enhanced cleavage action, but also for increased ribozyme stability. 
The half-lives achieved are comparable to those obtained by strategies for enhancing 
stabilities of other tRNA chimeric& These changes in the expression cassette give rise to 
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transcripts with stabilities comparable to those obtained from other stabilizing strategies. 
In one study, chimeric tRNAval-ribozyme constructs were constructed by attaching the 
ribozyme sequence to the 3' end of the tRNA and making the 3' terminus of the ribozyme 
complementary to the 3' terminus of tRNAv 1. These were found to be exported to the 
cytoplasm. The half lives of the constructs were about 35 to 100 minutes (Koseki et al.., 
1999). In another study, constructs with a ribozyme sequence inserted into the anticodon 
loop of tRNALYs3 with linkers were found to have half-lives of 50 to 80 minutes (Medina 
et al., 1999). In another study, constructs with a ribozyme inserted into the anticodon loop 
of tRNAme were found to have transcripts mainly localized to the nucleus (Cotton and 
Bimstiel, 1989). The transcripts have greater stability when assayed in a nuclear extract 
(data not shown in the paper). In another study, a tRNAmet expression cassette was 
modified so that the 3' terminus of the transcript was complementary to the 5' terminus 
and this resulted in improved accumulation of transcripts by >100 fold (Thompson et al., 
1995). Because the PIT loop and the overall shape of tRNA which has been found to be 
important for the export of the tRNA molecules (Lipowsy et al., 1999; Arts et A, 1998b) 
is modified, the subcellular localization of these transcripts deserves further study. Can 
we adopt these strategies in our chimeric tRNALYs3-ribozyme? Obviously, the strategy of 
putting our ribozyme into the anticodon of tRNA is not feasible for our chimeric 
tRNALYs3-ribozyme because of the resultant nuclear localization of the transcripts. The 
strategy of making the 3' end of the ribozyme complementary to the 5' end of the tRNA 
would be difficult in our case because of the requirement for the 3' 18 nt of tRNALYs3 to 
anneal to the PBS of HIV genome. 
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The half-life assay could be subject to some inaccuracies because the time that is 
required to process each sample could give rise to some errors. The tc/t ratio analysis 
could be more accurate because the ratio is obtained from the same lane (sample) and 
variations in loading would not affect the ratio. In such an analysis, the mutations in the B 
box were found to significantly increase the level of the transcripts. In a processing assay 
of transcripts made from pWW and RAGTRz in cell extracts, the transcripts from 
pAGTRz showed little if any processing, indicating a significant effect of the deletion of 
one G in the T stem on the stability of the chimeric tRNALYs3-ribozyme. This in vitro 
assay is much less error-prone, since the in vitro processing kinetics are slow (Adeniyi-
Jones et al., 1983).When AGTRz is expressed under the strong U6/tRNA promoter, the 
construct showed stronger inhibition of HIV infectivity than pU6MW (Fig. 6). As 
reported earlier (Chapter III, Part B), transcripts from AGTRz and MW could be exported 
to the cytoplasm. This is probably due to the maintenance of the overall shape of the 
tRNA structure and other properties recognized by the tRNA export machinery. 
As a result of increased promoter strength and increased transcript stability, the 
relative expression level of the chimeric tRNALYs3-ribozyme MW reaches a level close to 
that of tRNALYs3, which can consist of both native tRNALYs3 and processed chimeric 
tRNALYs3-ribozyme. This gives the chimeric tRNALYs3-ribozyme transcripts a chance to 
be effectively packaged into the virions. 
In conclusion, these modifications in tRNA-ribozyme expression cassettes, including 
the linear arrangement of `tRNA-FCCA-l-ribozyme' sequences, in combination with 
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mutations in the PIT loop, or especially with the deletion of one G in the T stem, have 
been shown to give rise to a higher overall level of tRNA-ribozyme transcripts. The 
transcripts can be exported to the cytoplasm. When expressed under the U6/tRNA dual 
promoter, these result in cytoplasmic accumulation of very high levels of chimeric 
tRNALYs3-ribozyme transcripts that are efficient in HIV inhibition. These modifications 
may prove valuable in the design of other chimeric tRNAs for expressing RNA-based 
therapeutics in general. The tc/t ratio analysis is an easy and accurate way for 
determining stability of chimeric tRNA transcripts different in size from the original 
tRNA molecule. It could be easier to perform and interpret because the tc/t ratio is 
obtained within the same sample and inter-sample experimental and quantitative errors 
that could be present in cell extract processing assays can be avoided. It may be valuable 
for the analysis of other chimeric tRNA chimerics to obtain constructs with optimal 
stability in studies using any tRNA expression cassette for expressing RNA-based 
therapeutics (ribozymes, antisense RNAs, decoys and aptamer RNAs). 
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IV. GENE A  L DISCUSSION 
Ribozymes are catalytic RNAs that can catalyze the endoribonucleolytic cleavage of 
RNA molecules (Cech, 1987). Ribozymes form a complex with their complementary 
target RNA molecule and then catalyze the degradation and inactivation of the target 
RNA via a cleavage reaction. Hammerhead ribozymes have shown great potential in 
inhibiting specific gene functions and have been designed to target a variety of RNAs. 
•Many diseases show undesirable expression of RNAs, such as malignant disorders, viral 
infections and genetic diseases and, therefore, are amenable to the actions of ribozymes 
(reviewed in Kiehntopf et al., 1995a and 1995b; Phylactou et al., 1998; Couture and 
Stinchcomb, 1996). 
A number of groups have reported the use of ribozymes in inhibiting HIV-1 infection. 
In 1990, Rossi and colleagues first reported the use of a hammerhead ribozyme targeting 
the gag sequences to inhibit HIV-1 replication (Sarver et aL, 1990). Hammerhead 
ribozymes against H1V-1 tat and tat/rev genes developed by this group (Zhou et al., 
1994) have already been under evaluation in clinical trials for several years. For more 
details on the application of ribozymes to HIV infection, see a review by John Rossi 
(Rossi, 1999). 
It can be conceived that ribozymes would work more efficiently if they can be 
localized to the same subcellular compartment with their targets inside the cells. The 
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importance of intracellular colocalization of ribozymes with their targets has been very 
well established (Sullenger and Cech, 1993; Bertrand et al., 1997; Pal et al., 1998). In 
particular, Rossi and colleagues demonstrated that a ribozyme was effective only when it 
was expressed cytoplasmically and colocalizes with the cytoplasmic targets (Bertrand et 
al., 1997). 
Enhancing the colocalization of anti-HIV ribozymes with their targets and enhancing 
the efficacy of these ribozymes is one of the major goals of my research. In reported 
colocalization studies, the retroviral Psi (w) signal tethered to ribozymes was utilized as a 
colocalization strategy (Sullenger and Cech, 1993; Pal et al., 1998). In this study, we 
employed a novel colocalization strategy in which anti-HIV ribozymes were fused to the 
3' end of tRNALYs3 sequence. tRNALYs3 is the natural primer employed by HIV-1 for 
initiating reverse transcription. It is recruited by the virions during virion packaging 
through inteactions with the polyprotein precursor of RT, Prl 6OGag- m from host cells 
(Mak et al., 1994). The tRNALYs3 moiety of the chimeric tRNA1 Ys3-ribozyme is expected 
to maintain the natural tertiary structure as demonstrated by computer modeling. The 
chimeric tRNALYs3-ribozyme also showed similar binding affinity to RT (Westaway et 
al., 1998), the portion of Pr160Gag-Pol  which is responsible for interacting with tRNALYs3 
(Mak et al., 1994). Therefore, we expect that the anti-HIV ribozymes can be brought into 
HIV virions through the interactions of the tRNALYs3 moiety with Pr160Gag-P°1 during 
virion encapsidation. Thus, the ribozymes can be expected to colocalize with the cleavage 
target site on HIV genome inside the virions, thereby, aiding in efficient viral inhibition.. 
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In addition, the ribozymes fused to the 3' end of the tRNALYs3 can be expressed from the 
internal promoters of tRNALYs3, generating chimeric tRNALYs3-ribozyme molecules. 
The chimeric tRNALYs3-ribozymes could go through a complex series of processing 
and transport events which could inhibit incorporation into HIV virions. For the chimeric 
tRNALYs3-ribozymes to be effective at inhibiting HIV infection, they should, (1) be 
produced at highest possible levels tolerable to cells, (2) be exported into the cytoplasm, 
(3) be stabilized in cells and, (4) interact with the precursor of RT for packaging into 
virions. To maximize anti-H1V activities by the ribozymes, I studied the colocalization of 
ribozymes with their target, determined the encapsidation of the ribozymes into the 
virions, explored a novel hybrid Pol III promoter expression cassette in order to increase 
the intracellular expression level of the chimeric tRNALYs3-ribozymes and also studied the 
intracellular stability of the chimeric tRNALYs3-ribozyme transcripts. The chimeric 
tRNALYs3-ribozymes were also studied for capability to inhibit HIV infectivity. 
The chimeric tRNALYs3-ribozyme was designed to target immediately upstream of the 
primer binding site of human immunodeficiency virus (HIV) and was fused to the 3' end 
of the tRNALYs3 gene. It was found to be catalytically active in vitro, and was efficiently 
recognized and bound by HIV-1 reverse transcriptase with affinities similar to tRNALYs3. 
The chimeric tRNALYs3-ribozyme could be detected in virions purified from cells 
cotransfected with the chimeric ribozyme and HIV proviral DNA, indicating that the 
chimeric tRNALYs3-ribozyme has been packaged into the virions. These virions were 
shown to have reduced infectivity in subsequent rounds of infection of CD4+ cells. 
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These results indicate that the natural primer of HIV, tRNALYs3, can be used as a 
carrier to bring therapeutic ribozymes into virions, thereby colocalizing the ribozyme 
with their targets RNAs. 
It is very important to maximize the ribozyme to substrate ratio to ensure maximal in 
vivo substrate inhibition by ribozymes (Cotten and Bimstiel, 1989). To achieve this goal, 
I inserted the chimeric tRNALYs3-ribozymes under a human U6 small nuclear RNA 
promoter. In such constructs, two promoters were put in tandem, with an extragenic 
upstream U6 promoter and an intragenic tRNA promoter (A box and B box). 
To compare the levels of expression of the chimeric tRNALYs3-ribozymes under the 
U6 promoter and under the tRNA promoter alone, Human embryonic kidney 293 cells 
were transiently transfected with the chimeric ribozyme plasmids and total RNAs were 
isolated and analyzed by Northern hybridization 48h later. The overall level of expression 
of the chimeric tRNALYs3-ribozymes under the U6/tRNA dual promoter was found to be 
elevated relevant to expression from the tRNA internal promoter alone. The highest 
expression was observed from the dual U6A4tRNA promoters, which includes the U6 
promoter upstream of a tRNA promoter harboring mutations in the B box 
(GCTACAAGTCC). This construct had more abundant expression than the dual 
U6/WtRNA promoters harboring the U6 promoter upstream of the tRNA promoter with 
wild-type B box(GGTTCAAGTCC). 
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The transcripts made from the tRNA promoter and the dual U6/tRNA promoters were 
also analyzed qualitatively. It was found that when the tRNA-ribozyme genes were 
placed under the U6 promoter, one species of the transcripts initiated downstream of the 
site normally utilized in the tRNA promoter. The lower level of expression observed 
when the wild type B box versus the mutant B box of tRNALYs3 was put under the U6 
promoter could be due to interference between the wild type B box and the U6 promoter. 
Transcription factors bound to the different promoter elements of the two promoters 
could sterically hinder each other. Such interference could change the initiation site of 
transcription and could also adversely affect the levels of transcription. However, the 
entire chimeric tRNALYs3-ribozyme sequence is present in all transcripts. The 5' end 
processing of these transcripts should generate the same 5' ends but this was not the case. 
Despite this interference between promoter elements, the two promoters juxtaposed in 
tandem do provide enhancement of transcription. The expression levels from these hybrid 
U6/tRNA expression cassettes are much higher than from the tRNA or U6 promoter 
alone. 
For the chimeric tRNALYs3-ribozymes to be packaged into virions, the transcripts have 
to be exported into the cytoplasm. There have been varying reports of the intracellular 
localization of transcripts made from chimeric tRNA genes. While several reports 
showed cytoplasmic localization of chimeric transcripts (Koseki et al., 1999; Ilves et al., 
1996; Westaway et al., 1995; Gebhard et al., 1997), there have been reports of nuclear 
localization as well (Good, 1997; Koseki etal., 1999). 
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Because the tRNA moiety in the chimeric tRNALYs3-ribozymes should maintain 
native tRNA folding, we expect that the tRNA could be exported to the cytoplasm. We 
also expect the transcripts from the dual U6/tRNA promoters to be localized to the 
cytoplasm, since the tRNA moiety is the determining factor for facilitating export, 
By transiently transfecting cells with different constructs and detecting the transcripts 
with riboprobes complementary to the ribozyme sequence, we demonstrated that the 
transcripts from the hybrid U6/tRNA promoters could be exported into the cytoplasm. It 
was demonstrated that transcripts expressed under the internal tRNA promoter alone 
localized to the cytoplasm and transcripts expressed under U6 and tRNA promoter in 
tandem localized evenly to both the cytoplasm and nucleus. The cytoplasmic expression 
makes the ribozymes available for packaging during virion encapsidation. HIV inhibition 
data showed that HIV inhibition corresponds with expression level, with the greatest 
level of inhibition deriving from the construct with dual U6/MtRNA promoters. These 
findings with the U6/tRNA expression cassettes are very important because they 
demonstrated that two juxtaposed RNA polymerase III promoters, namely, the U6 and 
tRNA promoters, could be used in tandem to express small RNA therapeutic genetic 
materials much more efficiently, allowing cytoplasmic accumulation. 
We also studied the effect of several modifications in the tRNA sequence of the 
tRNA expression cassette on the stability of transcripts. Natural pre-tRNAs are 5' 
processed by RNase P and 3' processed by 3' tRNase. A CCA sequence is added to the 3' 
end of native tRNA after the 3' trailer is processed by 3' tRNase. The chimeric tRNALYs3- 
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ribozymes may also be subjected to processing by the 3' tRNase, making the chimeric 
tRNALYs3-ribozymes unstable. The chimeric tRNALYs3-ribozymes were designed to have a 
CCA sequence between the tRNA and the ribozyme moieties. A stabilization effect was 
expected because the CCA sequence in between the tRNA and the ribozyme could 
protect against 3'-processing endoribonuclease (3'-tRNase) activity. It has been reported 
that tRNAs with CCA at 3' ends are not substrates for the 3'-tRNase in vitro (Mohan et 
al., 1999; Nashimoto, 1995). Constructs with the CCA sequence in between the tRNA 
and the ribozyme sequence were designed to have two point mutations in the TTC stern-
loop (MW and U6MW), or a one base deletion in the PFC stem (6,GTRz and 
U6dGTRZ). The point mutations in MW and U6MW would lead to a mutation in the 
PVC loop and one less base pair in the 'FTC stem. The deletion of one G in the PPC 
stem would also lead to one less base pair in the PPC stem. Changes in the PIT loop 
and basepairing in the TTC stem have been shown to reduce processing by the 3'-tRNase 
tRNase (Nashimoto, 1996 and Nashimoto et al., 1999). 
The stability of the transcripts of chimeric tRNALYs3-ribozymes were studied by 
expressing them in Human embryonic kidney 293 cells and subsequently blocking 
transcription by exposure to actinomycin D. Total RNAs were isolated at different time 
points after treatment with actinomycin D and the chimeric tRNALYs3-ribozyme transcript 
levels were analyzed by Northern hybridization. The half-lives of the transcripts were 
analyzed. The half-lives of the constructs analyzed were from 25-50 min (Figure 3 of 
Chapter III, part C). The half-lives of these were sufficiently long to give rise to high 
intracellular levels of the chimeric tRNALYs3-ribozymes. The half-lives achieved are 
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comparable to those obtained by other strategies for enhancing tRNA chimeric stability 
(Koseki et al., 1999; Medina et al., 1999). 
In a tc/t analysis, an analysis of the ratio of the intracellular level of tRNA chimerics 
(tc, chimeric tRNALYs3-ribozymes here) and tRNA (t, tRNALYs3 here) suggests that the 
MW construct is more stable than WW (Figure 2 and Table 1 of Chapter III, Part C). The 
Wit analysis proposed here can potentially be used in the screening of tRNA expression 
cassettes with increased transcript stability (Table 1 of Chapter III, Part C). 
Compared with pWW, the construct pAGTRz was shown to have reduced processing 
in a Human embryonic kidney 293 cell extract, which has active tRNA 3' processing 
enzyme activity. This chimeric tRNALYs3-ribozyme construct with one G deletion right at 
the 5' end of the B box could be more stable because the deletion leads to disruption of 
one base pair in the INIC stem, which was found to be related to the interaction of 3'-
tRNase with tRNA (Nashimoto et aL, 1999). This was supported by one HIV inhibition 
experiment in which this construct expressed under U6 promoter was found to have a 
stronger inhibition on HIV than the construct U6MW (Fig. 5, Chapter III, Part C). 
tRNA processing, tRNA export as well as the encapsidation and role in initiating 
reverse transcription are all very complex processes. Likewise, the chimeric tRNALYs3-
ribozymes are also inevitably involved in complex interactions with different cellular and 
viral components. An attempt to simplify these processes is outlined in Figure 1 with an 
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Mechanisms of HIV inhibition by the 
chimeric tRNALYs3 Ribozymes 
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Figure 1. An overview of the mechanisms of HIV inhibition by the chimeric 
tRNALYs3-ribozymes. 
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overview of the possible mechanisms of HIV inhibition by the chimeric tRNALYs3-
ribozymes. These mechanisms are now discussed in greater depth. 
The U6/tRNA expression cassette has an upstream U6 promoter and the intragenic 
tRNA promoter placed in tandem and resulted in much higher expression than the tRNA 
expression cassette alone. Therefore, U6 promoter acts synergistically with the tRNA 
promoter in enhancing the expression level of the chimeric transcripts. This is an 
important observation because U6 promoter and tRNA promoter have been traditionally 
utilized separately in expressing RNA therapeutics. The U6/tRNA expression cassette, 
therefore, has the potential to be used in expressing other RNA therapeutics including 
ribozymes, antisense and decoys. 
The tRNA moiety in the tRNALYs3-ribozyme chimera plays several pivotal roles. On 
one hand, it works symergistically with the upstream U6 promoter in enhancing 
expression from the hybrid Poi III promoter. On the other hand, the tRNA moiety acts 
through a piggyback mechanism to bring the anti-HIV ribozyme into virions. 
Endogenous tRNALYs3, the primer for initiating reverse transcription, is brought into the 
virions through interaction with the precursor polyprotein of RT, Pri 6Øflag- P°1 (Mak et al., 
1994). Our chimeric tRNALYs3-ribozymes showed affmities to RT and were therefore, 
expected to be incorporated into virions through a similar mechanism. 
In addition, the ability of the transcripts from these constructs to be exported 
cytoplasmically (Part B of Chapter III) most likely lies in the tRNA moieties of the 
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transcripts. The receptor, exportin-t, for tRNA export has only recently been identified 
(Arts et al., 1998a, Kutay et al., 1998) and not much is yet known about the interactions 
between exportin-t and tRNA molecules. The correct tRNA shape and the D4tiC loop 
were recently reported to be critical for exportin-t binding (Lipowsy et al., 1999; Arts et 
al., 1998b). Notably the tRNA moieties in the chimeric tRNALYs3-ribozymes should 
maintain their tertiary structure as demonstrated by computer modeling and therefore are 
expected to maintain their affinity to exportin-t. The cytoplasmic export of the transcripts 
makes these available for encapsidation into HIV-1 virions, which was demonstrated in 
virions obtained in a cotransfection assay with proviral 1IV-1 DNA and our constructs. 
Therefore, the tRNALYs3 moiety plays a crucial role in colocalizing the ribozyme with its 
target on the HIV genome. 
The tRNALYs3 moiety in the chimera could also function as a decoy for RT. Because 
the chimeric transcripts have affinity with RT, they can potentially compete with natural 
tRNALYs3 primer in interacting with RT or its precursor, Pr160Gag-m during encapsidation 
and reverse transcription when expressed at high intracellular levels. The 3' end of the 
tRNALYs3 moiety in the chimera is complementary to the PBS of HIV and, therefore, may 
have an antisense effect. The CCA sequence in between the tRNA moiety and the 
ribozyme, as well changes in the PPC stem-loop, may assist in stabilizing the chimeric 
transcripts. 
The ribozyme moiety of the chimera plays a relatively simple role when compared to 
the U6 promoter sequence and the tRNA moiety. Constructs with active ribozyme 
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moieties showed stronger inhibition than constructs with inactive ribozyme moieties, 
suggesting active ribozyme cleavage of 	genomic RNA in the virion. The anti-HIV 
effects demonstrable in the constructs with inactive ribozymes are presumably due to the 
inherent antisense effect of the inactive ribozyme and the tRNA moiety, as well as the 
decoy effect from the tRNA moiety. 
The intracellular stability of ribozymes has always been a great concern in practical 
applications. While our chimeric tRNALYs3-ribozymes are sufficiently stable to maintain 
the high level expression by the hybrid U6/tRNA cassette, their stability may deserve 
further improvement. While tRNA molecules are small (about 76 bp), they are involved 
in very complex interactions with different enzymes and translationally associated 
proteins. Some of the processes related to the use of tRNA expression vectors include 5' 
processing, 3' processing, intervening sequence splicing, base modifications and export 
into cytoplasm. The processes which would most likely affect the feasibility of using the 
tRNA expression vectors include 3' processing and export. 
While there have been reports that ribozymes expressed from tRNA promoters can be 
stabilized several ways, these designs are very likely to affect other aspects of the 
intracellular fates of these transcripts. Stability may be increased at the expense of export 
properties due to changes in the overall shape of the tRNA-based transcripts. The overall 
shape (tertiary structure) of tRNA has been shown to he very important for interactions of 
tRNA with exportin-t, part of the tRNA export machinery (Lipowsky et al., 1999; Arts et 
al., 1998b). Ribozymes that remain in the nucleus would have a narrow range of targets 
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including splice sites, introns or polyadenylation signals and would not be desirable for 
cleaving RNAs which are cytoplasmic. No comprehensive studies on this issue are 
available at the present time. Because tRNA promoters are very widely used in gene 
therapy, comprehensive studies addressing these issues should be carried out. Positive 
results from such studies would represent a big technical advancement for gene therapy 
applications using ribozymes and other small RNA based therapeutics. 
A few approaches have been attempted for improving the stability of transcripts 
expressed from tRNA promoters. These include 3' 11 base deletion of mature tRNA, 
insertion of the ribozyme sequence into the anticodon loop of tRNAs, and incorporation 
of structures at the 3' terminus of the transcripts which hybridize to the 5' terminus. 
Constructs with a deletion of the last 11 bases of the human tRNAmet gene were 
developed to produce an unprocessed co-transcript of a tRNAmet and downstream 
sequences (Adeniyi-Jones et aL, 1984). Nevertheless, transcripts from the 3' deleted 
cassette were found to localize to the nucleus in two studies (Good et al., 1997; Koseki et 
al., 1999). Another study showed 70% nuclear and 30% cytoplasmic localization from 
the same tRNAmet cassette (Du et al., 1998). Yet another report showed cytoplasmic 
expression from the cassette (Gebhard et al., 1997). Since the recent work of Koseki et 
al. (1999) confirmed the nuclear localization of transcripts from such a cassette using the 
same construct as Good et al. (1997), nuclear localization seems a more likely destination 
of such transcripts. The deletions would disrupt the secondary structure of the acceptor 
stem and change the overall shape of the resulting transcripts. These transcripts are not 
likely to interact with the exportin-t, which would lead to nuclear retention. Therefore, 
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the nuclear localization of transcripts from such expression cassette is in accordance with 
the findings that the overall shape of tRNAs are crucial for the export of tRNA transcripts 
studies (Good et al., 1997; Koseki et al., 1999). 
Another approach for inserting ribozymes or antisense in tRNAs involves placement 
into the anticodon loop of the tRNA sequence. Cotten and Bimstiel placed a ribozyme 
coding sequence between the A and B box of a Xenopus tRNAmet gene (Cotten and 
Bimstiel, 1989). The tRNA-ribozyme transcripts produced inside frog oocytes had half-
lives much shorter than tRNAmet. There was little evidence to support a hypothesis that 
placing the ribozyme within the tRNA structure enhanced its stability because the tRNA-
ribozyme transcripts appeared to decay more rapidly than tRNAmet. However, it was 
claimed that transcripts from such a construct had a greater stability than the linear 
ribozyme when assayed in a nuclear extract. The expressed tRNA-ribozyme was also 
found to remain nuclear with only a small portion entering the cytoplasm. 
Thompson et al. (1995) tried to insert a number of novel structural elements into a 
tRNA-ribozyme chimera. One construct was designed to have the 3' terminus of the 
transcript hybridize to the 5' terminus. This gave rise to more than a 100 fold 
accumulation of ribozymes expressed from a tRNAmet promoter. In another study, 
utilizing chimeric tRNA' al ribozymes, the last seven bases of the mature tRNA' al were 
removed in order to block 3' end processing of the transcript (Koseki et al., 1999). These 
sequences were replaced by a linker followed by a ribozyme and additional linker 
sequences that hybridize to the 5' terminus of tRNA'. The transcripts from these were 
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exported to the cytoplasm. The half lives of transcripts from three of these constructs 
were about 35,40 and 100 min. The most stable construct inhibited HIV most efficiently 
(Koseki et al., 1999). Although the cytoplasmic localization could be due to the 
maintenance of the native shape of tRNA, the increased stability could be due to the 
secondary structure of the ribozyme moiety, rather than the 3' seven base deletion of 
mature tRNA'. This deletion was intended to block 3' processing and was replaced by a 
linker that could restore the base pairs present in the native tRNAval. 
One of our chimeric tRNA-ribozymes, the pAGTRz, showed reduced processing in 
cell extracts. This is in agreement with Nashimoto's result (1999), showing that the 
number of base pairs in the TwC stem is one factor recognized by 3' tRNase. Further 
deletions or modifications in the secondary structure or sequences recognized by 3'-
tRNase have the potential of leading to even greater stability. The selection of these 
modifications should be guided by our ever-increasing understanding of the 3' processing 
process. Care should also be taken not to disrupt the recognition sequence utilized by the 
tRNA export receptor exportin-t. As our knowledge of the interactions between 3' 
tRNase and exportin-t and the tRNA molecules increases, the design of transcripts with 
increased stability should become more feasible. Modifications intended for increasing 
transcripts with increased stability can be tested by using the tc/t analysis (Table 1 of 
Chapter III, Part C). 
The deletion of eleven bases at the 3' end of tRNA have been widely adopted to 
increase the intracellular stability of transcripts expressed (see Chapter I for more 
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details). This would disrupt the secondary structure recognized by 3'-tRNase (Nashimoto, 
1999) and lead to increased stability, but would also result in nuclear retention of 
transcripts (Good et al., 1997; Koseki et al., 1999) because the tRNA shape is recognized 
by the tRNA export machinery (Lipowsky et al., 1999; Arts et aL, 1998b). 
The ribozyme can be attached to the 3' end of tRNALYs3 and secondary structure can 
be incorporated to make the 3' terminus hybridize with the 5' end of the transcript. This 
would result in greater stability (Thompson et al. 1995; Koseki et al., 1999). However, 
our chimeric tRNALYs3-ribozyrnes have a 3' end of 18 nucleotides which are 
complementary to the HIV PBS sequence. The secondary structure is likely to make 
annealing of these 18 nt with the PBS difficult. If this approach is to be tried, the 
ribozyme should be targeted to other sites, making the 3' end design more versatile for 
targeting other sites. Cytoplasmic localization of such transcripts appears to be possible 
(Koseki et al., 1999). 
SELEX (Systemic Evolution of Ligands by EXponential enrichment) is a procedure 
for isolating high-affinity ligands to a target protein from a pool of variant nucleic acid 
sequences (Tuerk and Gold, 1990). We intend to modify the in vitro SELEX procedure 
and use what we call an in vivo SELEX procedure to select mutant chimeric tRNALYs3-
ribozymes with increased stability, efficient export and increased affinity for RT, and 
hence increased encapsidation. Mutations would be introduced into the chimeric 
tRNALYs3-ribozymes by mutagenic PCR. These would be used in cotransfection of cells 
with proviral HIV DNA. The virions produced would preferably incorporate these variant 
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chimeric tRNALYs3-ribozyme mutants. This approach would select for decreased 
interaction with 3' tRNase, increased interaction with export machinery and increased 
interaction with RT simultaneously. 
The dual U6/tRNA expression cassette for expressing the chimeric tRNALYs3-
ribozymes has an additional advantage. Since the B box is likely to be involved in the 3' 
processing, it allows us to select for mutations in the B box which increase stability 
without compromising the transcription levels (with increased transcription levels as a 
matter of fact). 
Lastly, I would like to propose some additional experiments that deserve further 
considerations 
• Compare in greater details the expression levels from U6 promoter alone (without any 
tRNA sequences — the U6Rz construct) and U6/tRNA expression cassette to more 
definitively determine the superiority of the U6/tRNA expression cassette over the U6 
or tRNA expression cassette alone. 
• Compare the expression from U6AGTRz and U6MM, the two constructs with the 
highest stability. 
• Compare the HIV inhibition capabilities of more constructs including constructs with 
tRNALYs3  expression cassette alone, U6 promoter expression cassette alone and 
U6/tRNA expression cassette. 
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• Test the efficacy of the chimeric tRNALYs3-ribozymes expressed from the AAV vector 
and retroviral vector in anti-HIV assays. 
• Carry out in vivo SELEX (see above). 
Below are a couple of more distantly related research areas that I think are important: 
• Test the affinity of the chimeric tRNALYs3-ribozymes with exportin-t and assay the 
export properties in the Xenopus microinjection system. This study is important 
because tRNA promoters have been widely used in expressing RNA therapeutics but 
little is known about the export properties and mechanisms. 
• Use of tRNALYsl or tRNALYs2 instead of tRNALYs3 as a colocalization vehicle as well 
as a promoter. These can also be placed in the U6/tRNA expression cassette. This 
approach would allow targeting of additional sites on the HIV genome because these 
tRNAs would not interfere with the primer binding site, yet are incorporated into 
HIV-1 virions at high copy numbers (Huang et al., 1994). 
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VI. APPENDIXES 
1. List of constructs 
Table 1. List of plasmids used/constructed 
Name Parent Vector Features Constructed 
by 
pWW  pBlueScript SK+ Wild type tRNAI, wild type ribozyme2 Z. Chang 
pMW  pBlueScript SK+ Mutant tRNA3, wild type ribozyme Z. Chang _ 
pWM  pBlueScript SK+ Wild type tRNA, mutant ribozyme4 Z. Chang 
pMM  pBlueScript SK+ Mutant tRNA, mutant ribozyme Z. Chang 
pAGTRz  G.P. Larson 
pTZ U6+1 	_  pTZ U6+1 . , E. Betrand 
pU6WW  pTZ U6+1 WW under U6 promoter Z. Chang 
pU6MW  pTZ U6+1 MW under U6 promoter Z. Chang 
pU6WM  pTZ U6+1 WM under U6 promoter , Z. Chang 
pU6MM  pTZ U6+1 MM under U6 promoter Z. Chang 
pU6AGTRz  pTZ U6+1 AGTRz under U6 promoter Z. Chang 
pU6Rz  pTZ U6+1 Z. Chang 
pAAVU6WW  pAAV U6+1 WW under U6 promoter in AAV vector Z. Chang 
pAAVU6MW  pAAV U6+1 	, MW under U6 promoter in AAV vector Z. Chang 
pAAVU6WM  pAAV U6+1 WM under U6 promoter in AAV vector Z. Chang 
pAAVU6MM  pAAV U6+1 MM under U6 promoter in AAV vector Z. Chang 
pAAVU6AGTRz pAAV U6+1 AGTRz under U6 promoter in AAV vector S.K. Westaway 
Note: 
1. Wild-type tRNA: tRNA gene with wild type B box sequence: GGTTCAAGTCC 
2. Wild-type ribozyme: wild type ribozyme sequence with catalytic activity. 
3. Mutant tRNA: tRNA gene with two mutations in B box sequence: GCTACAAGTCC. 
The mutations were reported to abolish transcription from the tRNA promoter in vitro 
(Murphy et al., 1983). 
4. Mutant ribozyme: one mutation in the catalytic core of the ribozyme sequence, which 
was reported to abolish ribozyme catalytic activity (Ruffner et al., 1990). 
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2. Testing of anti-retroviral tRNALYs3-ribozymes in adeno-
associated virus (AAV) vectors 
Four different chimeric tRNALYs3-ribozymes with different combinations of wild type 
tRNA promoter, mutant tRNA promoter, wild-type ribozyme and mutant ribozymes were 
cloned into an AAV vector under a human U6 snRNA promoter. These constructs 
include WW, MW, WM and MM [the first letter indicates wild type (W) or mutant tRNA 
promoter (M) and the second letter indicates wild type (W) or mutant ribozyme (M)]. The 
constructs with mutations in the tRNA promoter and/or in the catalytic core of the 
ribozyme serve as controls. 
These anti-HIV chimeric tRNALYs3-ribozymes were successfully constructed into the 
adeno-associated virus vector and the constructs were named pAAVU6WW, 
pAAVU6MW, pAAVU6WM and pAAVNIM. The construction was more sophisticated 
than originally contemplated and took much longer time than originally planned. The 
AAV vector has two homologous sequences, the inverted terminal repeats (ITRs). These 
two ITRs are unstable and the constructs often have small deletions which include parts 
of ITRs. These are undesirable for the vectors because they are important in proper 
packaging and exprssion of the vectors in the host cells. 
The constructs from the first construction were found to have these deletions. In 
addition to checking for the correct inserts, they were checked via digestions with several 
restriction enzymes (Bgl II, Aisic l and Sma 1). These enzymes cleave at restriction sites 
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that are present in the ITRs and give rise to restriction digestion patterns that would 
suggest the intactness or presence of deletions in ITRs. The pattern of the digestion 
suggested the presence of small deletions in the ITRs. The construction was repeated and 
the constructs obtained were then transformed into a different bacterial strain. A 
commercially available bacterial strain called Max Efficiency Stb12 Competent Cells 
(Life Technologies) was used. We expect that the bacterial strain may potentially 
stabilize the inverted terminal repeats (ITRs) in the AAV vector. The constructs were 
checked and found to have intact ITRs. 
Instead of packaging the AAV vectors and analyzing the constructs in transduction 
assays as originally planned, we made stable cell lines in 293 cells by selecting with 
G418 for expression of the neo gene in the constructs. Several clones were picked and 
total RNA was isolated. The expression levels of the chimeric tRNALYs3-ribozymes were 
quantitated and compared in a Northern hybridization analysis. The intracellular 
localization of the transcripts was checked in a FISH (fluorescent in situ hybridization) 
assay. The FISH assay failed to detect the chimeric tRNALYs3-ribozyme in stably 
transfected cells, but they were detected in Northern hybridization (Figure 1). FISH 
analyses of the expression of these constructs following transient transfection detected 
the chimeric tRNALYs3-ribozymes in the cytoplasm. The clones with the highest 
expression levels (Figure 1) were used in analyses of the stabilities of the chimeric 
tRNALYs3-ribozymes in vivo. The half-lives of the constructs were analyzed and found to 
be about 30 minutes. 
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The stable clones with the highest expression levels were also studied in an anti-HIV 
assay. The assay failed to detect the levels of anti-HIV effects previously demonstrated in 
transient transfections. This could be due to the fact that the levels of expression from the 
AAV vectors in the stable cell lines were insufficient to elicit anti-viral activity. 
Therefore, enhanced expression in stable cell lines is a task that deserves more research 
efforts and is a source of future research efforts. 
3. Compilation of additional data 
1. 	Selection of clones of cells stably expressing chimeric tRNALYs3-ribozymes 
AAV 	1-p 1-2 1-4 2-lp 2-2p 2-1 2-2 2-3 2-4 3-1 3-2 3-5 	M 10bp M 	3-1 	3-2 	3-5 
Figure 1. Selection of clones of cells stably expressing chimeric tRNALYs3-ribozymes. 
293 Cells transfected with the plasmids pAAVTJ6WW, pAAVU6MW and 
pAAVU6WM are selected with G418 as described previously. The following clones were 
obtained: AAV U6+1 vector control: AAV; AAVU6WW: 1-p, 1-2, 1-4; AAVU6MW: 2-
























Total RNA samples were isolated from these clones and the expression levels of the 
chimeric tRNALYs3-ribozymes checked by Northern hybridization with a wild type 
ribozyme-specific probe (left-upper panel and a mutant ribozyme specific probe (right 
upper panel). The same membrane was stripped and rehybridized with a U6 snRNA 
specific probe to normalize for loading variations (lower left and lower right panels). The 
membranes were quantified with a phosphoimager and analyzed with ImageQuant 
software. The clones were compared for expression levels. Figure 2 shows that clones 1-2 
and 2-2 have the highest expression of WW and MW chimeric tRNALYs3-ribozymes. It is 
obvious from Figure 1 that clone 3-1 has the highest expression of WM. 
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Figure 2. Selection of stable clones with highest expression level of chimeric 
tRNALYs3-ribozymes (AAVU6WW and AAVU6MW). 
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2. Binding assay of chimeric tRNALYs3-ribozymes and reverse transcriptase 
The protocol for the experiment was described in Chapter II: Methods and Materials. 
1) The activity of HIV RT was tested and compared with AMV RT in a primer 
extension assay (see Chapter II: Materials and Methods). In vitro transcribed chimeric 
tRNALYs3-ribozyme transcripts are used as templates. An oligonucleotide 
complementary to the 3' end of the chimeric tRNALys3-ribozyme is used as primer, 
which was labeled with 32P. Equal units of ANIV RI (Promega) and HIV RI were 
used. The result is shown in Figure 5. The HIV RI was found to be active. 
Figure 3. Testing of activity of HIV RI in a primer extension assay. 
2) Several buffers were tested in the binding assay 
I X Buffer 1, the buffer I have been using, 20mM Tris-liCi, pH 7.5, 50 mM NaCl, 
0.1 mM EDTA, 5% glycerol; I X Buffer 2, a buffer recipe used by Dr. Gary Larson, 40 
mM Tris, pH 8.3, 60 mM NaCl, 6 mM MgC1, 5 mIVI DTT; 1X Buffer 3, a recipe from Dr. 
John Francis which was used in another gel shift experiment, 0.01 M K211PO4, 0.01 M 
NaH2PO4, 0.14 M KCi. 
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Figure 4. Testing of three buffers for the binding assay of chimeric tRNALYs3-
ribozyme transcripts with reverse transcriptase. 
Buffer 1 was found to be most efficient. 
3) Binding of tRNALYs3 with HIV RT and AMV RT (as a control) 
tR N A L Y s3 
-HIV RT 
Corn plex 
tR N A L Y s3 
Figure 5. Binding of tRNALYs3 transcripts with HIV RT. 
AMV RT was used as a control. AMV RT 1 was from Promega. AVIV RT 2 was 
from Life Science. AMV RT stuck in the wells and therefore was not a good control. 
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Therefore, in the next experiment, transcripts of tRNAval were transcribed and used as a 
control. 
4) Binding assay of WW and MW with HIV RT 
The binding of transcripts of WW and MW from U6WW and U6MW with HIV RT 
was compared with the binding of the transcripts of tRNAVal. The sequence of the 
tRNAVal gene was as follows: GTTT CCG TAG TGT AGT GGT TAT CAC GTT CGC 
CTA ACA CGC GAA AGG TCC CCG GTT CGA AAC CGG GCG GAA ACA. A 
DNA fragment with the tRNAVal gene under a T7 promoter is constructed by 
polyrnerase chain reaction. This DNA fragment was used in in vitro transcription to 
obtain radiolabeled tRNAVal transcripts (see Materials and Methods, Chapter II). 
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Figure 6. Binding assay of WW and MW with HIV RT. 
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Figure 7. Binding assay of WW and MW with HIV RT. 
Same gel as in Figure 6 with a longer exposure time. Two additional lanes were shown 
on the left. 
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